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Abstract of Thesis
The characteristics of the hypothetical ideal neuromuscular
blocking drug are described and some of the unwanted effects of the
older muscle relaxants are reviewed. The history behind the
development of short acting rapid onset non-depolarising
neuromuscular blockers is outlined. Attention is focused on the
benzylisoquinolinium compounds. The development of atracurium, the
animal pharmacology and the preliminary studies in man are
discussed.
Patient studies are performed to investigate how closely the
pharmacological characteristics of atracurium relate to those of
the ideal drug. Some potential clinical uses for atracurium are
investigated.
Atracurium is noted to have an onset time significantly slower than
suxamethonium. Onset time and duration are found to vary with the
mode of neuromuscular monitoring and anaesthetic depth. When 0.6
mg kg"' atracurium is injected rapidly, there is a significant
elevation in serum histamine concentration. The associated
haemodynamic response may be attenuated by slowing the speed of
injection or by pretreating with intravenous HI and H2 antagonists.
Onset time may be shortened by using 0.8 mg kg"' but at the expense
of a transient drop in blood pressure and increase in heart rate
unless administration is slowed. Priming provides no improvement
in onset time, nor in haemodynamic stability. Atracurium shows no
tendency to cumulate when administered as an infusion. The
pharmacodynamics and pharmacokinetics of atracurium in anephric
patients are found to be very similar to those of healthy patients.
Pretreatment with atracurium does not prevent postoperative
8
suxamethonium myalgia. When suxamethonium is administered during a
recovering atracurium block, very high doses of suxamethonium are
required to produce 100% blockade of the twitch. The response to
atracurium by patients with myasthenia gravis is described.
Initial studies with two further benzylisoquinolinium compounds are
reported.
BWB1090U is a benzylisoquinolinium non-depolarising muscle relaxant
hydrolysed by plasma cholinesterase. The initial laboratory
studies with Rhesus monkeys and the neuromuscular and
cardiovascular effects on volunteers are reported. BWB1090U
appears to be a potent drug with a short duration, minimal
cumulative activity and reasonable cardiovascular stability. The
transient changes observed in the haemodynamic parameters are
thought to be due to histamine release.
BWA938U is discussed and the first pilot study is described. The
first study in patients in Europe is also reported. BWA938U
appears to be a very potent long acting non-depolarising blocking
drug devoid of haemodynamic effects. It is well reversed with
neostigmine but not by edrophonium.
Finally, current and future research in the development of new,
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Ever since civilised man identified curare, the arrow tip poison,
as a neuromuscular blocking agent with essentially no central
nervous system effect, there has been increasing interest in this
mechanism of achieving muscle relaxation in clinical situations.
Over the years, curare has been used for a variety of muscle
dystonias from acute sprains to a pharmacological substitute for
the 'spasmolytic' warm packs in the treatment of acute
poliomyelitis during the early 1950s. The introduction of curare
to anaesthesia by Griffith and Johnson [1] in 1942 was to promote
the most important use of this drug. The flaccid patient greatly
facilitated abdominal surgery. However, it took over a decade
before Beecher and Todd [2] were to point out that 'using curare
for many trivial purposes is not justified' [2]. They remarked
that 'despite artificial respiration of a generally effective type
[bag squeezing], many curare patients die of circulatory collapse.
It is not hertofore been recognised that a common cause of death
from curare is circulatory failure'. Because some of the
methodology in Beecher and Todd's report was flawed, the
conclusions were invalid. Nevertheless, it took some years to
recognise that spontaneous ventilation is unsafe when neuromuscular
blocking agents are given. Additional years of practice and astute
observations were required before ganglionic blockade and histamine
release were recognised as sequelae to tubocurarine administration.
Suxamethonium was hailed as tubocurarine's successor and was
thought to be devoid of ganglion blocking and histamine releasing
properties.
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The rapid onset of action and evanescent period of paralysis meant
that suxamethonium quickly achieved universal acceptance. However,
over the ensuing decade after its introduction, it became apparent
that a number of undesirable side effects occurred, mostly as a
consequence of its depolarising action.
Foldes and Churchill-Davidson first suggested that a short acting
neuromuscular agent which did not have the agonist or depolarising
properties of suxamethonium may well avoid these unwanted effects.
Many of the unwanted side effects of neuromuscular blocking drugs
are produced by the interaction of quarternary molecules with
cholinoceptors other than those at the myoneural junction. A
number of promising experimental non-depolarising drugs which
possessed the desired muscle relaxing properties in animals have
not been suitable for clinical use because of this.
Histamine release is a non-cholinoceptive side effect which has
also prevented the introduction of certain experimental compounds,
in particular the benzylisoquinolinium agents.
A hypothetical ideal neuromuscular blocking drug has been described
by Savarese and Kitz [3].
This drug should have the following clinical characteristics:-
1. A rapid onset of action.
One hundred per cent blockade of the single twitch would
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occur in 30-45 seconds permitting rapid intubation of the
trachea. This would make it a suitable alternative to
suxamethonium for a rapid sequence induction technique.
None of the traditionally used non-depolarising agents have
onset times as rapid as suxamethonium.
2. Rapid dissipation of neuromuscular blockade.
Muscle activity would recover to 90% of control levels
within 10-20 minutes after intubation of the trachea.
Generally speaking, the shorter-acting a muscle relaxant is,
the more flexible and forgiving its usage becomes.
In terms of duration, however, it may be argued that three
types of muscle relaxants are required. In addition to
the short acting muscle relaxant described above, an
intermediate duration non-depolarising agent without
cumulative effects would provide an action span shorter
than the more traditional non-depolarising agents.
Savarese and Kitz [3] proposed that a drug with a rapid
recovery (15-20 minutes) would decrease the need for reversal
of neuromuscular blockade at the termination of anaesthesia,
thereby decreasing the possibility or danger of
postoperative residual curarisation.
Also, the anticholinesterase agents are not without morbidity
in their own right and may on occasion deepen blockade. They
went on to suggest that a drug metabolised by the body whose
action was terminated by its own destruction would also be
very appealing.
14
A third type of agent, a long acting non-depolarising
agent devoid of cardiovascular side effects, might also be
useful, particularly in cardiac surgical procedures.
3. Lack of cumulative effects
Neuromuscular activity would recover to 90% of control
levels within 10-20 minutes of stopping an infusion or
following multiple incremental doses.
4. Antagonism of blockade bv suitable antidote.
This will usually be by an anticholinesterase agent. It is
important that the muscle relaxant does not also
significantly inhibit acetylcholinesterase otherwise the
effectiveness of the anticholinesterase agent will be
reduced. This problem arose with one experimental drug
called benzoquinonium [4]. The powerful
acetylcholinesterase inhibiting action of benzoquinonium
which would otherwise have been a useful relaxant lead to
its withdrawal as a neuromuscular blocking drug.
5. Absence of pharmacological action or toxicity of
metabolites.
6. High potency.
Although not always true, generally speaking the more potent a
muscle relaxant is, the less side effects it will have. The
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therapeutic index or margin of safety will be greater.
Furthermore, it avoids the cumulation of large quantities of
metabolites.
7. Histamine release.
With muscle relaxants, histamine release by chemically
mediated reactions happens much more frequently than by
immunologically mediated reactions [5]. This occurs when the
injected substance acts directly on the tissue mast cells or
circulating basophil leucocytes leading to the release of
histamine without antibody or complement involvement.
8. Absence of cardiovascular effects.
As well as releasing histamine and possibly other vaso¬
active mediators, muscle relaxants may also stimulate
or inhibit peripheral autonomic sites [6]. (See Figure
1).
Tubocurarine blocks ganglionic nicotinic receptors and
produces some ganglionic blockade in a dose range slightly
greater than that required to produce neuromuscular blockade.
It may have a slightly more powerful action on parasympathetic
than on sympathetic ganglia [7]. Autonomic reflexes arising
in the course of surgical operations may be impaired by this
ganglion blocking action, and this action may contribute to
hypotension [8,9]. However, there is evidence suggesting that





Diagrammatic representation of the automonic nervous system with
respect to the heart and sites of action of some neuromuscular
blocking agents on this system. The muscarinic receptors have been
divided into three subclasses (Ml, M2, M3).
N = nicotinic receptor P = pancuronium G = gallamine
F = fazadinium dTc = tubocurarine
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tubocurarine is possibly less important than its ability to
release histamine [10]. Metocurine and alcuronium are weaker
ganglion blockers and other neuromuscular blocking drugs such
as gall amine and pancuronium have no ganglion blocking
activity in the doses used clinically. Suxamethonium has a
weak ganglion stimulant action which may occasionally cause a
rise in blood pressure [11],
By definition, all muscarinic receptors are stimulated by
muscarine and blocked by atropine. However, evidence has
accumulated in recent years that these receptors are probably
not a homogeneous group. A lucid account by Bowman [12]
describes how they may differ with respect to their
interaction with other agonists and antagonists. Figure 1 is
a diagrammatic representation of the main components of the
autonomic nervous system with respect to the heart. For the
purpose of this diagram, the muscarinic receptors have been
labelled Ml, M2 and M3 receptors, but this is not a strict
classification and is probably an oversimplification [13].
9. Independence of renal function.
Most of the traditionally used muscle relaxants are
dependent to a greater or lesser extent on the kidney for
their elimination and hence their termination of action.
In patients with impaired renal function, a prolongation of
effect is usually observed.
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THE DEVELOPMENT OF HEW MUSCLE RELAXANTS
All potent neuromuscular blocking agents are quarternary ammonium
compounds. Less potent neuromuscular properties have been
demonstrated with other positively charged organic molecules, such
as tertiary sulphonium, quarternary phosphonium, quarternary
arsonium, and quarternary stibonium groups [14].
The quarternary structure is analogous to the quarternary group of
acetylcholine and is the principle chemical feature responsible for
the interaction of quarternary molecules with receptor sites which
bind acetylcholine and at which acetylcholine exerts its
physiological actions. The interactions of quarternary molecules
with cholinoceptors other than those at the myoneural junction
produce the unwanted side effects present 1n most clinically used
neuromuscular blocking drugs. These interactions are also
responsible for the failure of a number of promising experimental
non-depolarising agents, some of which possessed a brief duration
of action in animals.
Many short acting drugs have been produced over the last three
decades. All of these compounds when tested in the cat have
demonstrated a spontaneous recovery from 95% blockade in less that
15 minutes.
The short acting non-depolarising neuromuscular blocking agents
that have been studied may be classified on the basis of their
chemical structure.
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1. Aryl imidazobispyridinium Compounds.
2. Bis-dihydroisoquinolinium Compounds.
3. Phenyl ammonium Ketothiosemicarbazones.
4. Quarternary Steroidal Compounds.
5. Non-depolarising Ester Neuromuscular Blocking Agents.
(Figures 2 and 2A)
A series of arylimidazobispyridinium compounds studied by Bolger et
al, 1972 [15], and Brittain and Tyers, 1972 [16], were shown to
produce a non-depolarising type neuromuscular blockade of short
duration in a wide variety of species. NADPH dependent azo
reduction of one of the compounds AH8165 (fazadinium) [Figure 2]
was shown to occur rapidly in liver microsomes [Bolger et al, 1972]
and explained its brief action. Although a rapid onset of action
was noted in man [17] recovery times were no faster than the
traditionally used non-depolarising drugs [18]. Furthermore,
blockade was always accompanied by a marked tachycardia and
increased cardiac output. After a brief clinical exposure,
fazadinium has been withdrawn from routine use.
A series of bis-dihydroisoquinolinium compounds synthesised by Copp
et al, 1972 [19] demonstrated a brief, potent, neuromuscular
blocking action of the non-depolarising type, particularly in the
dog and cat. The short action span in the cat was attributed to
rapid hepatic and renal clearance of the agents from the blood
stream. The duration of action of these drugs, however, was much
longer in monkeys and man. In addition, considerable
anticholinesterase activity was noted with 252C64 and excessive







































Chemical formulae for some neuromuscular blocking agents.
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The latter problems were attributed to a combination of blockade of
the cardiac vagus and B-adrenoceptor stimulation.
The clinical features of these dihydroisoquinolinium compounds
illustrates three major undesirable actions encountered in the
pharmacological evaluation of neuromuscular blocking agents.
1. Excessive Anticholinesterase Properties.
2. Blockade of Cardiac Muscarinic Receptors.
3. Poor Correlation of the Duration of Action of the Compounds in
Experimental Animals with that Noted in man.
A series of mono quarternary compounds were studies by Bamford et
al [20]. The phenyl ammonium kethothiosemicarbazones represented by
M+B 15944A [Figure 2] demonstrated desirable properties in
experimental animals. In all species, the neuromuscular blocking
action of M+B 15944A was similar in duration to that of
suxamethonium but had a non-depolarising character, reversible by
anticholinesterase agents. Considerable autonomic ganglion
blocking activity was noted in the cat and hypotension consistent
with a ganglion blocking action also occurred in man [21].
Despite the interesting nature of the previous three groups of
compounds, the most recent and by far the most productive research
in the field of neuromuscular blockade today is with two groups of
compounds, namely the quarternary steroids and the ester compounds.
In 1960, Quevauvilier and Huu-Lain6 [22] described non-depolarising
neuromuscular blocking properties in a naturally occurring
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bis-quarternary aminosteroid, malouetine [Figure 2]. The duration
of action of this compound was similar to that of suxamethonium in
the cat and chicken, but in contrast to suxamethonium the paralysis
could be antagonised by anticholinesterase agents. The drug was
not tested clinically because of its hypotensive effects [23],
however, the fact that malouetine had a brief action stimulated the
subsequent synthesis of many more mono and bis quarternary
steroidal neuromuscular blocking agents.
Unfortunately, the duration of action of most of the earlier
steroids was found to be considerably longer in the primates than
in the cat. Also, clinical neuromuscular blockade was often
accompanied by a tachycardia secondary to a vagal blocking effect.
Nevertheless, these experimental studies resulted in the
introduction in 1967 of pancuronium [Figure 2A] following clinical
studies by Baird and Reid [24], and more recently in the
intermediate duration compound vecuronium. Vecuronium is not only
shorter acting than the traditionally used agents, but following
administration the patients remain haemodynamically stable.
The initial work with the ester neuromuscular blocking agents was
carried out by Bovet et al, 1951 [25], the outcome of which was the
development of suxamethonium [Figure 2A]. Until 1959 most of the
investigations of quarternary ester compounds were concerned with
esters of choline and resulted in the production of depolarising
agents. In 1959, Haining et al [26] studied a series of tropanium
esters. Compound DF596 [Figure 2A] produced a short duration of
action when tried clinically, but as might have been expected from
the tropanium quarternary grouping, the atropine like qualities of
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compound DF596 resulted in excessive tachycardia.
Gamma-oxalolaudoniurn bromide [27] [Figure 2A] was a laudanosinium
ester whose duration of action in the cat was half that of
suxamethonium. Its neuromuscular blocking action could be
antagonised by neostigmine. The low potency of
gamma-oxalolaudonium and its tendency to cause hypotension
precluded any clinical trial. The brief duration of action was
thought to be due to the hydrolysis of the ester linkage; although
actual hydrolysis by plasma cholinesterase was not demonstrated,
the compound was noted to be unstable in solution.
The bulky ester concept (Kitz et al, 1969 [28], Ginsburg et al,
1971 [29]) states that substitution of groups larger than ethyl
upon the quarternary nitrogen atom may improve the potency of
non-depolarising ester neuromuscular blocking agents.
For over 15 years Savarese and colleagues at the Massachusetts
General Hospital at Harvard Medical School have been designing,
synthesising and evaluating a series of bisbenzylisoquinolinium
diester compounds. These compounds are hydrolysed at varying rates
by plasma cholinesterase.
More recently, the agents BWA785U, BWA444U, BWB1090U and BWA938U
have been studied.
BWA785U [30] was an interesting compound with a short duration of
action in animals and man, not dissimilar to suxamethonium.
Unfortunately, it was even less potent than tubocurarine as a
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muscle relaxant and had an even lower margin of safety for
histamine release.
BWA444U [31] showed an intermediate duration of action and lack of
cardiovascular effects in animals. However, BWA444U was also noted
to release histamine in humans at the ED95 range (0.16 mg kg -1)
BWA444U and BW33A (atracurium) were produced more or less
simultaneously by the same manufacturer, Burroughs-Wellcome.
Clinical trials indicated the pharmacological superiority of
atracurium over BWA444U in humans, a difference which would have
been difficult to anticipate on the basis of animal studies.
Consequently, the further development of atracurium was scheduled
to continue while additional human studies with BWA444U were not
planned.
The relative success of BWA444U in its own right, however, did
suggest that further developmental research in the area of
non-depolarising ester relaxants might yield clinically useful
compounds.
During a two year spell at the Massachusetts General Hospital and
Harvard Medical School, the author was engaged in research with two
further benzyl isoquinolinium esters, namely BWB1090U and BWA938U,
which have since reached full scale clinical trials. This work
will be reported in the latter part of this thesis.
Since 1980, however, the author has been involved with clinical
studies of another benzylisoquinolinium compound, namely
atracurium.
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This thesis will describe clinical studies undertaken by the author
in collaboration with colleagues at the Nuffield Department of
Anaesthetics in Oxford; Harvard Medical School and the
Massachusetts General Hospital in Boston, USA; and the University






While Savarese and colleagues continued work on the
benzylisoquinolinium esters, Stenlake and colleagues in the United
Kingdom were working with a similar group of compounds. Their
philosophy, however, was that quarternary esters wholly dependent
on plasma pseudocholinesterase or liver acetylase metabolism for
biodegradation were unlikely to provide the key for the much sought
after short acting muscle relaxant.
In an entirely unrelated study they observed that a nitrogenous
constituent of a plant leontice leontopetalum was a simple
1-benzyltetrahydroiso-quinoline quarternary salt which underwent
unexpectedly fascile degradation in mild alkali by the well known
Hofmann elimination pathway. This observation prompted Stenlake to
the possibility of designing a novel class of short acting
neuromuscular blocking agents capable of rapid biodegradation by
this purely chemical pathway activated solely by the mild alkaline
conditions which are obtained at physiological pH.
Four series of isoquinol ine type structures were subsequently
synthesised. All were designed to undergo the Hofmann elimination
in which a quarternary nitrogen group degrades to a tertiary amine
at relatively high temperature and alkaline pH.
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The benzyl isoquinolinium structure of the quarternary group of
atracurium was chosen for a number of reasons. This group when
quarternised provides good neuromuscular blocking potency when a
chain of appropriate length is interposed between two of the
structures. Laudexium, a now obsolete relaxant which achieved
slight popularity during the mid 1950s, is an early example of such
a structure. The quarternary group of laudexium is the quarternary
form of laudanosine, which also appears in atracurium. The chain
in atracurium is longer (n = 13 vs 10 atoms in laudexium) and
includes two ester linkages. It is, however, the reversed ester
groups in atracurium that enhances susceptibility to a Hofmann
reaction [Figure 3].
The benzylisoquinoline structure (laudanosine) has long been known
to confer neuromuscular blocking potency without vagolytic
property, hence it was felt that synthesis of molecules of this
type would avoid the vagolytic side effect responsible for the
demise of BW403C65. In the atracurium series the ratio of
neuromuscular blocking potency to vagolytic property was compared.
The safety ratio was greatest in atracurium where n=5 in the
central chain carbons. Neuromuscular blocking potency, however,
was greatest when n=6. Thus a compound with lesser potency was
chosen because of its greater safety regarding potential vagolytic
side effects. The histamine releasing potencies of the two
compounds, however, were not carefully compared. Since potential
histamine release is the only prominent side effect inherent in
benzylisoquinoline-type neuromuscular blocking agents this may have
been an oversight in the pre-clinical evaluation of the series.









Proposed pathways of inactivation of atracurium by Hofmann
elimination reaction and Ester hydrolysis.
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Promotion of the Hofmann reaction was achieved by spacing the
quarternary nitrogen two carbons away from the ester group. These
two molecular features both withdraw electrons from the beta-carbon
atom to allow the elimination of a proton to occur under
physiological conditions. In the atracurium series the Hofmann
reaction proceeds rapidly to completion resulting in the breakdown
products pentamethylene diacrylate (the central chain) and
laudanosine (the quarternary group).
In studies of the degradation of atracurium in-vitro it was
observed that the process occurs more rapidly in plasma than in
buffer suggesting that another route of degradation (ester
hydrolysis), possibly enzyme catalysed, occurs in the plasma.
Molecular fragmentation by these two routes is the unique feature
of atracurium which distinguishes the drug from all other
non-depolarising relaxants, and which is the underlying basis for
much of its clinical and basic pharmacology.
Animal Pharmacology
The initial animal studies were reported by Hughes and Chappie
[32]. In a chick biventer-cervicis preparation, atracurium
produced a neuromuscular block typical of a non-depolarising drug.
In chloralose anaesthetised cats, intravenous doses of 0.25 or 0.5
mg kg -1 were sufficient to produce complete neuromuscular
paralysis of the tetanic and single twitch responses of the
gastrocnemius muscles within one to two minutes. Full recovery of
both responses occurred within 37 minutes. Neuromuscular paralysis
was also antagonised by neostigmine 0.05 mg kg -1 iv.
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In the dog, cat and monkey, the potency and duration of atracurium
was remarkably constant, a unique feature. Atracurium was slightly
more potent that tubocurarine in the cat and approximately
equipotent in the dog and monkey.
In the chloralose anaesthetised cat, vagal blockade only became
apparent after doses of 2 mg kg -1 iv, that is, at eight times the
full neuromuscular paralysing dose. Sympathetic blockade was only
evident after supramaximal doses of 4 mg kg -1 when systemic
arterial pressure was reduced by a mean of 34%. Rhesus monkey
studies demonstrated similar results.
In all species, the only side effect of any note was histamine
release. At a dose of 2 mg kg -1 atracurium, evidence of histamine
release was obtained in two chloralose anaesthetised dogs. HI and
H2 receptor antagonists (mepyramine 10 mg kg -1 and burimamide 15
mg kg -1) reduced the hypotension caused by atracurium 2 mg kg -1
(eight times the full paralysing dose) from 52% to 16% and from 42%
to 25% respectively in each dog.
Preliminary Studies in Man
Hunt, Hughes and Payne [33] were the first to report studies in
anaesthetised man. They reported than an intravenous dose of
atracurium 0.2 mg kg -1 was sufficient to cause complete paralysis
of the tetanic responses of the adductor policis muscle. Blockade
was of medium duration and readily antagonised by neostigmine. No
cardiovascular changes were observed at this dose.
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A dose of 0.6 mg kg -1 atracurium also produced minimal changes in
blood pressure and heart rate. In two patients receiving this
dose, tracheal intubation was performed within one minute of
receiving the drug and full block was completely reversed after 10
and 20 minutes respectively by neostigmine.
A lack of cumulative effects in patients given multiple incremental
doses was noted.
Atracurium - Clinical Studies
Payne and Hughes [34] reported the first formal evaluation of
atracurium in anaesthetised man. A quantitative assessment of the
time course of blockade showed that the onset of complete block was
significantly shortened when the dose was increased from 0.3 to 0.6
mg kg -1 iv.
The tetanic contraction of the adductor policis muscle following
supramaximal stimulation of the ulnar nerve at the wrist every 12
seconds with tetanic bursts of 50 Hz for one second was recorded.
Onset (n=3) was reported to be 1.1 minute at 0.6 mg kg -1 using
this mode of stimulation. In three patients good intubating
conditions were provided in 50 to 55 seconds.
This report of a rapid onset of action stimulated the author to
carry out the study in the next chapter.
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CHAPTER 2A
ATRACURIUH: ITS SPEED OF ONSET - A COMPARISON WITH SUXAMETHONIUM
Many studies have evaluated the speed of onset of muscle relaxants.
In some, judgement of paralysis has been largely subjective using
clinical criteria such as jaw relaxation, ease of tracheal
intubation and the absence of response to laryngoscopy and
intubation (Harrison and Feldman, 1981 [35]; Hey, 1973 [36]).
Despite all efforts to eliminate bias, ease of intubation depends
not only upon the degree of neuromuscular blockade but also upon
the depth of anaesthesia, the anatomical configuration of the
patient and not least upon the skill of the anaesthetist. An
objective comparison of the rate of onset of neuromuscular blocking
drugs can best be obtained by recording the response of a muscle to
stimulation of its motor nerve.
In this study the speed of action of atracurium was monitored using
a repeated 2 Hz train-of-four stimulus and compared with
suxamethonium. This comparison was chosen since the fast onset
time reported in Payne and Hughes' [34] preliminary study had
suggested to the investigators that this new non-depolarising
muscle relaxant could well be used as an alternative to
suxamethonium.
Methods
Forty healthy patients undergoing minor dental surgery requiring
intubation were studied. Patients who gave informed consent to the
trial were between 18 and 45 years of age. Any patient receiving
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concurrent medication apart from the contraceptive pill or in whom
pregnancy was suspected was excluded. Ethical consent for this
study was obtained and the trial was conducted with the authority
of a clinical trials certificate issued by the Committee on the
Safety of Drugs.
After a premedication with papaveretum and hyoscine a modified
Elcomatic transducer (Armstrong, Goat and Loach, 1977) [37] was
attached to the patient's dominant hand and positioned to achieve
maximal mechanical response to thumb adduction. Anaesthesia was
induced with fentanyl 3 //g kg -1 and thiopentone 5 mg kg -1 and
maintained with nitrous oxide and oxygen; ventilation of the lungs
was assisted by a face mask. Stimulation of the ulnar nerve at the
wrist was carried out by cutaneous electrodes using a Grass S48
nerve stimulator with an SIU5 isolation unit. The stimulus width
was 0.2 milliseconds. Once it was certain that the stimulus was
supramaximal, the stimulator was set to produce a 2 Hz
train-of-four stimulus repeated once every 12 seconds. The
mechanical response to nerve stimulation was measured by the
transducer and displayed on an Elcomatic recorder.
The patients had been randomly selected to receive either
atracurium 0.6 mg kg -1 or suxamethonium 1 mg kg -1 diluted to the
same volume for injection. All drugs were administered via a
peripheral indwelling needle and the relaxant injected at the time
of nerve stimulation, the start of injection coinciding with the
first stimulus of the train. The time from administration of the
muscle relaxant to the first depression of any response in the
train was noted. This was called the initial onset time. The time
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at which 100% block of all four peripheral twitches occurred was
also noted. At this time no recorded response was obtained from
the stimulus. Tracheal intubation was attempted by the author at
100% block using the nasal route under direct vision.
During induction of anaesthesia the ECG was monitored continuously
and changes in heart rate noted. After intubation 1% halothane was
added to the anaesthetic; this concentration was reduced during
surgery to allow a rapid return of consciousness at the end of the
procedure. Neuromuscular monitoring was not continued during
surgery and at the completion of the operation those patients who
had received atracurium were given neostigmine 2.5 mg with atropine
1.2 mg. The time of administration of these drugs was noted and
reversal of paralysis shown by the ability of the patient to
maintain a head lift for five seconds (Dam and Guldmann, 1961)
[38].
After surgery all patients received standard analgesic and
anti-emetic drugs and were interviewed at 24 hours. They also
received a questionnaire which they were asked to return after 72
hours in order to detect any major problems.
Results were analysed using the unpaired two tailed student T test.
The results are summarised in Table 1. There were no significant
differences between the groups with regard to age and weight. The
initial onset of neuromuscular block was faster by almost 15
seconds in those patients receiving suxamethonium and this
difference in initial onset time was significant (p < 0.01).
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No of Mean age Mean wt Mean initial Mean tine to
patients (yr) (kg) onset tine 1001 block of T1
Suxanethoniun 20 24.9 64.9 34.8 69.9
(SD 5.4) (SD 11.9) (SD 11.6) (SD 18.5)
Atracuriun 20 24.3 63.8 49.8* 129.0**
(SD 6.0) (SD 11.1) (SD 8.9) (SD24.3)
Table 1
Patient characteristics and neuronuscular blockade data. Significance (Students T test).
* P < 0.01 ** P < 0.001
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One hundred per cent block (absence of all four twtches) occurred
in all patients in both groups. A highly significant difference
was seen in the time to 100% block with atracurium taking nearly
twice as long as suxamethonium.
Changes in heart rate were minimal in both groups and there was no
significant difference between the two groups (Table 2). No
specific problems were encountered after surgery in those patients
receiving atracurium, although 11 patients in the suxamethonium
group complained of moderate to severe muscle pains.
Discussion
While Payne and Hughes [34] reported the mean onset of maximal
effect to be 1.2 minutes at a dose of 0.6 mg kg -1. This study
found the time to maximal effect was just over two minutes (129
seconds). The discrepancy between these results could be explained
by the mode of stimulation used. Although the response to tetanic
stimulation is a more sensitive indication of receptor occlusion
than either the single twitch response or the train-of-four,
tetanic stimulation may distort subsequent neuromuscular
transmission (Lee and Katz, 1980) [39] and increase the apparent
degree of neuromuscular blockade. The train-of-four stimulus was
chosen for this study since it is slightly more sensitive to
receptor occlusion than is the single twitch. It also lacks the
equivalent of post-tetanic distortion of a subsequent muscle
response and is therefore suitable for repeated application up to




No with heart rate change
>10 beats min -1 <10 beats min -1
Suxamethonium 20 2 2




The use of volatile anaesthetic agents was avoided until after
monitoring had been discontinued because of the well documented
interaction between volatile and neuromuscular blocking agents
(Waud and Waud, 1979) [40).
In conclusion, atracurium appeared to be a relatively potent
competitive neuromuscular blocking agent. Although its onset of
blockade seemed fast with 100% block of T1 occurring in just over
two minutes, this was found to be significantly slower than the




SINGLE TWITCH AND TRAIN-OF-FOUR RESPONSES FOR ATRACURIUM AND
VECURONIUM
It became apparent at the First International Symposium on
Atracurium in 1982 that workers were reporting different onset
times. It was obvious that the onset time of atracurium was not
only dose dependent but that the results were affected by the
nature of the anaesthetic and the mode of peripheral nerve
stimulation used to monitor the block.
Two common methods of evaluating responses to muscle relaxant
administration are evoked single twitch nerve stimulation and
evoked train-of-four nerve stimulation. Single twitch stimulation
at 0.15 Hz has been found to be clinically relevant for determining
adequate neuromuscular blockade for tracheal intubation and
abdominal surgical relaxation [41]. Train-of-four stimulation (2
Hz for two seconds once every 10 -12 seconds) offers the advantage
of being able to monitor recovering neuromuscular blockade without
the need to establish a control response. In addition, it has been
shown for the older relaxants (tubocurarine, metocurine and
pancuronium) that when the single twitch returns spontaneously to
control height the mean train-of-four ratio is less than 50% [42].
This study was undertaken to define for the new relaxants




ASA Class 1 and 2 patients aged between 18 and 59 years were
studied. Each patient gave written institutionally approved
informed consent to the study. All patients were premedicated one
hour preoperatively with diazepam 0.15 mg kg -1 PO and morphine 0.1
mg kg -1 i.m.
Anaesthesia was induced with fentanyl (6 ug kg -1) and thiopentone
(4-8 mg kg -1). The trachea was intubated without a relaxant
following the use of topical anaesthesia to the vocal cords and
trachea with a 4% lignocaine spray. Ventilation was controlled to
maintain an end tidal C02 in the range of 4-5 kilopascals.
Anaesthesia was maintained with N20/02 at a ratio of 2:1. Once the
mechanical response of the adductor pollicis muscle to ulnar nerve
stimulation had been stable for 10 minutes, a bolus dose of
relaxant was administered and onset time to maximum block and
duration to 95% recovery were recorded. The dosage groups were as
follows (mg kg -1): atracurium 0.1, 0.2, 0.4 and 0.5; vecuronium
0.02, 0.04, 0.06 and 0.1. For each drug half of the subjects were
monitored using single twitch responses at 0.15 Hz and half using
train-of-four responses at 2 Hz for two seconds repeated every 10
seconds. These responses were generated by stimulating the ulnar
nerve at the wrist using square wave supramaximal pulses from a
Grass S44 nerve stimulator and recording the mechanical response of
the adductor pollicis muscle on a Grass polygraph. In the single
twitch groups when the response had returned to control levels a
train-of-four was performed and the ratio documented.
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Dose response curves were generated for each group using the method
of Litchfield and Wilcoxon [43]. Results were analysed using a
students T test where appropriate. A p value <0.05 was considered
statistically significant. Values expressed are means +/- standard
error.
Results
Dose response curves for single twitch and train-of-four
stimulation for atracurium showed a good fit and parallelism but
ED95 values differed significantly.
The same was true for vecuronium. Single twitch ED95 for
atracurium was 0.26 mg kg -1 and 0.20 mg kg -1 for train-of-four.
Single twitch ED95 for vecuronium was 0.056 mg kg -1 while for
train-of-four it was 0.037 mg kg -1.
The neuromuscular response data is displayed in Table 3 for
atracurium and Table 4 for vecuronium.
Conclusion
In this study train-of-four stimulation was found to be more
sensitive in detecting changes in neuromuscular function for both
atracurium and vecuronium as shown by lower ED95 values, shorter
onsets and longer durations of action. Clinically, when assessing
potency and time to good intubating conditions, single twitch data
yield more useful information. In assessing recovery, when the
single twitch returned to control the train-of-four ratio for both
drugs is greater than 75%. Thus for assessing recovery from
neuromuscular blockade train-of-four nerve stimulation remains
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Dose no Stimulation % Block Onset
mg kg -1 (min)
O IX) 10 ST 73.2±11.1 6.6±0.4
10 T04 94.1±0.3* 3.9±0.5*
0.4 10 ST 98.9±0.7 3.9±0.5
10 T04 99.8±0.1 1.7±0.2*
0.5 10 ST 100 2.3±0.2
10 T04 100 1.7±0.1*
* P at least <0.05 ** T4/T1 at 95% ST = 0.69±0



































































































































































































superior to single twitch.
In this thesis, both mechanomyographic and electromyographic
approaches to neuromuscular monitoring are used. The technique
selected was by necessity dictated by the availability of equipment
in the particular department the author was working. It should be
noted, however, that no attempt is made to compare pharmacodynamic
parameters generated by these two different modes of neuromuscular
monitoring.
The next chapter will focus attention on haemodynamic stability,
another of Savarese and Kitz criteria for the ideal neuromuscular
blocking agent. The inter-relationship between onset time and
haemodynamic stability in the clinical use of atracurium will
become apparent in subsequent studies.
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CHAPTER 3
ATRACURIUM: CLINICAL STRATEGIES FOR PREVENTING HISTAMINE RELEASE
AND ATTENUATING THE HAEMODYNAMIC RESPONSE
Pre-amble
Atracurium demonstrates a wide margin of safety for cardiovascular
effects in animals. Dogs appear to be the most sensitive to the
cardiovascular effects of atracurium, but even so, eight times the
full paralysing dose (2 mg kg -1) was required to cause a
significant fall in mean arterial blood pressure. This hypotensive
effect was thought to be due to histamine release.
The original report by Payne and Hughes [34] in man was consistent
with the haemodynamic stability found in animals. Other workers
also noted little or no cardiovascular changes in dosages up to
0.5-0.6 mg kg -1 [44-46]. Indeed, in our initial study in Oxford
we found no significant change in heart rate.
Basta [47] and colleagues using direct monitoring of arterial
pressure also noted that at all doses up to and including two times
the ED95 (0.4 mg kg -1) atracurium produced no statistically
significant changes in arterial pressure or heart rate when paired
T test comparisons were made between control values and maximum
changes from control values within the first 10 minutes after the
administration of atracurium. However, with very careful
observation these workers noted that at 2.5 (0.5 mg kg -1) and
three times (0.6 mg kg -I) the ED95 dose there were mild decreases
in arterial pressure to 86.7% and 79.5% of control levels
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respectively. There were also mild increases in heart rate to
105.5% and 108.3% of control levels respectively. Changes in
arterial pressure were statistically significant only at the 0.6 mg
kg -1 dose (p <0.05). Heart rate changes were significant for both
the 0.5 mg kg -1 and 0.6 mg kg -1 doses (p <0.05). These changes
were of short duration, the maximal effect occurring 1-1.5
minutes after drug injection with a total duration of less than
five minutes. These cardiovascular changes were associated with
slight facial flushing.
Previous studies with tubocurarine [48] and with the experimental
neuromuscular blocking agents BWA785U [30] and BWA444U [31] showed:
(1) that there was a dose dependent release of histamine, and (2)
that the level of plasma histamine concentration correlated with
heart rate and arterial blood pressure changes following
administration of these drugs. It also appeared from these studies
that the dose of neuromuscular blocking agent which increased
plasma histamine to about 200% of control values resulted in
clinically and statistically significant changes in heart rate and
arterial pressure in healthy patients.
In another study, Basta [49] and colleagues observed a similar
effect with atracurium.
Using a sensitive isotope radioenzymatic assay technique for
histamine, they compared the histamine releasing potencies of
atracurium, dimethyltubocurarine and tubocurarine. They found
that the ability of atracurium to release histamine relative to its
neuromuscular blocking potency was approximately one half that of
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dimethyltubocurarine and less than one third that of tubocurarine.
Previously, the lack of a sensitive and reliable assay for plasma
histamine had made it difficult to document the role of the
histamine so released in drug induced cardiovascular changes. The
development of the radioenzymatic technique used above (Snyder,
Baldasserarini and Axelrod, 1966 [50]; Beavan, Jacobsen and
Horakova, 1972 [51]; Beavan and Horakova, 1978 [52]; Iverson,
Iverson and Snyder, 1979 [53]) and its improvement by the discovery
of renal histamine methyl transferase (Shaff and Beavan, 1979 [54])
have greatly enhanced the ability to detect histamine clinically in
important situations.
Using the above histamine assay the author elected to investigate
clinical strategies for preventing the histamine release by
atracurium and thereby attenuating the associated haemodynamic
response.
A number of clinical strategies have been used to attenuate the
adverse reactions to the histamine release by certain drugs. It
has been shownthat even small time differences in the rate of
administration of intravenous agents can lead to significant
changes in the likelihood of generating clinically significant
histamine release (Rosow et al, 1980 [30]; Basta et al, 1981 [55]).
Furthermore, there is abundant evidence suggesting that this
prophylactic use of HI and H2 antagonists can also attenuate the
haemodynamic responses to certain histamine releasing drugs
including morphine (Philbin et al, 1981 [56]), BW785U (Rosow et al,
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1980 [30]) haemaccel (Lorenz et al, 1980 [57]) and tubocurarine
(Moss et al, 1982 [10]).
This study was designed to determine the effects of a rapid bolus
dose of atracurium 0.6 mg kg -1 on arterial pressure, heart rate
and plasma histamine concentration and to compare these values with
those obtained by (a) giving the same dose of atracurium slowly
over 75 seconds, and (b) pretreating with HI and H2 antagonists.
Patients and Methods
Twenty seven (ASA Class 1 or 2 ) patients gave institutionally
approved informed consent to the study and were assigned to one of
three sub-groups at the discretion of the investigator. All the
patients were aged between 18 and 60 years, weighed 45-110 kg and
were undergoing elective surgical procedures. Any patient with
recent exposure to antihistamines or antidepressants was excluded
from the trial.
Premedication consisted of morphine 0.1 mg kg -1 i.m. and diazepam
0.2 mg kg -1 by mouth. Anaesthesia was induced with fentanyl 3-4
ug kg -1 and thiopentone 5 mg kg -1 intravenously and maintained
with nitrous oxide in oxygen by a face mask. Heart rate (by
tachograph), ECG and intra-arterial pressure were recorded
continuously on a Grass model 7 polygraph. After a stable 10
minute baseline period a single bolus of atracurium 0.6 mg kg -1
was administered over five seconds to patients in group 1.
Patients in group 2 received the same dose of atracurium slowly
(over 75 seconds). The patients in group 3 were pre-treated with
cimetidine 4 mg kg -1 and chlorpheniramine 0.1 mg kg -1
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intravenously 15 minutes before induction. They were then given
atracurium 0.6 mg kg -1 as a five second bolus. Maximum changes in
heart rate and arterial pressure were noted. Intubation of the
trachea was delayed for 10 minutes following the administration of
atracurium to avoid a cardiovascular response to laryngoscopy.
Arterial blood samples were drawn immediately before the injection
of atracurium and at two and five minutes after injection; these
samples were analysed for histamine by an isotope radioenzymatic
assay technique (Moss et al, 1981 [10]). End tidal carbon dioxide
concentration was kept within the normal limits during the course
of the study.
Results
The results are summarised in Tables 5 and 6: the data displayed
are mean values. The changes in mean arterial pressure and heart
rate are the maximum changes that occurred in the 10 minutes
following the administration of atracurium calculated as a
percentage of the base line values. The absolute values at base
line, two minutes and five minutes for mean arterial pressure and
heart rate are displayed in parenthesis in Table 5. Figure 4
illustrates the mean changes in plasma histamine concentration in
the three groups, and figure 5 the changes in plasma histamine
concentration in the individual patients. Patients in group 1
demonstrated a significant increase in plasma histamine
concentration at two minutes (p <0.05; analysis of variance).
Seven patients (77%) in this group showed clinical signs of
histamine release with the development of mild to moderate erythema
over the trunk and face. The changes in heart rate and arterial
no Map*





















MAP = mean arterial pressure
HR = heart rate
* Actual values at baseline, 2 and 5 minutes for mean arterial
pressure and heart rate are shown below in brackets. The units are
mm Hg and beats per minute respectively.
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* P < 0.05 (one way analysis of variance)
Table 6
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Figure 4
Mean plasma histamine concentrations in the three groups at
control, two minutes and five minutes following administration of

























Plasma histamine concentrations in individual patients in the three
groups at control, two minutes and five minutes following
administration of atracurium 0.6 mg kg -1 i.v.
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pressure in this group were all transient and had almost returned
to base line values by five minutes. Figure 6 illustrates the
transient haemodynamic response observed following a bolus of 0.6
mg kg -1 of atracurium.
A moderate increase in histamine concentration at the two minute
sample in group 3 approached but did not reach a statistical
significance 0.1 >p > 0.05.
None of the patients in groups 2 or 3 showed clinical signs of
histamine release nor any haemodynamic changes of statistical or
clinical significance.
Discussion
All basic compounds may disrupt mast cells and cause release of
histamine if the dose is large enough (Paton, 1957 [58]). Among
the neuromuscular blocking drugs this effect appears to be most
pronounced with d-tubocurarine, possibly because of its free
hydroxyl groups which are thought to enhance histamine releasing
potency (Buckett and Frisk-Holmberg, 1979 [59]).
Simple histamine release by many drugs including neuromuscular
blocking agents does not involve immunological mechanisms, but
rather a non-specific displacement of histamine and possibly other
vaso-active substances from vascular mast cells. The transient
nature of the changes in arterial pressure and heart rate following
a bolus dose of atracurium 0.6 mg kg -1 i.v. and the significant
increases in plasma histamine concentration would seem to confirm















The transient haemodynamic response occasionally observed following
a bolus of 0.6 mg kg -1 of atracurium. Illustrated are the heart
rate (by tachograph), intra-arterial blood pressure, and the single
twitch at 0.15 Hz. Atracurium 0.6 mg kg -1 was injected as a rapid
bolus at the arrow mark to a patient under balanced anaesthesia.
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histamine. Atracurium has a very high margin of safety for
ganglionic blockade (Hughes and Chappie, 1981 [32]), the duration
of which tends to parallel neuromuscular blockade (Savarese, 1976
[60]). Thus a hypotensive response to atracurium, mediated by a
ganglionic blockade, would seem unlikely.
It appears that small differences in the plasma concentration of a
histamine releasing drug can produce large changes in the amount of
histamine liberated. In this study slowing the administration of
atracurium appeared to prevent the increase in histamine
concentration and subsequent change in haemodynamic variables.
The wide variety of agents with which combined histamine receptor
blockade is effective demonstrates the clinical importance of
histamine release as well as the effectiveness of combined
blockade. In the present study the patients receiving a rapid
bolus of atracurium intravenously who were pre-treated with HI and
H2 antagonists did show an increase in plasma histamine
concentration. The haemodynamic response, however, was markedly
attenuated.
It should be noted that not all patients will release histamine at
high doses of atracurium as indicated by the large standard error.
However, as the size of the bolus dose increases there is a greater
likelihood of this response occurring (Basta et al, 1981, [55]).
Although this transient haemodynamic response is probably of little
clinical significance in healthy patients the effect may be more
important in the haemodynamically unstable patient who is
hypovolaemic or has cardiovascular disease.
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In conclusion, it appears that the release of histamine by large
bolus doses of atracurium (0.6 mg kg -1) and any associated
haemodynamic response can be prevented by administering the dose
slowly (over 75 seconds). In addition, the haemodynamic response
to a rapid (5 second) bolus can be minimised by pre-treatment with
HI and H2 receptor antagonists such as chlorpheniramine and
cimetidine given intravenously 15 minutes before atracurium.
Rapidity of onset and cardiovascular stability were two
characteristics of the ideal muscle relaxant described by Savarese
and Kitz. In the previous studies, the author has examined both of
these aspects with regard to atracurium. The clinical
inter-relationship between these two characteristics are studied in
more detail in the subsequent paper.
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CHAPTER 4
THE CLINICAL PHARMACOLOGY OF HIGH DOSE ATRACURIUM
While atracurium appears to have come closer to the ideal in terms
of duration of action and cardiovascular stability than the earlier
agents, the onset time is still significantly slower than that of
suxamethonium in the clinical dose range [61]. For rapid sequence
induction, suxamethonium remains the drug of choice.
Other workers have shown that the speed of onset of atracurium is
dose dependent [34, 47]. Theoretically, its administration in very
high dose should provide a more rapid onset of action without the
excessively prolonged duration of action that may be observed
following high doses of the longer acting agents. Indeed,
Waldburger, Nielsen and Mulroy, 1984 [62] have suggested that
atracurium 0.8 mg kg -1 will allow satisfactory intubating
conditions in all patients within 90 seconds of injection without
prolonged blockade or significant variation in haemodynamic
indices. This, of course, is at variance with our previous study
which showed that atracurium at 0.6 mg kg -1 causes a moderate
reduction in mean arterial pressure as a result of histamine
release [63], an effect which may be prevented by injecting the
drug slowly over 75 seconds or by pre-treating with i.v. HI and H2
antagonists.
More recently, it has been demonstrated that the speed of onset and
degree of blockade of competitive neuromuscular blocking drugs may
be enhanced if the agents are administered in divided doses
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(Schwartz et al, 1985 [64]; Mehta et al, 1985 [65]). From these
data it is postulated that an initial sub-paralysing dose (priming
dose) may occupy 70-75% of chol inoceptors without causing
unpleasant symptoms in awake patients. Tracheal intubation might
then be performed more rapidly after a second larger dose that
increases receptor occupancy quickly to the 90-95% level necessary
for paralysis. Furthermore, priming may improve the haemodynamic
profile by releasing less histamine as divided dosing may have the
same effect as slow injection.
This study was designed to determine the safety and efficacy of
administering atracurium 0.8 mg kg -1 to healthy patients. The
speed of onset and the haemodynamic response were studied in an
attempt to find modes of administration that would combine fast
onset times with haemodynamic stability. Some of the data are
compared with data obtained using the same investigative procedure
but with the lower dose of 0.5 mg kg -1, the highest recommended
dose in the United States.
Patients and Methods
Fifty six (ASA Class 1 or 2) patients gave informed consent for the
study and were assigned to one of seven sub groups at the
discretion of the investigator. The patient criteria were the same
as for the previous study.
Premedication consisted of morphine 0.1 mg kg -1 i.m. and diazepam
0.2 mg kg -1 orally. In groups 1 to 5 anaesthesia was induced with
fentanyl 5 ug kg -1 and thiopentone 5 mg kg -1 i.v. The trachea
was intubated without the use of a neuromuscular blocking drug,
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additional increments of thiopentone being administered when
appropriate to facilitate this procedure. Ventilation of the lungs
was controlled to produce normocapnoea and anaesthesia was
maintained with nitrous oxide in oxygen. Volatile agents were not
used. Heart rate, ECG, radial arterial pressure and the single
twitch adductor response at the thumb were recorded continuously on
a Grass polygraph. A Grass S44 stimulator with subcutaneous needle
electrodes and a Statham strain gauge were used. The single twitch
was produced at a frequency of 0.15 Hz with a stimulus duration of
two milliseconds. After a stable base line period (10 minutes) a
bolus dose of atracurium 0.8 mg kg -1 was administered over five
seconds to patients in groups 1 and 4. This dose was given over 30
seconds to patients in group 2 and over 75 seconds to patients in
group 3. Group 5 patients received a priming dose of 0.08 mg kg -1
followed six minutes later by a 0.72 mg kg -1 bolus. Patients in
group 4 were pre-treated with cimetidine 4 mg kg -1 and
chlorpheniramine 0.1 mg kg -1 i.v. 15 minutes before induction.
Maximum changes in heart rate and arterial pressure were noted.
Arterial blood samples were drawn immediately before administration
of the atracurium and at two and five minutes after injection.
These samples were analysed for histamine concentration by a
radioenzymatic assay technique (Moss et al, 1981 [48]).
In groups 6 and 7 anaesthesia was induced with thiopentone 5 mg kg
-1 only. Group 6 patients received a priming dose of atracurium
0.08 mg kg -1 five minutes before induction followed by a bolus of
0.72 mg kg -1 30 seconds after induction. Group 7 patients
received a bolus of atracurium 0.8 mg kg -1 given in five seconds,
30 seconds after induction. In these two groups the trachea was
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intubated 90 seconds following this last dose of atracurium and the
intubating conditions were classified as 1 (excellent), 2
(satisfactory), 3 (fair), or 4 (poor) according to the criteria of
Lund and Stovner, 1970 [66].
Blood samples were not analysed for histamine concentrations in
these two groups as it would be difficult to correlate any changes
in plasma histamine concentration with the inevitable haemodynamic
response to intubation. Furthermore, the histamine response in
these two dose regimes had already been analysed in groups 1 and 5
under stable haemodynamic conditions.
Results
The results are summarised in Tables 7, 8 and 9. The data
displayed are mean values with standard errors of the mean (SEM).
The changes in mean arterial pressure and heart rate are the
maximum changes calculated as a percentage of the base line values
that occurred in the 10 minutes after the administration of
atracurium. The actual values at control, two minutes and five
minutes for mean arterial pressure and heart rate are displayed in
parenthesis in Table 7. The data on mean arterial pressure, heart
rate and histamine concentration (Table 8) at base line and two
minutes were analysed according to a three factor analysis of
variance with group and time crossed and patient (a random factor)
nested within group. In order to stabilise their variability and
more closely satisfy the assumptions underlying the analysis of
variance the histamine data were analysed on a logarithmic scale.
Tests of significance for the change from base line to two minutes












































MAP = Mean Arterial Pressure
HR = Heart Rate
Actual values at baseline, 2 and 5 minutes for mean arterial
pressure and heart rate are shown above in brackets. The units are
mm Hg and beats per minute respectively.
The range of the maximum per cent, change in MAP and HR is shown
above in square brackets.
t-test * = P < 0.05 (simultaneous)
Cardiovascular Data.




PLASMA HISTAMINE pg ml -1
n Control +2 mins 5 mins
Group I 8 557±232 *1646+419 721+167









Group IV 8 485+100 **6154±4063 2251+1463









t-test P < 0.05 (simultaneous) ** P < 0.01
Table 8
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All data in brackets refers to 0.5 ng kg -1 atracurium (n=10)
Table 9
Pharmacodynamic data (Mean values with standard errors).
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according to Bonferroni's inequality so that the simultaneous
significance level would not exceed 0.05 (or 0.01 as appropriate).
There were significant decreases in mean arterial pressure in
groups 1, 2 and 5 (p <0.05) (Table 7). The moderate decrease in
group 4 approached but did not reach statistical significance (0.1
> p> 0.05). In all patients the changes in arterial pressure and
heart rate were transient and had returned to base line values by
five minutes.
Patients in groups 1, 4 and 5 demonstrated significant increases in
plasma histamine concentrations at the two minute sample (Table 8).
There were no significant differences in onset time (Table 9)
between any of the techniques of administration when atracurium 0.8
mg kg -1 was administered during nitrous oxide and fentanyl
anaesthesia. Nor was there a significant difference between groups
6 and 7 in which atracurium was administered following induction
with thiopentone. Atracurium 0.8 mg kg -1 produced a significantly
shorter onset time (p >0.05) than 0.5 mg kg -1 under nitrous
oxide-opiate anaesthesia. Atracurium 0.8 mg kg -1 also produced a
significantly more rapid onset than 0.5 mg kg -1 following
induction with thiopentone alone (p <0.05).
The depth of anaesthesia appeared to have an effect on onset time
and both the bolus (group 1) and prime (group 5) groups had
significantly shorter onset times (p <0.05) under nitrous
oxide-fentanyl anaesthesia when compared with the bolus (group 7)
and prime (group 6) groups respectively receiving thiopentone
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alone.
There were no significant differences between the recovery times or
the durations of action in the four groups in which these were
recorded.
The intubation score was slightly better 1n the prime group (6)
than in the bolus group (7) but this was not significant. The
intubation score produced by the 0.8 mg kg -1 bolus group at 90
seconds was the same as that produced by 0.5 mg kg -1 at 150
seconds.
Discussion
We have shown previously that atracurium 0.6 mg kg -1 given over
five seconds is associated with a doubling of plasma histamine
concentration and a significant reduction in mean arterial
pressure. These changes can be prevented by administering the drug
over 75 seconds or by pre-treating with antihistamines (cimetidine
4 mg kg -1 and chlorpheniramine 0.1 mg kg -1 iv) 15 minutes before
the injection of the neuromuscular blocker.
In this study decreasing the rate of injection of atracurium 0.8 mg
kg -1 to 75 seconds also minimised the haemodynamic changes and
prevented the increase in histamine concentration. However, in the
antihistamine group the haemodynamic protection was incomplete and
was associated with a highly significant increase in plasma
histamine concentration. The patient with the most marked increase
in plasma histamine concentration and the greatest decrease in mean
arterial pressure was in this group. This large increase in plasma
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histamine concentration may have been the result of the known
inhibitory effect of cimetidine on histamine-n-methyltransferase,
the enzyme responsible for one of the major catabolic pathways of
histamine. The substantial increase in plasma histamine
concentration in this group may have overcome the protection
offered by the antihistamines by a simple dose response effect.
Although there was almost a five fold increase in plasma histamine
concentration following the 30 second injection, this was not found
to be statistically significant because of the large between
patient variation and hence the large standard deviation in this
group. Considerable variability for histamine release among
subjects is well recognised. Not all patients will release
histamine after high doses of atracurium but as the size of the
bolus dose increases there is a greater likelihood of this
occurring in most individuals. In animal studies mast cells from
different species and even individual tissues within a single
animal are shown to vary markedly in their response to a given
inducer of histamine release (Pearce, 1982 [67]).
This histamine releasing response to the higher doses of atracurium
must be kept in perspective. Basta and colleagues, 1983 [49] have
shown that the ability of atracuriura to release histamine relative
to its neuromuscular blocking potency is only one half that of
di-methyltubocurarine and less than one third that of tubocurarine.
Nevertheless, this response could be of significance in the
hypovolemic patient or the patient with cardiovascular disease.
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Several studies have demonstrated more rapid onset of blockade and
superior intubating conditions when the priming principle was used
(Hutton et al, 1983 [68]; Bevan et al, 1984 [69]; Nagashima et al,
1984 [70]; Mehta, 1985 [65]; Schwartz et al, 1985 [64]). However,
there is little uniformity among these studies in terms of the
drugs used, the priming dose, the intubating dose, the time between
priming and intubating dose and the anaesthetic technique used.
These variables may require proper adjustment for each competitive
neuromuscular blocking agent. We can only conclude that with the
dose regime and time interval used in this study priming does not
improve onset times or intubating conditions; nor does it have any
protective haemodynamic effect.
A wide variety of onset times at a number of different doses has
been reported for atracurium (Payne and Hughes, 1981 [34]; Scott
and Goat, 1982 [61]; Foldes et al, 1983 [71]; Gergis et al, 1983
[72]). However, standardisation of anaesthetic technique is very
important before any effective comparison can be made. In
particular, the starting point and end point in the measurement of
onset time, the mode of peripheral nerve stimulaton and the
anaesthetic agents used should all be defined clearly. This is
emphasised 1n this study by the significantly shorter onset times
under nitrous oxide-opiate anaesthesia compared with those
associated with thiopentone alone. The different measurements
recorded when using different modes of peripheral nerve stimulation
have already been emphasised in a previous paper in this thesis.
It is concluded that atracurium 0.8 mg kg -i will produce a
significantly more rapid onset of blockade than 0.5 mg kg -1 with a
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similar intubation score one minute earlier (at 90 seconds compared
with 150 seconds). This may be associated with a transient but
significant decrease in mean arterial pressure. This effect which
is probably of little importance in the healthy patient can,




ADVERSE EFFECTS OF SUXAMETHONIUM - A STUDY OF PREVENTION BY
ATRACURIUM OR FAZADINIUM
It is now apparent that while atracurium may have a speed of onset
as fast as the other non-depolarising agents it is still not a
substitute for suxamethonium. It does not, therefore, fulfil the
first criteria of Savarese and Kitz for an ideal muscle relaxant
and cannot be recommended for routine use in a rapid sequence
induction technique.
Unfortunately, suxamethonium has many side effects. These include
muscle fasciculations, post-operative myalgia [73,74] and a
transient rise in serum potassium [75, 76]. Historically an
alternative approach to this problem has been to advocate
pre-treatment regimes to reduce the incidence and severity of these
side effects. The most widely accepted approach is the use of a
sub-paralysing amount of a non-depolarising drug given two to three
minutes before suxamethonium [77, 78]. This technique, however, is
not without side effects itself and may result in clinical
neuromuscular blockade during the pre-treatment period with a
decrease in the paralysing action of suxamethonium, as well as
making intubation more difficult.
Atracurium was selected as a mode of pre-treatment in the
prevention of these adverse effects of suxamethonium. Its action
was compared with that of fazadinium, another non-depolarising
relaxant, which has been used for pre-treatment [79] and was




One hundred healthy patients aged between 18 and 45 years
participated in the study which was approved by the local Ethics
Committee. Informed verbal consent was obtained from all
participants. The patients were to undergo minor oral surgical
procedures and required nasal intubation. They were receiving no
concurrent medication apart from the contraceptive pill.
They were allocated randomly into four groups to receive
pre-treatment as follows: GroupA - atracurium 2.5 mg; Group B -
atracurium 5 mg; Group C - fazadinium 3.75 mg; Group D - normal
saline 1 ml. In each case the volume administered was 1 ml.
Premedication of papaveretum and hyoscine was given by
intramuscular injection approximately one hour before induction of
anaesthesia. On arrival in the anaesthetic room the patient's
arterial blood pressure was measured and electrocardiograph
monitoring was established to record heart rate continuously. An
18 gauge cannula was inserted into a large vein in the antecubital
fossa of the non-dominant arm and a blood sample taken without the
use of a tourniquet and stored in a heparinised tube for the
subsequent estimation of serum potassium. All samples were
analysed within four hours of collection. The mean of three
estimations was recorded. The cannula was used for all sampling
and drug administration and was flushed with saline between each
use.
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Prior to induction of anaesthesia a modified Elcomatic [37]
transducer was attached to the dominant hand and positioned to
measure the optimal response to thumb adduction. Disposable
pre-gelled ECG electrodes were positioned over the ulnar nerve at
the wrist and connected via an isolation unit to a nerve stimulator
(Grass S48).
Anaesthesia was induced with fentanyl 3 ug kg -1 and thiopentone 5
mg kg -1 and maintained with nitrous oxide 70% in oxygen.
Ventilation was assisted mechanically using a face mask and
ventilator connected via a Bain system. Immediately after
induction of anaesthesia stimulation of the ulnar nerve was
commenced (pulse width 0.2 milliseconds) and adjusted to produce
the maximum mechanical response from contraction of the adductor
pollicis muscle. When the stimulation was supramaximal the
stimulator was set to repeat a 2 Hz train-of-four stimuli every 12
seconds. A control response to the stimuli was recorded before the
pre-treatment drug was injected and the start of the injection was
timed to coincide with the first response of the next train. Three
minutes later suxamethonium 1 mg kg -1 was administered and the
presence or absence of fasciculations was noted. As soon as there
was no detectable response to nerve stimulation laryngoscopy was performed and
intubation was attempted by the nasal route. All intubations were
performed by one of the investigators, who also noted the
intubating conditions and who was not aware of the nature of the
pre-treatment drug.
Neuromuscular monitoring was continued until the first response of
the train of four had returned to 80% of its control height.
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Halothane was then added to the inhaled anaesthetic and surgery was
begun. Further venous blood samples were taken two and 30 minutes
after the administration of suxamethonium.
Neuromuscular blockade during the pre-treatment period was assessed
by measuring the height of the most depressed first twitch of a
train of four and expressing it as a percentage of the control
first twitch response obtained before the pre-treatment drug was
given. Fade within the train of four was also measured and was
expressed as the ratio of the fourth twitch to the first. Onset of
paralysis following suxamethonium was monitored and expressed as
the time from injection of suxamethonium to maximum depression of
the first twitch response.
The rate of recovery of neuromuscular function was measured and
expressed as the time from maximum paralysis to 25% recovery of the
first twitch response. The recovery index was also measured,
namely the rate of recovery of the first twitch response from
25%-75% of its control value.
The patients were visited by one of the investigators approximately
24 hours following anaesthesia and helped to complete a simple
questionnaire. A number of questions were asked, some relating to
muscle pains and the site of the pain was noted. Because of the
nature of the surgery head and neck pain was considered to be of
surgical origin and was not included. The muscle pains were
classified as follows: mild, not requiring analgesia or interfering
with normal activity; moderate, requiring simple analgesia but not
interfering with normal activity; severe, not controlled by simple
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analgesics and interfering with normal activity.
A similar questionnaire was given to all patients to complete 72
hours after anaesthesia. These were completed at home and returned
by post. Post-operatively oral analgesics were prescribed for pain
relief as required.
Results
Table 10 shows that the four groups were comparable with regard to
age, weight and sex.
Neuromuscular Blockade During the Pre-Treatment Periods
Small degrees of depression of the first twitch T1 and of the ratio
T4/T1 were seen in a number of patients in all groups except those
who received saline as pre-treatment. Three patients, all of whom
received atracurium 5 mg, showed depression of the first twitch of
the train to 70% or less of control.
Fasciculations
The incidence of fasciculations was significantly less (p <0.01,
chi-squared test) in patients who had received pre-treatment with
one of the non-depolarising drugs than in those who received saline
(Table 11). There was no relationship between the intensity of
fasciculations and the severity of the post-operative muscle pains.
All patients in groups A, C and D achieved 100% block T1 of the
adductor of the thumb. In group B, four patients failed to become
fully paralysed. The mean onset time in this group was 79.7
seconds which was significantly longer than in the other groups.
76
GROUP ATRACURIUM ATRACURIUM FAZADINIUM SALINE
2.5 MG 5 HG 3.75 MG
Mean age 24.29 25.36 24.41 27.93
(Years) (5.93) (6.9) (6.8) (7.7)
Mean weight 62.59 61.75 62.39 63.26
(kg) (8.7) (10.1) (10.2) (9.5)
No of 25 25 25 25
Patients





GROUP A Atracurium 2.5 mgs 8 17
GROUP B Atracurium 5 mgs 4 21
GROUP C Fazadinium 8 17




There was no significant difference between the other three groups
(Table 12).
Intubating Conditions
All patients were intubated without the need for additional muscle
relaxants. Although not statistically significant, features likely
to result in a difficult intubation were found more frequently in
those patients receiving the larger dose of atracurium (Table 13).
Recovery from Neuromuscular Blockade
Recovery to 25% of control was faster in the atracurium 5 mg group
than all others and was slowest in the saline group. These
differences were significant (p <0.01). There was no difference
between atracurium 2.5 mg and fazadinium and no difference in the
recovery index between any group (Table 12).
Incidence of Pain
There was no significant difference in the incidence of muscle pain
between groups at either 24 or 72 hours. It was noted that in all
groups the incidence of muscle pain was greater at 72 hours than at
24 hours (Table 14).
Potassium
The blood samples were analysed for potassium using a Nova 1 ion
selective electrode. The results are shown in Table 15. Two way
analysis of variance, Duncan's multiple range test and a one way
analysis of variance were performed on these results. For all
groups, the sample taken 30 minutes after induction differed from
that taken at two minutes and from the pre-induction sample (p
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PRETREATMENT ONSET 0-25% (Tl) 25-75% (Tl)
(sees) (sees) (sees)
Atracurium 2.5 mg 58.08 265.56 87.04
(11.32) (65.65) (33.37)
Atracurium 5 mg 79.68* 166.28* 81.14
(22.68)* (87.54)* (23.97)
Fazadinium 3.75 mg 57.5 264.57 98.18
(8.65) (90.47) (47.80)
Saline 55.2 430.33* 107
(14.28) (116.75)* (40.02)
* P = 0.01
Table 12
Mean onset and recovery times of neuromuscular block following
pre-treatment and suxamethonium 1 mg kg -1.
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Jaws Cords Reaction to
Intubation
Relaxed Not Not Moving Absent Present
Relaxed Moving
Group A 24 1 21 4 15 10
Group B 22 3 18 7 13 12
Group C 25 0 25 0 12 13
Group D 24 1 25 0 20 5
Table 13
Intubation conditions following pre-treatment and suxamethonium.
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Incidence at 24 Hours Incidence at 72 Hours
Group n Mild Moderate +
Severe
A 25 5 6
B 25 2 4
C 25 5 2








Incidence of pain following pre-treatment and suxamethonium.
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Pre-treatment
Group Potassium Levels (SD)
A Atracurium 2.5 mg
B Atracurium 5 mg













Potassium levels (mmol 1 -1) taken before suxamethonium (Kl) and 2
mins (K2) and 30 mins (K3) after suxamethonium
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<0.001 for both differences for all drugs) However, there was no
difference between the groups and no value exceeded the normal
range.
Discussion
Non-depolarising muscle relaxants used for the prevention of muscle
fasciculation and post-operative myalgia following the use of
suxamethonium delay the onset of paralysis and reduce its duration
of action [80, 81]. The amount of non-depolarising drug required
for this purpose remains unclear; some advocate a weight related
dose of pre-treatment drug [82] while others prefer a fixed dose
regime [78], Because of the problem of administering variable
small doses of drugs accurately, it was decided to use a fixed dose
regime and to select the dose of fazadinium which appeared from
preliminary studies to be the minimum effective in preventing
muscle fasciculations. Two doses of atracurium were compared to
determine which would be most effective.
In all cases, pre-treatment with a non-depolarising muscle relaxant
delayed the onset of paralysis produced by suxamethonium and the
duration of blockade was reduced compared to controls. These
effects were maximal with the larger dose of atracurium. In
addition, of the 100 patients studies during the pre-treatment
phase, only three, all of whom received atracurium 5 mg, developed
clinically significant neuromuscular blockade during the
pre-treatment.
It is surprising that there was no initial increase in serum
potassium following suxamethonium and curious that in all cases the
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level of serum potassium fell to below the control value at two
minutes, although this was not significant. The values at 30
minutes showed an increase to above control levels and it is
possible that the sample at two minutes was taken before an
increase in potassium would be detectable, although in all cases
paralysis had occurred.
The incidence of muscle pains following suxamethonium varies widely
and is thought to be influenced by the choice of anaesthetic, the
patient's age and sex, and by time to ambulation. These patients
would, by these criteria, be considered to be highly at risk for
developing post-operative myalgia. However, the incidence of
muscle pains was surprisingly low even in the control group (36% at
24 hours rising to 66% at 72 hours). The apparent failure of all
the pre-treatment regimens may be explained by the use of an
analgesic premedication and post-operative medication which had
largely worn off by the time of the assessment at 72 hours.
In conclusion, in this small group of subjects atracurium and
fazadinium failed to influence the incidence of muscle pains
following suxamethonium when used as part of a pre-treatment
regime. The larger dose of atracurium resulted in a shorter period
of paralysis with a delay in onset and the quality of intubating
conditions was impaired. Although there was a significant rise in
plasma potassium at the 30 minute sample when compared to the




THE EFFECT OF SUXAMETHONIUM GIVEN DURING RECOVERY FROM ATRACURIUM
While the previous study outlined the effect of a small
pre-treatment dose of atracurium on a suxamethonium block, it
occurred to the author that some anaesthetists occasionally give
suxamethonium at the end of a non-depolarising block with the
belief that they are creating a short period of increased blockade.
This study looks at the effect of suxamethonium on a recovering
atracurium block.
An alternative approach to neuromuscular monitoring, the
electromyograph was used.
Introduction
At the end of an abdominal operation, muscle relaxation may be
inadequate and a transient increase in block may be needed to
facilitate closure. Suxamethonium is the only short duration agent
currently available and has been used in these circumstances.
Whilst its interactions with long acting competitive agents have
been described [83-87], its effects on recovery from the block
produced by atracurium have not. This study was designed to assess
the effects of increasing doses of suxamethonium on the recovery of
block produced by atracurium and on the subsequent interaction with
neostigmine.
Methods
Thirty eight patients aged between 18 and 70 years and weighing
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between 45 and 110 kg were studied after they had given informed
consent. They were undergoing elective surgical procedures and
were divided into 10 sub groups. The protocol included the same
exclusion criteria as in previous studies.
Diazepam (0.1 - 0.2 mg kg -1) and metoclopramide (10 mg) were given
orally one hour before anaesthesia was induced with thiopentone
(4-6 mg kg -1) and fentanyl (2-4 ug kg -1). Anaesthesia was
maintained with nitrous oxide (66%) and enflurane (0.5%),
supplemented by additional doses of fentanyl and thiopentone as
required. When paralysed following neuromuscular blockade, the
lungs were artificially ventilated and the end-tidal carbon dioxide
tension maintained between four and five kilopascals.
The integrated rectified and gated electromyographic response of
the hypothenar muscles was recorded in response to supramaximal
train-of-four stimuli delivered to the ulnar nerve at 20 second
intervals using a Datex Relaxograph. Control values were obtained
after induction of anaesthesia but before the administration of 0.4
mg kg -1 of atracurium. Once the first twitch response of the
train-of-four (Tl) had recovered to 50% of the initial value, a
predetermined dose of suxamethonium of between 0.25 and 3 mg kg -1
was given. To mimic a possible clinical situation, in four
patients neostigmine (35 ug kg -1) was given when Tl had returned
to 25% following the initial atracurium dose and 3 mg kg -1 of
suxamethonium. Neostigmine (35 ug kg -1) was also given to some
patients in each combination group once Tl had returned to 100%
following suxamethonium. Three groups of patients were studied to
provide data for the spontaneous recovery following atracurium, for
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recovery from atracurium accelerated by neostigmine, and for
recovery from suxamethonium.
Results
Giving suxamethonium when T1 had returned to 50% after atracuriura
could produce either no response, a slight reversal of the block,
and enhancement or a combination with a biphasic response. Figure
7 illustrates some of these responses. There was a wide between
patient variability in response particularly at the lower doses.
When 0.5 and 1 mg kg -1 of suxamethonium were used the mean net
effect was one of slight reversal, whereas with doses of 1.5 mg kg
-1 and more the block was increased. Only at 3 mg kg -1 was 100%
block consistently produced: the full block then lasted on average
some eight minutes. The results are summarised in Table 16.
Table 17 summarises the recovery indices in five groups of four
patients for the final recovery phase. When atracurium was given
alone the mean recovery index (25%-75% recovery Tl) was 13.1
minutes, and when neostigmine was given at Tl of between 10-25%
this time was shortened, on average to 4.5 minutes. Suxamethonium
in a dose of 1.5 mg kg -1 given without any preceding atracurium
produced a recovery index of 3.0 minutes. When 3 mg kg -1 of
suxamethonium was given at the 50% Tl point of recovery from
atracurium, after the 8.0 minute period of complete block, the
index was 2.75 minutes. This recovery pattern resembled a
spontaneous suxamethonium recovery except that fade always
persisted following the combination block. The fade was, however,
always reversed by neostigmine administered at 100% Tl recovery.
Neostigmine also reversed fade when administered at 25% recovery Tl
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Effect of Suxamethonium
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Figure 7
Suxamethonium (2 mg kg -1) is administered at 50% T1 recovery from
an atracurium (0.4 mg kg -1) blockade. Illustrated is the
subsequent biphasic response followed by a brief period of 100%







Mean % change in T1 100%
block (± SD) block time (min)
0.25 1 0 -10
0.5 4 2 -1.25 (±10.3)
1.0 4 2 -1 (±12.5)
1.5 3 2 34 (±17.7)
2.0 6 4 40.5 (±13.5)
3.0 8 3 50*
* A 50% change in block represents 100% block of Tl.
Table 16
The effect of suxamethonium on a recovering (50% Tl) atracurium
block.
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Group no 25-75% Recovery 5-95% Recovery
(± SD) (min) (± SD) (min)
AS 4 2.75 (± 0.28) 8.25 (± 0.95)
AS + N 4 7.25 (± 3.6) 12.3 (± 5.9)
S 4 3 (± 0) 7.75 (± 0.5)
A 4 13.1 (± 1.8) 38.3 (± 7.6)
A + N 4 4.5 (± 0.57) 14.5 (± 1.73)
Key:
AS = Suxamethonium 3 mg kg -1 administered at a 50% T1
atracurium recovery
AS + N = Neostigmine administered at T1 25% recovery of a AS block
S = Suxamethonium 1.5 mg kg -1
A = Atracurium 0.4 mg kg -1




of a combination block (3 mg kg -1 suxamethonium), but lengthened
the mean recovery index to 7.25 minutes and in one case transiently
increased block by 10% prolonging the 5-95% recovery time to 19
minutes. Thus, the recovery index was fastest after suxamethonium
alone or when suxamethonium was used to potentiate the atracurium
block. The addition of neostigmine as an extra reversal agent
slowed recovery. Suxamethonium given after atracurium never
produced muscle fasciculations.
Piscussion
This study was designed to mimic a clinical problem The relaxation
produced by atracurium was allowed to wear off to a point at which
T1 had recovered to 50% and where all four responses to
train-of-four stimulation were apparent. This level is usually too
light to allow closure of the abdomen without deep general
anaesthesia, and the clinician needs to intensify the block. One
clinical approach is to use a small dose of suxamethonium for this
rather than give an increment of a long acting competitive blocker.
Our results show that low doses of suxamethonium may antagonise the
partial block seen during the recovery from atracurium, but that
larger doses will usually enhance the block. The subsequent
recovery pattern of a combination block is faster than that seen
with atracurium alone or when antagonised by neostigmine. However,
during the recovery of a combination block, fade of the
train-of-four response is seen. Similar results have been reported
with the interaction of suxamethonium with longer acting
competitive blocking drugs [83-87]. Young [86] and Walts [83]
demonstrated similar patterns of dose related effect with
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tubocurarine as did Katz [85] for pancuronium. The biphasic
pattern has been described by Walts [83] and in more detail by
Buzello and his colleagues [87]. This last study demonstrated that
with a constant dose of suxamethonium (0.5 mg kg -1) the
proportional relationship between reversal and subsequent increase
of blockade depends on the stage of recovery from non-depolarising
neuromuscular blockade at the time of suxamethonium administration.
Gray [84] and Young [86] have reported similar findings with other
drugs.
What are the mechanisms which produce these interactions? The
traditional view would be that atracurium produces mainly a
competitive block of the post-synaptic receptors. Such a block can
be overcome by increasing the concentration of agonist usually in
clinical practice by the anticholinesterase action of neostigmine.
However, suxamethonium also acts as an agonist and interacts with
the post-synaptic receptors leading to the opening of ionic
channels and a depolarisation of the membrane. This in turn may
initiate the muscle action potential and the contraction. If the
amount of suxamethonium is too great the depolarisation is
maintained and the muscle membrane becomes unexcitable. Hence low
doses could act as agonists, but larger ones as the depolarisation
develops will produce a block. During recovery from the
combination block we still need to explain why the recovery index
is quicker, why neostigmine slows it and why fade of the
train-of-four response persists. Again the traditional views of
neuromuscular block can offer explanations. The enhanced recovery
index by itself is somewhat of a red herring. It is likely that
what we are observing is a simple competitive displacement by the
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law of mass action at the post-junctional receptor. The dose
response curve of suxamethonium is shifted to the right because of
the presence of atracurium molecules on the receptor. It appears
from Buzello's study that when suxamethonium is administered during
a pancuronium recovery phase, 100% T1 recovery was not achieved at
30 minutes following suxamethonium when administered at 25% or 75%
recovery of Tl. In this study every patient had recovered to 100%
T1 from a combination (3 mg kg -1 suxamethonium) block within 20
minutes of administration of suxamethonium. This observation
supports the above hypothesis. As suxamethonium is catabolised and
the local concentration declines at the end plate the
post-junctional receptors could again be occupied by the longer
acting pancuronium molecules, which are eliminated more slowly.
This does not occur with the intermediate duration drug atracurium
because elimination is occurring more rapidly than with pancuronium
during the time suxamethonium is being hydrolysed. Thus, the fast
recovery index reflects the fact that most of the block will be due
to suxamethonium. The fact that neostigmine slowed recovery after
suxamethonium may be due to its effect on plasma as well as acetyl
cholinesterase delaying the breakdown of suxamethonium.
Fade is now believed to be due either to a block of pre-junctional
acetylcholine receptors by competitive drugs or to a use-dependent
post-junctional ion channel occlusion [45]. However, the latter
hypothesis ignores the findings of Hutter [88] and Otsuka [89] and
colleagues that tubocurarine induced fade is associated with a
diminished acetylcholine release, and certainly the evidence from
drugs used in clinical circumstances favours the first of these two
mechanisms. The fade demonstrable during the recovery from
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suxamethonium following atracurium is most probably accounted for
by the residual pre-junctional action of atracurium. It could be
due to the development of a phase 2 [90] blocK by suxamethonium but
this would seem unlikely with the rapid recovery time.
Furthermore, neostigmine did not shorten the recovery time and on
one occasion actually increased block adding substance to the
hypothesis that a depolarising block is present. In any case all
these explanations are speculative, especially with the
difficulties inherent in comparing the evoked electromyographic
responses demonstrable in man with the precise studies now possible
in the laboratory. A detailed study of the interactions would
presumably need voltage [91] and patch clamp studies to ascertain
which effects are due to interaction with the acetylcholine
receptor on the muscle and which to effects on the nerve terminals.
Although we did not see a prolonged block when suxamethonium in a
dose of 3 mg kg -1 was given after recovery from atracurium to a
50% T1 level, we would not recommend giving such a dose to enhance
muscle relaxation in clinical practice unless a peripheral nerve
stimulator was used to monitor the degree and duration of block.
If such a technique was used then neostigmine appears not to
accelerate the subsequent recovery and should not be used. It is
important to remember that we gave the suxamethonium at the 50% T1
point at which time all four responses to train-of-four stimulation
were present. An alternative clinical solution would be to
increase the block with a small increment of atracurium. The
intensity, duration and subsequent recovery of the block would then
obviously depend on the size of dose used. A laboratory model may
elucidate the events at the neuromuscular junction.
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CHAPTER 7
CONTINUOUS INFUSION OF ATRACURIUM: DOSAGE TIMING AND ANTAGONISM OF
RESIDUAL BLOCKADE
The speed of onset of atracurium and its cardiovascular effects in
particular in relation to histamine release have been examined.
The next study examines the cumulative potential of atracurium, its
dissipation of action following single bolus doses and infusions,
and its ability to be antagonised by an anticholinesterase. Since
atracurium has a relatively short duration of action and in animal
studies has been shown to have a low propensity for cumulation,
this would seem to make it an ideal agent for administration by an
infusion technique.
Initial studies by Basta et al [47] and Payne and Hughes [34]
showed lack of cumulation, ie repetitive bolus injections of
identical doses resulted in neuromuscular blockade of unvarying
depth and duration. Bolus doses require to be given relatively
frequently because atracurium has an intermediate duration of
action and this might be considered an inconvenience during long
operations.
In this study, in order to achieve a stable level of surgical
relaxation without the inconvenience of frequent dosing atracurium
was administered as a continuous infusion. The aims of this
investigation were (1) to evaluate a large number of patients
receiving atracurium by infusion in order to establish limits for
infusion rates necessary to provide levels of neuromuscular
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blockade which are usually consistent with good clinical relaxation
(90-99% twitch depression); (2) to ascertain whether or not a
cumulative property might be evident during infusion; and (3) to
determine ease of antagonism of residual blockade by neostigmine
after termination of the infusion. For the purpose of this study
evidence of a lack of 'cumulative effect' was defined as (a)
maintenance of a constant percentage twitch inhibition for a period
of 30-60 minutes or more without alteration of atracurium infusion
rate; and (b) 5-95 and 25-75% twitch recovery times after
termination of infusion which were comparable to times recorded
after single bolus doses of drug.
Methods
One hundred and twenty nine ASA Class 1 or 2 patients, 19-59 years
of age undergoing elective surgery, gave institutionally approved
written informed consent. All subjects were premedicated with
morphine (0.1 - 0.15 mg kg -1) i.m. and diazepam (0.1 - 0.2 mg kg
-1 P0) one hour before surgery. Neuromuscular function recording
was begun under local anaesthesia at least five minutes prior to
induction of general anaesthesia. Single twitch responses of the
adductor pollicis stimulated through 23 gauge steel needle
electrodes at 0.15 Hz were evoked via the ulnar nerve at the wrist
using square wave pulses 0.2 milliseconds in duration, which were
generated by a Grass S 88 stimulator through an isolation unit.
Mechanical responses of the thumb were recorded on a Grass model 7
polygraph.
Anaesthesia was induced with thiopentone (5 mg kg -1) i.v. and the
trachea was intubated after an intravenous bolus of atracurium
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(0.3, 0.4 or 0.5 mg kg -1). Ventilation was controlled to keep end
tidal C02 within normal limits. Anaesthesia was maintained using
nitrous oxide and oxygen (4 litres - 2 litres) in a semi-closed
system with additional morphine, fentanyl and/or thiopentone given
i.v. as needed to maintain stable cardiovascular responses.
Automated oscillotonometric blood pressure (Dinamap) and the
electrocardiogram were also monitored.
Forty four patients received a single dose of 0.3 (n=18), 0.4
(n=13) or 0.5 (n=13) mg kg -1 atracurium. The block was allowed to
recover spontaneously.
Eighty five additional subjects received an initial bolus of 0.5 mg
kg -1 atracurium followed by an infusion begun when twitch height
had recovered to 5% of base line. Atracurium was diluted in 5%
dextrose in water at a concentration of 0.5 mg ml -1, the infusion
rate was always set initially at 10 ;ug kg -1 minute -1 and was then
adjusted upward or downward to maintain 90-99% suppression of the
twitch. The infusion rate was controlled by an Imed volumetric
infusion pump. Duration of atracurium administration was measured
from the initial 0.5 mg kg -1 bolus to the termination of the
infusion.
Fifty-five of the 85 patients who received atracurium infusions
were allowed to recover spontaneously from neuromuscular blockade
after the infusion was discontinued. Measurements were made of:
(a) recovery from 5-95% twitch height, and (b) recovery from 25-75%
twitch height. This group was further subdivided into patients
receiving long infusions (greater than 120 minutes: n=33) or short
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infusions (less than 120 minutes: n=22). Recovery rates were
compared in these two sub groups. In the 30 additional patients
who received atracurium infusions, residual block was antagonised
5-15 minutes after termination of the infusion by administering
neostigmine (60 ug kg -1) together with atropine (30 ug kg -1) as a
slow (one minute) i.v. bolus.
In all patients a steady state infusion rate (SSIR) was calculated
over the last 30-60 minutes of the atracurium infusion. During
this period the infusion rate was not altered.
Results were compared with students T test by analysis of variance
and by linear regression. Statistical comparisons were considered
to show significant differences if p <0.05.
Results
The results are summarised in tables 18 to 20. The duration of
infusion of atracurium varied from 58 to 416 minutes (mean 142.3
minutes). The steady state infusion rate for all patients who
received infusions was 7.9 ± 0.4 ;ug kg -1 minute -1. Neuromuscular
blockade was maintained at 90-99% twitch suppression during this
time interval.
The spontaneous recovery rates following discontinuation of the
atracurium infusion were compared with those obtained following
single bolus doses of 0.3, 0.4 and 0.5 mg kg -1 atracurium (Table
18). Both 5-95% and 25-75% recovery rates showed no statistically
significant differences between patients who received infusions or
single bolus doses. In those patients with greater than 5% twitch
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Recovery Rates (min ± SE)
Dosage Group No 5-95%* 25-75%*
Infusion 55 27.7 ± 0.9 (NS) 12.0 ± 0.5 (NS)
0.3 mg kg -1 bolus 18 27.1 ± 1.7 (NS) 11.1 ± 0.8 (NS)
0.4 mg kg -1 bolus 13 28.2 ± 2.2 (NS) 11.9 ± 1.0 (NS)
0.5 mg kg -1 bolus 13 28.8 ± 2.5 (NS) 11.5 ± 1.1 (NS)
* Twitch heights, expressed as percentage of control values
(NS) = Not significant
Table 18
Comparison of spontaneous recovery from atracurium given by
repetitive bolus or by infusion
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n Duration of SSIR* Recovery Rate (min) ± SE
Infusion (/zg/kg/min) 5-95% 25-75%
(min ± SE) ± SE
22 92.1 ± 4.4 8.4 ± 0.5 26.5 ± 1.2 11.3 ± 0.7
(58.2 - 117.5)
33 175.8 ± 8.0 7.7 ± 0.4 28.7 ± 1.3 12.6 ± 0.7
(121.2 - 415.7)
(p > 0.2) (p > 0.2) (p > 0.2)
*SSIR = Steady State Infusion Rate necessary to maintain 90-99%
twitch inhibition
Table 19
Recovery rates following long and short atracurium infusions.
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Group no Recovery Time (min ± SE)
from 25 to 95% twitch height
Induced recovery*
Spontaneous recovery
13 7.0 ± 1.2
55 18.1 ± 1.2
(p < 0.01)
♦Reversal with neostigmine (60 ng kg -1) and atropine (30 ng kg -1)
Table 20
Comparison of induced* versus spontaneous recovery from atracurium
infusion
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recovery at the end of infusion only 25-75% recovery rates were
measured.
Using linear regression analysis no relationship could be found
between the duration of atracurium infusion and the spontaneous
recovery rates (Figure 8, p > 0.1 for both 5-95% and 25-75%
recovery times).
Comparisons were made of spontaneous recovery rates and steady
state infusion rates (SSIR) after infusions lasting less than and
more than two hours (Table 19). There were no statistically
significant differences (p > 0.2).
In 30 patients residual atracurium blockade was readily antagonised
(Figure 9) with neostigmine (60 ug kg -1) and atropine (30 fig kg
-1). In eight of these subjects reversal took place at similar
depths of block (mean 75.6% twitch suppression). In these patients
the average time from neostigmine injection to recovery of twitch
to 95% of control was 7.1 minutes. Comparative data for patients
receiving repetitive bolus increments of atracurium in a study by
Basta et al [47] showed a mean reversal time of 8.2 minutes, when
the identical neostigmine dose (60 ug kg -1) was given at a similar
block depth of 75.3% twitch suppression. The difference is not
statistically significant.
Discussion
A lack of cumulative property during atracurium blockade is
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Figures 8A and 8B
Linear regression analysis comparing 25-75% recovery interval (A)
and 5-95% interval (B) with duration of atracurium infusion. Speed
of recovery was not related to duration of infusion in either case.
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NEOSTIGMINE ANTAGONISM OF RESIDUAL ATRACURIUM BLOCK
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Figure 9
Scattergram relating speed of reversal to depth of block after
atracurium infusion. Each dot is a single patient in whom
atracurium infusion was stopped 2-15 minutes beforehand. At
time 0, each patient received neostigmine (60 /zg kg -1) and
atropine (30 /zg kg -1) together as one bolus i.v. The general
pattern is similar to that seen after reversal of atracurium and
other non-depolarising relaxants administered as repetitive
boluses; speed of reversal is inversely related to depth of block
at time of reversal.
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1. Achievement of constant infusion rates of atracurium.
2. Maintenance of stable levels of neuromuscular blockade.
3. Demonstration that spontaneous recovery rates after
termination of infusions are unrelated to duration of
infusion.
Until the advent of the intermediate acting non-depolarising muscle
relaxants, suxamethonium had been the only relaxant commonly used
as an infusion during operations of relatively short to moderate
duration. During infusion the characteristics of a suxamethonium
induced neuromuscular blockade often change from an initial
depolarising phase (phase 1) to a second phase which shows
monitoring characteristics (fade of train-of-four response or of
tetanus) which resemble a non-depolarising block. This is called
phase 2 block. The simultaneous occurrence of tachyphylaxis with
phase change was seen consistently in studies by Lee et al [92] and
Donati and Bevan [93, 94] using suxamethonium under enflurane,
isoflurane, and halothane, and by Ramsey [90] et al under balanced
anaesthesia.
In 25% of the subjects studied by Ramsey et al phase 1 block
persisted throughout the infusion even after some subjects received
up to 17 mg kg -1. In the remaining 75% of the subjects phase 2
(train-of-four ratio less than 0.5%) developed in every individual.
One half of these patients (12 out of 24) showed very slow recovery
after the infusion was stopped with diminished twitch strength and
train-of-four fade persisting for 30 minutes or more. Neostigmine
antagonism of residual phase 2 block was uniformly successful in
these individuals. Most importantly Ramsey et al found that (1)
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speed of recovery from phase 2 block was unrelated to dose of drug
or to duration of infusion and (2) tachyphylaxis was evident in 25%
of all patients studied.
These observations of Ramsey et al demonstrate classical clinical
difficulties with suxamethonium infusions: (1) change in character
of the block, (2) tachyphylaxis, (3) unpredictably slow recovery in
a high percentage of subjects (33%). In addition, the clinical
management of slow recovery from suxamethonium during well
established phase 2 block is still somewhat controversial. While
antagonism of phase 2 block using anticholinesterase agents is
often successful this type of block must be clearly identified
before reversal is attempted. Furthermore, at least 10-20 minutes
should have elapsed from termination of the suxamethonium infusion
to injection of reversal agents. This waiting period allows plasma
suxamethonium levels to diminish thus avoiding possible inhibition
of suxamethonium hydrolysis by anticholinesterase drugs [93, 94,
95]. For these reasons, suxamethonium infusions are usually
maintained for no more than one hour and total dosage is kept under
10 mg kg -1. These difficulties contrast markedly with the
unchanging characteristics of an atracurium block and the ease of
clinical management of an atracurium infusion.
Since atracurium is a non-depolarising substance neuromuscular
blockade retains this mechanism throughout the infusion with the
advantages of lack of tachyphylaxis or cumulative effect and an
unvarying infusion rate once a steady state is achieved. In
addition, the non-depolarising nature of the block ensures that
antagonism of residual blockade with anticholinesterase agents may
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be elected at any time after the infusion is terminated. Reversal
then should proceed along a time course similar to reversal of
atracurium block where intermittent bolus doses were given [47].
Some studies of vecuronium infusions [96] also suggest that
relatively constant levels of neuromuscular blockade may be
maintained without tachyphylaxis or cumulation. Mean 25-75%
recovery times were longer following vecuronium infusion when
compared to bolus administration and 25-75% recovery times which
averaged 26 minutes after infusion seemed longer than after
atracurium infusions. In a more recent study however by Gramstad
and Lilleaasen [97], a prolonged 25-75% recovery index was not
observed after vecuronium infusions in young healthy patients.
Vecuronium infusions may exhibit age dependent dose responses.
D'Hollander et al [98] studied the pharmacodynamics of vecuronium
infusions under balanced anaesthesia. Three groups of patients
were studied: under 40 years of age, 40-60 years of age and over 60
years old. The infusions lasted at least 90 minutes and infusion
rates were adjusted to maintain 10% of control twitch height.
Significant decreases in steady state infusion rate and increases
in 25-75% recovery time were observed in patients more than 60
years old. In a comparative study of atracurium [99] under similar
conditions no age differences were noted.
D'Hollander's findings suggest that age related decreases in the
function of the organs of elimination may lower the maintenance
dose requirements and slow the speed of recovery from muscle
relaxants such as vecuronium which are eliminated by the kidneys or
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liver. These parameters seem less affected by age when atracurium,
which undergoes extensive decomposition, is infused.
As with any other relaxant the wide individual variation in steady
state infusion rate for atracurium emphasises the importance of
objective monitoring of neuromuscular blockade during infusions.
Monitoring should provide finer adjustment of depth of
neuromuscular blockade and should also confirm return of normal
function following spontaneous or induced recovery (reversal).
Because of the relatively rapid spontaneous recovery rates after
termination of atracurium infusions normal neuromuscular function
may often be restored without the need for anticholinesterase
drugs.
When reversal is necessary, however, the pattern of antagonism of
residual block following an atracurium infusion seems similar to
antagonism of atracurium following repetitive bolus administration.
The pattern also seems to be similar to neostigmine antagonism of
the long acting agents metocurine, tubocurarine and pancuronium.
Although Katz [100] administered less neostigmine (2.5 mg per
subject or approximately 35 fig kg -1) than was given in the present
study, time for reversal was directly related to the depth of block
at the time of neostigmine injection, ie reversal at deeper levels
of block occurred more slowly than at shallow levels. Patients
showing 90% or more twitch inhibition required as long as 15-25
minutes for full reversal. Savarese, Ali and Antonio [101] found
that when neostigmine 50 ug kg -1 was given to patients showing 79%
twitch inhibition by metocurine, reversal took place within 7.6
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minutes. This timing does not differ significantly from data for
atracurium reversal presented in this study or previously by Basta
et al [47].
In summary, atracurium produces 90-99% single twitch suppression
under balanced anaesthesia at an average steady state infusion rate
of 7.9 H9 kg -1 minute -1. Spontaneous recovery intervals after
infusion are comparable to intervals observed after single bolus
doses of 0.3, 0.4 or 0.5 mg kg -1. Length of atracurium infusion
does not seem to influence recovery time or steady state infusion
rate. Reversal of residual block following termination of
atracurium infusion requires similar neostigmine dosage and timing
as reversal following bolus administration at a comparable depth of
block. The administration of atracurium by infusion is readily
accomplished and may be advantageous under certain clinical
circumstances where steady depth of relaxation might be important
for periods of one hour or more.
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CHAPTER 8
PHARMACOKINETICS AND PHARMACODYNAMICS OF ATRACURIUM DURING
ISOFLURANE ANAESTHESIA IN NORMAL AND ANEPHRIC PATIENTS
In this study, atracurium will be assessed in relation to the final
characteristic of an ideal muscle relaxant outlined in the
introduction to this thesis; that is the ability to be used without
change in dosing technique in patients with renal disease.
While Hofmann elimination has been considered to be the main
breakdown process for atracurium more recent work has suggested
that enzymatic hydrolysis by nonspecific plasma esterases is also
involved and may be of even greater importance [102, 103]. Studies
in animals [104, 105] and humans [106-108] have confirmed that both
pathways are responsible for deactivating pharmacologically
atracurium in the systemic circulation. Consequently, normal
kidney function may not be essential for elimination of atracurium.
This study evaluates the pharmacokinetics and pharmacodynamics of
atracurium in normal and anephric patients under isoflurane
anaesthesia.
Methods
Sixteen patients gave informed consent to the study which received
prior approval from the local institutional Review Board. Eight
patients (ASA Class 1 or 2) with normal renal function served as
the control group. Eight patients (ASA Class 2 or 3) without renal
function served as the anephric group. All patients in the
in
anephric group were scheduled for elective kidney transplant and
were haemodialyzed within 24 hours prior to surgery. Premedication
consisted of 5-10 mg diazepam orally one hour prior to surgery.
Anaesthesia was induced with 4 mg kg -1 thiopentone and tracheal
intubation was performed under 0.75 - 2.0% isoflurane and nitrous
oxide/oxygen anaesthesia without the use of muscle relaxants.
Ventilation was controlled and anaesthesia maintained with 0.8%
isoflurane in 60% nitrous oxide and 40% oxygen. The PC02 was
maintained between 4-5 kPa as measured by end tidal capnometry, and
oesophageal temperature was maintained within 35-37°C.
Neuromuscular function was measured by recording the force of
contraction of the adductor of the thumb with a Grass FT 10 force
displacement transducer. Supramaximal single twitch stimuli of
0.15 Hz were used to indirectly stimulate the ulnar nerve at the
wrist using subcutaneous electrodes.
After stabilisation of vital signs and the twitch response
atracurium 0.5 mg kg -1 was injected over 20 seconds. Blood
samples for determination of plasma levels of atracurium were drawn
2, 4, 6, 8, 10, 15, 20, 25, 30, 45, 60, 75, 90 and 120 minutes
later. Samples were handled and analysed according to a
modification [109] of the method of Neil and Jones [110]. One of
the difficulties in measuring atracurium concentration in the
systemic circulation is the continuous decay of atracurium in
plasma outside the body unless preventative steps such as
acidification and freezing to -20*C are not performed rapidly. The
plasma of each blood sample was immediately separated from the red
cells by centrifugation in an Eppendorf 5414 bench model and
transferred into glass vials pre-rinsed with 0.1 N1HC1. The plasma
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samples were then embedded in dry ice to facilitate quick freezing.
The sensitivity of the assay was 10 mg ml -1. The plasma
atracurium concentration versus time data was fitted to a
biexponential equation that describes a two compartment
pharmacokinetic model with input into the central compartment and
elimination from both compartments. The computer programme NONLIN
was used in the curve fitting procedure yielding values for four
pharmacokinetic parameters (A, a, B and B). The a and (3 half lives
were calculated by the relationship of 1 n 2 divided by the
macroscopic rate constants (a and B) respectively. The clearance
(CL) was calculated from the dose area relationship and the volume
of distribution (Vd B) was calculated by taking the ratio between
CL and B. Onset, duration and recovery times were measured from
the twitch recordings. In the statistical analysis students T test
was used and p <0.05 was considered statistically significant.
Results
The mean plasma decay curves for atracurium in normal and anephric
patients are shown in figures 10 and 11 respectively. There were
no differences between the two groups in the major pharmacokinetic
parameters as can be seen from Table 21. Similar results were
obtained in the comparison of pharmacodynamic data in the two
groups (Table 22). Onset, duration of action and recovery time
were almost identical in the two groups and parallel the behaviour
of the pharmacokinetic parameters. This observation is further
supported by plotting the plasma levels of atracurium versus twitch
suppression during the elimination phase of the injection. The
similarity of the two families of curves in both normal and
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Figure 10
Plasma concentration of atracurium measured 2 - 120 mins after
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Figure 11
Plasma concentration of atracurium measured in anephric patients
(n=8) 2 - 120 minutes after injection of 0.5 mgs at time zero. The
exponential decay of the concentrations show that atracurium is
virtually eliminated from plasma after 50 minutes.
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Normal Anephric
Parameter Units Mean SEM Mean SEM
A ng ml -1 8770 1620 7960 2190
a min -1 0.30 0.03 0.30 0.07
B ng ml -1 2500 210 2100 410
B min -1 0.04 0.002 0.04 0.004
t\B min 16.9 0.8 21 .1 2.5
VI L kg -1 0.05 0.007 0.10 0.028
CI ml min kg 5.93 0.64 6.89 0.71
VDB L kg -1 141.9 12.3 211.8 31.0
A - zero time intercept
a - rate constant (distribution phase)
B - zero time intercept
B - rate constant (elimination phase)
t%B - half 1ife
VI - volume of distribution
CI - clearance
VDB - volume of distribution (steady state)
Table 21
Pharmacokinetic parameters derived from a two compartment model.
There are no statistically significant differences between the
normal and anephric group.
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Parameters Normal Anephric
(min ± SD) (min ± SD)
Onset 2.3 ± 0.9 2.7 ± 0.9
(inj ->• max block)
Duration 38 ± 8 37 ± 9
(inj -» start recovery)
Duration 52 ± 10 52 ± 9
(inj -*• 25% twitch recovery)
Duration 72 ±17 73 ± 14
(inj -► 75% twitch recovery)
Duration 80 ±18 80 ± 10
(inj 95% twitch recovery)
Duration 21 ± 8 21 ± 10
(25% -> 75% twitch recovery)
Table 22
Pharmacodynamic parameters after a single bolus injection of 0.5 mg
kg -1 atracurium i.v. to normal and anephric patients. (There are










Recovery of twitch suppression during the elimination phase of
atracurium from plasma in normal and anephric patients. Each curve
represents the data points collected from individual patient. The
similarity of the two families of curves show that the potency of
atracurium is no different in normal and anephric patients.
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is no different either in normal or in anephric patients.
Discussion
This study demonstrates that during isoflurane anaesthesia renal
function has no specific effect on uptake, distribution and
elimination of atracurium. The kidney plays no significant role in
the rate of decline of plasma concentration of atracurium following
a single injection. A two compartment pharmacokinetic model with
elimination from both compartments was used to describe the
pharmacokinetic behaviour of atracurium because the drug is
eliminated by two processes (ester hydrolysis catalysed by
nonspecific esterases and degradation via Hofmann elimination) that
take place in the systemic circulation and the tissues
simultaneously. Although it was feasible to determine the
macroscopic rate constants (a and B), the microscopic rate
constants (k 12, k 21, k 10 and k 20) and the volume of
distribution at steady state (VDSS) could not be determined because
these latter parameters were interdependent on each other
mathematically. The remaining pharmacokinetic parameters (eg,
clearance, half life and volume of central compartment) so obtained
are useful to clinicians for estimation of dosage scheduling and
for the determination of infusion rates for use in surgical
procedures. Attempts to fit simultaneously the twitch and plasma
atracurium data to the Hill equation were unsuccessful because the
best approach to such an analysis would require a constant rate
infusion of the drug for 10-20 minutes with frequent collection of
blood samples and twitch data during this period.
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The pharmacokinetics of atracurium were first described by Ward et
al [106] in healthy anaesthetised patients and subsequently in
patients [107] with severe hepatic and renal disease. The results
of our study in anaesthetised patients are similar. Our data
obtained during isoflurane anaesthesia also confirmed the
observation of Fahey et al [108] during halothane anaesthesia that
the pharmacokinetics and pharmacodynamics of atracurium in anephric
patients are no different from normal patients.
It is recognised that the pharmacodynamics of neuromuscular
relaxants may be affected by volatile anaesthetic agents. Thus
before the injection of atracurium the concentration of isoflurane
to each patient was adjusted so that there was no somatic response
to the incision. Thereafter during maintenance of anaesthesia the
isoflurane concentration was kept constant at about MAC. This
satisfied the clinical needs of the patients within the constraints
of the study. Not surprisingly patients given slightly higher
concentrations of isoflurane showed somewhat slower recovery of
twitch suppression but the mean values for both groups were not
significantly different.
This study demonstrated that anephric patients distribute and
eliminate atracurium in a similar manner to normal patients.
Pharmacodynamic measurements show almost identical times for
duration and recovery from neuromuscular blockade in normal and
anephric patients under isoflurane anaesthesia. This study
confirms previous observations that atracurium appears to be a
neuromuscular blocking agent well suited for administration to
patients in renal failure.
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CHAPTER 9
THE RESPONSE OF ATRACURIUM TO MYASTHENIA GRAVIS
Patients with myasthenia gravis are generally believed to have
increased sensitivity to non-depolarising muscle relaxants. Some
authors, however, do not agree with this conclusion. For example,
two clinical reports describe the response of myasthenic patients
receiving steroids and pyridostigmine therapy. In the first the
author concluded that myasthenic patients are quite sensitive to
tubocurarine and require greatly reduced doses [111], but in the
second report the authors did not find an increased sensitivity to
tubocurarine [112]. Other authors [113] reported on the use of
very small doses of pancuronium 5.0 ug kg -1 which produced 90%
twitch suppression with uneventful recovery. On the other hand
resistance and early appearance of phase 2 block have been reported
following the administration of suxamethonium [114]. More
recently, the use of atracurium has been reported in six patients
with myasthenia gravis [115-117]. The unique mode of elimination
of atracurium may offer an advantage over the previously available
long acting muscle relaxants.
This review presents two additional case reports of the anaesthetic
management of myasthenic patients using atracurium. These findings
are compared with previous reports.
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Report of Two Cases
Case 1
A 64 year old woman weighing 76 kg was scheduled for an elective
sigmoid colectomy for diverticulitis. She presented with a two
year history of myasthenia gravis manifesting bulbar symptoms and
progressive limb weakness. She was diagnosed in 1982 with
electromyography and a positive edrophonium test. The patient also
had a history of hypertension and insulin dependant adult onset
diabetes mellitus. Initially, treatment with pyridostigmine led to
an improvement. However, increasing gastrointestinal symptoms as
well as dysphagia and a possible history of aspiration of gastric
contents resulting in her physician prescribing a regime of
steroids and reducing the dose of pyridostigmine which was stopped
in January 1983. The patient underwent plasmapheresis in August
1983 and experienced a marked improvement of her symptoms. Upon
admission her pulmonary function tests were 85% of normal with a
vital capacity of 2.5 litres. Prior computerised axial tomography
and chest X-rays showed no evidence of thymoma. Her prednisolone
dosage had been increased to 12 mg per day. Pre-operatively she
received 5 mg diazepam PO, 30 units of NPH insulin subcutaneously
and 100 mg hydrocortisone i.v. Anaesthesia was induced using a
total of 300 ug fentanyl, 10 mg diazepam and 200 mg thiopentone
intravenously.
Force of thumb adduction was monitored in response to ulnar nerve
stimulation (0.2 milliseconds at a frequency of 0.15 Hz) at the
wrist via two percutaneous needle electrodes using a Grass FT10
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force transducer and a Grass polygraph. Incremental doses of
atracurium 0.065 mg kg -1 (5 mg) were given every four minutes
until the twitch height was depressed to 5% of control. A total
dose of 25 mg (0.33 mg kg -1) was required to achieve 95%
depression of the control response (Figure 13). Two incremental
doses of atracurium 5.0 mg each were given further as clinically
indicated over the next hour. One hour after induction of
anaesthesia halothane was added at an inspired concentration of
1.0% and up to 20 mg hydralazine was given to control hypertension.
After the last 5 mg dose of atracurium the twitch was allowed to
recover spontaneously to 95% of control. Arterial pH was
maintained between 7.43 and 7.46 with a PaC02 between 4-5 kPa.
Serum sodium and potassium concentrations were normal and blood
sugar was 233 mg dl -1. The 5-95% recovery time was estimated to
be 83 minutes. The recovery index (25-75% recovery time) was 32
minutes (Figure 13). Four hours after induction of anaesthesia
clinical relaxation was again required and further incremental
doses of atracurium to a total of 20 mg were given over the next
half hour without complete ablation of the first twitch of the
train-of-four. The operation ended six hours after induction of
anaesthesia and the patient was taken to the Intensive Care Unit.
She was arousable and had a tidal volume of 300 ml. During the
following hour she became more alert and her tidal volume increased
to 400 ml with a vital capacity of 1600 ml and a negative
inspiratory pressure of 40 cm H20.
Decreasing rates of intermittent mandatory ventilation (IMV) were
instituted followed by a trial of spontaneous ventilation with
continuous positive airway pressure (CPAP). Four and a half hours
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Evoked thumb adduction in response to ulnar nerve stimulation at
0.15 Hz. Upper panel de monstrates the response to five increments
of atracurium of 0.065 mg kg -1 each. In the second panel, two
further increments of 0.065 mg kg -1 were given 15 minutes after
the arrow, (denoting 5%), with minimal effect. At the second arrow
(7.5%) spontaneous recovery was allowed to occur. The following
three arrows denote 25, 75 and 95% recovery of the single twitch
compared with the control. Note at the end of the last panel
(right side) train-of-four response showed almost complete
recovery.
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postoperatively her trachea was extubated without difficulty with a
vital capacity of 1500 ml. Postoperatively she progressed well and
was discharged on a daily dose of 12.5 mg prednisolone. Muscle
function upon discharge was reported to be good.
Case 2
A 28 year old woman weighing 60 kg presented with a three year
history of myasthenia gravis. She was admitted to undergo
trans-sternal thymectomy for treatment of her disease. At the
time of her admission the condition was well controlled with a
daily dose of 480 mg pyridostigmine and steroid therapy. She had
no bulbar symptoms or limb weakness. The night before surgery she
was given a long acting spansule containing 180 mg of
pyridostigmine. Anaesthesia was induced with 250 mg thiopentone
intravenously and maintained with 60% nitrous oxide in oxygen and
1.5% inspired concentration of isoflurane. Her trachea was
intubated without the use of muscle relaxants after spraying the
vocal cords and trachea with 4% lignocaine. Anaesthesia was
maintained thereafter with isoflurane 0.7% (end tidal
concentration) and 60% nitrous oxide in oxygen and controlled
ventilation. Thumb twitch was monitored visually in response to
ulnar nerve stimulation at the wrist via percutaneous needle
electrodes using train of four nerve stimulation. Initially 1 mg
atracurium was administered intravenously with no visible effect.
Five minutes later an additional 2 mg of atracurium was given ( a
total dose of 0.05 mg kg -1). This resulted in approximately 95%
depression of the first twitch of the train-of-four response.
Twenty five minutes later the train -of-four appeared to have
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recovered completely. Upon completion of surgery 90 minutes after
induction the patient received 10 mg pyridostigmine intravenously
and her trachea was extubated shortly thereafter in the operating
room. She was returned to the Intensive Care Unit in a stable
condition. Postoperative course was uneventful.
Discussion
Previous reports [111-113] suggest that the response of patients
with myasthenia gravis to non-depolarising relaxants (pancuronium
and tubocurarine) is variable, probably depending on the stage of
the disease, preoperative control and whether the patient is in
remission. The use of atracurium has been reported previously in
six myasthenic patients. In the first report [115] approximately
0.18 mg kg -1 of atracurium administered incrementally was required
to suppress the evoked twitch tension to 95% of control response.
In the second report [116] a total dose of 0.25 mg kg -1 atracurium
given in three increments was required to depress the evoked
compound action potential of the adductor pollicis muscle to 90% of
control and 0.1 mg kg -1 in the third report [117]. In this
report, the dose required to suppress evoked thumb adduction varied
between 0.33 and 0.05 mg kg -1 respectively. It appears that as
with other non-depolarising relaxants, the response of myasthenic
patients to atracurium (onset and depth of block) is variable. In
three of eight patients who received atracurium the ED95 (the
effective dose to 95% twitch suppression) was not different from
that reported in normal non-myasthenic patients [34, 47] (0.2 mg kg
-1). The important finding in these reports is that the myasthenic
patients who were given atracurium recovered spontaneously from
their neuromuscular blockade within a relatively short time. In
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our first case the recovery index (25-75% recovery time) and the
5-95% recovery time were 32 minutes and 83 minutes respectively
compared with approximately 12 minutes and 30 minutes respectively
in normal patients [47]. The recovery time was shorter in the
other myasthenic patient. This relatively rapid spontaneous
recovery from atracurium neuromuscular blockade as compared with
the older relaxants tubocurarine and pancuronium may be related to
its mode of biodegradation and elimination.
The 5-95% recovery time of 83 minutes in our first patient followed
a total dose of atracurium of 0.46 mg kg -1. The latter dose is
equivalent to two times the ED95 [47]. A comparable dose of
tubocurarine and pancuronium would be approximately 1.0 mg kg -1
and 0.14 mg kg -1 respectively [101]. It is conceivable that if
either of the latter two doses of tubocurarine or pancuronium were
administered to this myasthenic patient the recovery from
neuromuscular blockade would have been markedly prolonged in
comparison with atracurium. This is based on the finding that the
recovery from injection of tubocurarine 0.6 mg kg -1 and
pancuronium 0.1 mg kg -1 to only 25% of control is 80.5 ± 6.9
minutes and 99.3 ± 15.0 minutes (mean ± SEM), respectively, in
normal patients [101].
In summary, atracurium appears to be a reasonable choice for
myasthenic patients to provide surgical relaxation when clinically











BWB1090U (Figure 14) is a unique compound developed by the Wellcome
Research Laboratories in Research Triangle Park, North Carolina, in
collaboration with John J Savarese, MD, of the Massachusetts
General Hospital in Boston. Similar to several other experimental
muscle relaxants that this group has developed, it is a
bisbenzylisoquinolinium compound.
Initial pre-clinical pharmacological studies showed that BWB1090U
was a potent neuromuscular blocking agent in dogs and cats.
Complete paralysis was produced by intravenous doses of 0.02 to
0.06 mg kg -1. Onset was 3-5 minutes in the cat and dog. The time
to 95% recovery of the ED95 dose (the dose that produces 95%
suppression of the indirect twitch response) was approximately 15
minutes. These initial animal studies suggested that BWB1090U
should be classified as 'short acting' with its duration in these
animal models being approximately twice that of suxamethonium and
one half that of the intermediate duration agents atracurium and
vecuronium.
Neuromuscular blockade in the cat and dog was of the
non-depolarising type as characterised by the absence of muscle
fasciculations; the presence of tetanic fade; post-tetanic
potentiation; and antagonism of the block by acetylcholinesterase
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following termination of prolonged (1% - 3 hours) 95-100%
neuromuscular blockade produced by continuous intravenous infusion
of BWB1090U suggests that the drug exhibits no cumulative
properties in the cat or dog.
Pre-clinical animal studies also revealed that BWB1090U had no
significant cardiovascular effects at doses that produce partial to
complete neuromuscular paralysis in cats and dogs. Doses up to
15-20 times the ED95 dose were essentially devoid of cardiovascular
and haemodynamic effects in these animals.
The effects of BWB1090U on the autonomic nervous system were
evaluated in cats. Doses as high as 25-50 times the ED95 dose did
not affect the contraction of the nictitating membrane in response
to sympathetic nerve stimulation, and only minimally decreased
(less than 10% of base line values) the cardiac and vasopressor
response to parasympathetic (vagus) nerve stimulation.
Pre-clinical investigation showed that BWB1090U is a substrate for
plasma cholinesterase; hence the duration of neuromuscular blockade
may be influenced by the concentration and activity of this enzyme.
The rate of hydrolysis of BWB1090U by purified human cholinesterase
is approximately 90% of the rate of hydrolysis of suxamethonium.
It is likely that the brief action of BWB1090U may be explained by
rapid enzymatic breakdown in plasma; however, the relative roles of
the plasma, liver and kidneys in determining the pharmacokinetic
profile invivo remain to be determined. It should be noted that it
is the acetyl-choline-1ike ester of BWA1090U that permits
hydrolysis by plasma cholinesterase whereas the reversed ester
group in atracurium facilitates the Hofmann reaction.
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On the basis of these initial animal studies it was decided to
study the effects of BWB1090U in the Rhesus monkey. This animal
model probably parallels the human situation in terms of
neuromuscular blockade more closely than any other model.
Furthermore, the Rhesus monkey tends to be more sensitive to the
histamine releasing effects of neuromuscular blocking agents, the




COMPARATIVE PHARMACOLOGY OF BWB1090U IN THE RHESUS MONKEY
In this study the neuromuscular and cardiovascular effects of
BWB1090U in the Rhesus monkey arereported.
Methods
Adult Rhesus monkeys (n=6) of either sex weighing 8-13 kg were
anaesthetised with thiopentone 30 mg kg -1 and diazepam 1 mg kg -1
i.m. The trachea was intubated and anaesthesia maintained with
halothane (0.5 - 1.0%) in nitrous oxide and oxygen (70:30 ratio).
Intermittent positive pressure ventilation was instituted using a
small animal ventilator but no muscle relaxant was administered at
this stage. The peroneal nerve was stimulated by a Grass S44
stimulation unit at 0.15 Hz. A small slither of tendon was
dissected out and attached via silk to a Statham strain gauge
(Figure 15) and the force of the indirectly elicited twitch of the
tibial!is anterior muscle was measured. The intra-arterial
pressure, heart rate and single twitch were recorded on a Grass
polygraph (Figure 15). Ventilation was controlled to maintain
normal arterial gas values. Cumulative dose response curves for
neuromuscular blockade and cardiovascular effects were constructed.
Appropriate statistical comparisons were made by T test, analysis
of variance or linear regression on probit values.
In five separate experiments the neuromuscular and cardiovascular
effects of a very large dose of BWB1090U (0.2 mg kg -1 or five
times ED95) were noted when BWB 1090U was given as a first bolus to
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Figure 15A
The Grass neuromuscular nerve stimulator and polygraph used for
recording neuromuscular and haemodynamic data derived from Rhesus
monkeys.
Figure 15B
The Statham strain guage attached to a slither of tendon by silk.
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virgin preparations. Ninety five percent block was then
re-established and maintained by continuous infusion for two hours.
Recovery times from bolus doses and infusion were compared.
Results
Using a cumulative dose response approach, the ED95 was calculated
to be 0.04 mg kg -1. The duration of action at this dose was 13
minutes. At 1\ times the ED95 the duration was 17 minutes and at
five times the ED95 was 21 minutes. Onset times and recovery rates
are summarised in Table 23, specific details of the first bolus
virgin preparation study at 0.2 mg kg -1 are given in Table 24.
The continuous infusion data are reported in Table 25.
Cardiovascular changes only became significant at 0.8 mg kg -1 (20
times ED95) (Figure 16). Cardiovascular effects after five times
ED95 (0.2 mg kg -1) when given either as the fourth dose in the
series or as the first dose to a virgin preparation were not
different and did not differ significantly from control values.
However, changes at 0.8 mg kg -1 were accompanied by facial
erythema, showed tachyphylaxis and were inhibited by HI and H2
blockers.
The neuromuscular blockade showed fade of tetanus and train-of-four
which was antagonised by anticholinesterases.
Discussion
In 1979 Savarese [118] and colleagues described the pre-clinical
pharmacology in the Rhesus monkey of BW785U, a short acting
















0.01 0 - - - -
0.02 68 8 ±
0.04 1 95 1.7 3.4 8.5 13 ±
0.10 2.5 100 1.4 3.5 8.6 17 ±
0.20 5 100 1.0 4.1 9.1 21 ±
0.40 10 100 27 ±
0.80 20 100 36 ±
Table 23
Part A - BWB1090U: Neuromuscular blocking effects in the Rhesus
monkey. Single twitch stimulation at 0.15 Hz.
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68(124) 17.14 9.68 1.72 4.02 113.7 97.2
Table 24
Part B - BWB1090U: Neuromuscular effects in the Rhesus monkey.
First bolus virgin preparation study.
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Monkey 95% Blocking Rate Duration 5-95% 5-25% 25-75'
Wormtongue 9 /zg/kg/min 2 hrs 4.5 2 1.5
Wojo 13 ^g/kg/min 2 hrs 8 2 2.2
Ectasia 7 /zg/kg/min 2 hrs 12.5 2.7 3.2
Boniface 7.5 /zg/kg/min 2 hrs 15.5 3.5 6.5
Wilhelmina 17 /zg/kg/min 2 hrs 10 3 3
10.7 (± 4.2) 10.1±4.2 2.64 3.28
Table 25






















0.02 0.04 0.10 0.20 0.40 0.80
DOSE (mg/kg)
Figure 16
The effects of bolus intravenous injections of BWB1090U on mean
arterial pressure, heart rate and tibialis anterior twitch in
Rhesus monkeys anaesthetised with N20/02/halothane. The results
are expressed as a percentage of the initial control values prior
to drug treatment. The initial mean arterial pressure and heart
rate was 88 ± 4 mm Hg and 116 ± 5 bpm, respectively. Each point
represents the mean ± SE of six animals, respectively. The mean
duration of neuromuscular blockade at the 0.02, 0.04, 0.10, 0.20,
0.40 and 0.80 mg kg -1 dose was 8 ± 4, 13 ± 3, 17 ± 6, 21 ±3, 27 ±
4 and 36 ± 5 minutes.
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brief clinical trial the neuromuscular blocking activity of BW785U
was found to be very short. However, it had been noted to cause
hypotension in animals when doses equivalent or greater than the
ED95 were administered. This effect, apparently due to histamine
release, was much more prominent in humans and forced the
cancellation of further trials [30]. Additional structure activity
studies have since led to the development of BWB1090U. Like
BW785U, BWB1090U is a short acting non-depolarising agent.
From this study and other animal studies it appears that the
duration of action of BWB1090U is about one third to one half of
that of atracurium. The pharmacodynamics in the three animal
species that have been studied, namely the cat, dog and Rhesus
monkey, are similar. However, while the onset time in the cat and
dog was 3-5 minutes, in the Rhesus monkey it was only 60-70
seconds, a value approaching that of suxamethonium.
The margin of safety for cardiovascular side effects would appear
to be 10 times as great when compared with BW785U in the Rhesus
monkey. Only supramaximal neuromuscular blocking doses (0.8 mg kg
-1, 20 times ED95) of BWB1090U produced transient decreases in mean
arterial pressure and transient increases in heart rate in the
Rhesus monkey. The magnitude of these effects was less than 15% of
baseline values. It is concluded that BWB1090U has no significant
cardiovascular effects at doses that produce partial or complete
neuromuscular paralysis in cats, dogs or Rhesus monkeys.
From this study and from previous animal studies it seemed that
BWB1090U was worthy of clinical trial.
140
CHAPTER 12
NEUROMUSCULAR AND CARDIOVASCULAR EFFECTS OF BWB1090U IN
anaesthetisep volunteers
Introduction
Prior to the volunteer study pre-clinical safety studies were
carried out. These consisted of: (a) a three week assessment of
toxicity following multiple i.v. bolus and infusion doses of
bwb1090u in beagle dogs; (b) a 14 day subcutaneous toxicity study
in rats; (c) a seven day perivenous and intramuscular irritation
study in beagle dogs; and (d) a subcutaneous teratology study over
gestation days 6 to 15 in pregnant rats. No toxicopathological or
teratogenic effects related to drug administration were observed.
Pre-clinical investigation shows that bwb1090u is a substrate for
plasma cholinesterase; hence the duration of neuromuscular blockade
may be influenced by the concentration and activity of this enzyme.
It is possible that the brief action of bwb1090u may be explained
by rapid enzymatic breakdown in plasma; however, the relative roles
of the plasma, liver and kidneys in determining the pharmacokinetic
profile in vivo remain to be determined.
On the basis of the pre-clinical studies it was concluded that
bwb1090u is a neuromuscular blocking agent with potential clinical
advantages over currently available agents because of its short
action, rapid onset and lack of cardiovascular and autonomic
nervous system effects in animal models at doses within clinically
useful range. Investigation of the safety and efficacy of bwb1090u
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in clinical trials was thus considered justified.
Objectives
1. To evaluate the safety of single i.v. bolus injections of
BWB1090U and of single bolus injections followed by
continuous i.v. infusion of BWB1090U in anaesthetised
volunteers.
2. To determine whether i.v. bolus injections of BWB1090U
produce suppression of muscle twitch and to estimate the
onset, duration and dose response curve for neuromuscular
blockade.
3. To estimate the rate of i.v. infusion of BWB1090U required to
maintain 95% suppression of twitch tension for up to two
hours.
4. To estimate the rate of spontaneous recovery of
neuromuscular transmission following bolus injection and
following cessation of infusion of BWB1090U and to
determine whether neostigmine can reverse the blocking
effect of BWB1090U.
Methods
Eighteen (ASA 1) male volunteers (ages 21-40) gave institutionally
approved written informed consent. The volunteers were taking no
medications and had no significant medical or surgical history.
They received no premedication. Arterial and venous cannulae were
placed under local anaesthesia.
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General anaesthesia was induced with fentanyl (6-8 /zg kg -1) and
thiopentone (6-8 mg kg -1) and the trachea was intubated under
topical anaesthesia. Ventilation was controlled with nitrous oxide
and oxygen (4 litres to 2 litres) to maintain end tidal carbon
dioxide in the range of 4-5 k Pa. The ulnar nerve was stimulated
by needle electrodes with supramaximal pulses to elicit the single
twitch adductor response of the thumb at 0.15 Hz. A Grass S44
peripheral nerve stimulator was used. Intra-arterial blood
pressure, heart rate (by a tachograph) and single twitch were
simultaneously recorded on a Grass polygraph. After a 15 minute
stable base line period BWB1090U was injected as a rapid bolus
(5-10 seconds) into a rapidly running intravenous stream.
Volunteers number 1 and 2 received graded doses spaced 15-30
minutes apart until 10-20% depression of the twitch was achieved.
Volunteers number 3-18 each received a single bolus dose of
BWB1090U. Dosage was increased in a graded sequence in volunteers
number 3-18 from 0.04 - 0.25 mg kg -1. In volunteers numbers 7-18
a second dose of BWB1090U was given after complete recovery from
the first dose in order to re-establish full paralysis of the
twitch. When 5% twitch recovery was achieved from this dose an
infusion of BWB1090U was begun. The infusion rate was controlled
to maintain 90-95% twitch depression for 30-120 minutes. Infusion
duration (30, 60, 90 and 120 minutes) was increased sequentially in
pairs of volunteers. Volunteers number 13-18 received the longest
infusions (120 minutes). When the infusion was terminated
spontaneous recovery was observed in the odd numbered individuals.
In the even numbered volunteers antagonism of residual blockade was
tested by administering neostigmine (0.06 mg kg -1) and atropine
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(0.03 mg kg -1).
Results were analysed where appropriate by linear regression on
probit values by analysis of variance and by Students T test.
Results
The individual pharmacodynamic and haemodynamic data for each
patient is displayed in Table 27. The neuromuscular data is
summarised in Tables 26 and 28. Figure 17 displays the
neuromuscular and cardiovascular dose response curves which were
constructed for BWB1090U.
The ED95 was found to be approximately 0.07 mg kg -1. The duration
of action (injection to 95% return of twitch) was 26.3 minutes at
0.1 mg kg -1, the lowest dose producing 100% block.
Spontaneous recovery time (5-95%) averaged 15.8 minutes for all
doses above 0.08 mg kg -1 (n=10). Corresponding time after 1-2
hour infusions (n=5) averaged 16.9 minutes. Similarly recovery
times (25-75%) averaged 7.5 minutes and 6.9 minutes after all
single bolus doses producing 100% block (0.1 - 0.25 mg kg -1) and
after 1-2 hour infusions respectively. The differences were not
significant. In six cases where neostigmine was given to
antagonise residual block at the end of an infusion, reversal from
an average twitch height of 20-25% required 5.6 minutes. The
25-75% recovery time averaged 2.6 minutes.
At up to 0.15 mg kg -1 changes in heart rate and arterial pressure
were less than 5%. At 0.2 and 0.25 mg kg -1 (approximately 3-4
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Dose











0.024 2 12 3.2 6.9 -
0.04 2 62 4.0 15.6 -
0.06 2 70 4.0 20.6 -
0.08 2 75 4.3 14.6 -
0.10 2 100 3.8 26.3 15.9
0.15 2 100 2.7 34.6 18.7
0.20 3 100 2.5 29.0 15.8
0.25 3 100 1.7 32.0 13.7
Average
= 15.8
* to 95% of control twitch
Table 26
BWB1090U: Pharmacodynamic data in volunteers.
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Pt Bolus Onset Max \ Duration of Inj-951 5-951 25-75% KAXiMAP MAXiHR Flush
ig/kg (nin) Block 1001 block (min) (fc) (%c)
3 0.04 3.5 32 12.7 66-65 62-60 None
(98) (97)
4 0.04 4.5 90 - 18.5 - 6.0 93-94 52-51 None
(101) (96)
5 0.06 3.5 27.5 - 11.2 - - 76-78 56-59 None
(103) (105)
6 0.06 4.5 100 4.0 30.0 20.0 9.2 91-89 60-56 None
(98) (93)
7 0.08 4.5 63 - 14.5 - - 61-62 56-55 None
(102) (98)
e 0.08 4.0 85 - 14.7 - 6.0 91-93 55-53 None
(102) (96)
9 0.10 3.5 100 6.0 24.5 13.5 5.2 80-81 60-63 None
(101) (95)
10 0.10 4.0 100 3.0 28.0 18.2 7.7 92-91 44-40 ? Very slight
(99) (91)
11 0.15 2.2 100 16.2 40.2 19.2 9.7 75-73 54-53 Very slight
(97) (98)
12 0.15 3.2 100 5.7 28.7 18.2 10.2 80-75 70-71 Slight
(94) (101)
13 0.20 2.5 100 12.5 45.0 25.0 11.5 61-46 60-76 Slight
(75) (127)
14 0.20 3.2 100 2.7 16.0 9.0 4.0 77-59 70-74 Mild
(77) (106)
15 0.25 1.7 100 9.2 23.2 11.0 5.7 81-72 66-73 Mild
(89) (HI)
16 0.25 1.7 100 12.0 26.7 11.7 5.5 82-58 55-66 Moderate
(71) (120)
17 0.25 1.7 100 10.2 26.5 13.5 6.7 82-38 50-88 Slight
(46) (176)
18 0.25 1.7 100 22.7 46.0 18.5 9.2 63-52 42-58 Mild
(83) (138)
Table 27
BWB1090U: Volunteer study pharmacodynamic data for individual patients
(Ic) = change expressed as a percentage of baseline values.
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Pt Duration % Rec at Inf off 25-75% % Rec at Rev - 25-75%
of Inf term, of - 95% (mins) Reversal 95%
(min) Inf (mins) * Rec
(mins)
7 30 8% 13.0 5.2 - - -
8 32 - - - 18.0 2.5 2.0
9 60 2 15.0 5.2 - -
10 69 - - 30.0 4.0
11 90 7 21.2 9.5 - -
12 83.5 - - - 22.0 5.5 2.5
13 121.0 2 28.0 12.0
14 120.5 - - - 23.0 3.0
15 120.0 2 9.5 4.7 - -
16 121.0 - - - 5.0 11.5 4.5
17 120.0 5 11.0 5.0 - - -
18 120.0 - - - 28 4.2 2.5
Means 4.3 16.3 6.9 22 5.6 2.6
* Reversal with neostigmine (60 //g kg -1) and atropine (30 /j.g kg
-1)
Table 28
































times the ED95) decreases in arterial pressure and increases in
heart rate were noted. In the six individuals who received these
highest doses heart rate increased an average of 25% and arterial
pressure decreased an average of 25%. These changes were brief,
lasting 1-3 minutes.
Conclusion
BWB1090U would appear to be a potent non-depolarising neuromuscular
blocking drug with a short duration of action, minimal cumulative
effect and reasonable cardiovascular safety. Previous experience
with benzylisoquinolinium compounds would suggest that the
transient change in haemodynamic parameters observed were most
likely to be due to histamine release.
Because of BWB1090U's unique neuromuscular profile further studies
in surgical patients seemed justified.
The author was subsequently involved in the first clinical trial of





In 1975 Savarese and Kitz publicised the deficiencies of available
neuromuscular blocking agents and identified in particular the need
for a novel short acting muscle relaxant but also for intermediate
and long acting non-depolarising blockers that would be free of
cardiovascular effects and not show cumulative effects upon
repeated administration. This thesis has examined in detail the
intermediate duration muscle relaxant atracurium and has reported
initial studies with the short acting agent BWB1090U.
The search for a new long acting agent has continued because
cardiovascular effects and cumulative properties are associated
with the available long acting agents such as pancuronium,
metocurine, tubocurarine and gall amine [101, 119, 120]. The well
described vagolytic properties of pancuronium infrequently have
clinical consequences in normal patients, but may be particularly
deleterious in patients with cardiovascular disease. Metocurine
lacks vagolytic effects and is frequently used to induce
neuromuscular blockade in patients with cardiovascular disease in
the United States. However, the histamine releasing potential of
metocurine often requires that this agent be administered as a slow
bolus or in divided doses to avoid adverse haemodynamic sequelae.
The induction of tachycardia by gallamine and the histamine
releasing and ganglion blocking activities of tubocurarine
generally prevent the routine use of either agent in patients with
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cardiovascular disease and may limit their use in normal patients.
The cumulative effects of the most commonly used long acting agent
pancuronium have been well described. Fahey et al [121]
demonstrated that the duration of action of repeated injections of
pancuronium (0.02 mg kg -1) increased from 50 minutes following the
first dose to 120 minutes following the fourth dose. Such
cumulation makes the appropriate timing of pancuronium maintenance
doses difficult to predict in the clinical setting.
The Wellcome Research Laboratories have been involved with an
ongoing programme to develop novel long acting non-depolarising
neuromuscular blocking agents. A result of this programme is
BWA938U dichloride (Figure 18).
Pharmacological studies performed at the Wellcome Research
Laboratories in cats, dogs and Rhesus monkeys have shown that
BWA938U is a potent neuromuscular blocking agent. Compared with
atracurium, BWA938U was more potent, had a longer onset time and a
significantly longer (2-4 times) duration of action. The ED95
neuromuscular blocking dose for BWA938U in the monkey was estimated
to be 0.017 mg kg -1 with a duration of action (time from injection
to 95% recovery) estimated to be 50-60 minutes. Importantly,
comparisons of the patterns of recovery in monkeys after single
bolus injections and after a final dose in a series of five
consecutive maintenance doses indicated than BWA938U had no
cumulative properties. BWA938U induced neuromuscular blockade
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The safety of BWA938U was studied in monkeys, dogs and cats. Bolus
doses approximating five times and ten times the estimated dog
ED100 doses were administered to anaesthetised dogs. These doses
produced no or minimal effects on arterial blood pressure and heart
rate. In dogs a cumulative BWA938U dose equivalent to 62 times the
ED100 resulted in minimal (less than 15-20%) transient changes in
mean arterial blood pressure and heart rate immediately following
the final (32 times the ED100) BWA938U dose.
In doses that produced 95-100% neuromuscular blockade BWA938U had
no effect on sympathetic or parasympathetic efferent pathways in
the cat. High cumulative doses (greater than 50 times the ED95)
produced no or minimal inhibition of the contraction of the
nictitating membrane in response to pre-ganglionic stimulation and
there were no vasodepressor or bradycardic responses to vagus nerve
stimulation.
BWA938U was found to be a weak substrate for plasma cholinesterase.
The rate of hydrolysis by human cholinesterase was estimated to be
6% of the rate of suxamethonium hydrolysis. The relative roles of
plasma enzymes, the liver, and the kidney in the disposition of
BWA938U remain to be determined.
Pre-clinical toxicology studies for BWA938U consisted of:
1. A three week assessment of toxicity following multiple
intravenous doses of BWA938U in beagle dogs.
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2. A perivenous and intramuscular irritation study in beagle
dogs.
3. A 14 day subcutaneous toxicity study in rats.
4. A subcutaneous teratology study over gestation days six
through 15 in pregnant rats.
No toxicopathological or teratogenic effects relating to BWA938U
were observed in these studies. However, during the subacute
intravenous toxicity study, dogs receiving BWA938U often produced a
thick viscous saliva during recovery from anaesthesia that was not
observed in control dogs. The mechanism and significance of this
effect remain to be determined.
On the basis of these pre-clinical studies it was concluded that
BWA938U is a long acting neuromuscular blocking agent with
potential advantages over currently available agents (eg,
pancuronium, tubocurarine, metocurine) because its effects are
non-cumulative upon repeated administration and would appear to be
devoid of cardiovascular effects at several multiples of the
estimated clinically useful dose.




A PILOT STVPY OF THE SAFETY AND EFFICACY OF BWA938U IH VOLUNTEERS
UNQER NITROUS QXIQE/NARCQTIC ANAESTHESIA
Objectives
1. To evaluate the safety of intravenous bolus injections of
BWA938U at several dose levels in anaesthetised volunteers.
2. To determine the dose of BWA938U required to produce muscle
twitch suppression; to estimate the onset, depth and
duration of neuromuscular blockade produced by several
BWA938U doses; and to estimate the BWA938U dose-response
relationship.
3. To estimate the spontaneous recovery rate from BWA938U
induced neuromuscular blockade and obtain initial estimates
of the reversibility of BWA938U induced neuromuscular
blockade.
This was an open escalating dose study in which healthy volunteers
received one or more intravenous bolus injections of BWA938U while
under steady state nitrous oxide/oxygen narcotic anaesthesia. The
initial eight volunteers were studied in order to obtain a
preliminary estimate of the BWA938U dose response relationship and
safety. The safety and efficacy of BWA938U administered at
increasing multiples of the estimated ED95 was subsequently studied
in five further volunteers.
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Methods
Each volunteer received 2-5 ug kg -1 of fentanyl prior to the
induction of general anaesthesia with 4-6 mg kg -1 of thiopentone
intravenously. The volunteers were maintained on nitrous oxide (4
litres per minute) and oxygen (2 litres per minute) for the
duration of the base line and treatment phases. Thiopentone (2-3
mg kg -1) and/or fentanyl (0.5 - 2.0 ug kg -1) were administered
intravenously as required to maintain the desired depth of
anaesthesia.
Blood pressure was monitored using intra-arterial cannulae, 12 lead
electrocardiographs were obtained and plasma histamine levels were
measured before and after bolus administration of BWA938U.
The ED50, ED75 and ED95 doses were estimated using the observed
responses to BWA 938U using a cumulative dose response technique
for volunteers 1-2, 1-4 and 1-6 respectively. The first eight
volunteers were each allowed to spontaneously recover from the
BWA938U induced neuromuscular blockade.
Once recovery was complete, (T4:T1 ratio 0.75 or greater) each of
these volunteers received the same bolus dose which was initially
administered (ie, estimated ED50, ED75, ED95). Once the response
to this second BWA 938U dose was maximal each volunteer received
sufficient cumulative doses (as required) of BWA938U to approach
the 95% twitch suppression range. Once 90-99% twitch suppression
was obtained one volunteer from each pair (ie, numbers 3, 5 7) was
allowed to undergo spontaneous recovery to greater than 95%
recovery. The second volunteer of each pair (ie, number 4, 6 8)
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was allowed to spontaneously recovery to approximately the 25%
recovery level. At approximately this level of recovery reversal
of neuromuscular blockade in each of these volunteers was attempted
with an intravenous bolus dose of neostigmine (0.06 mg kg -1) in
conjunction with atropine (0.03 mg kg -1).
Volunteers 9-13 received single i.v. bolus doses of BWA 938U
according to an escalating design (ie, an ED95 multiple) each
volunteer was allowed to spontaneously recover to at least 25%
twitch height. No additional doses were administered. The
decision to proceed to each successive dose level was based on the
investigators and medical monitors clinical evaluation of responses
observed at previous dose levels.
Intra-arterial blood pressure, heart rate and single twitch were
continuously recorded on a Grass polygraph.
Results
Table 29 shows the efficacy data from this study. Onset and
duration of neuromuscular blockade following BWA938U administration
appeared to be dose dependent. Neuromuscular blockade was
reversible with neostigmine once spontaneous recovery was underway.
There were no consistent or clinically significant effects on mean
arterial pressure or heart rate (Table 30) after administration of
BWA938U at doses up to approximately four times the estimated ED95.
Conclusion
BWA938U was found to have a long duration of action in volunteers














12 2 70 11.9 27.8 61.7 +
18 2 68 13.8 32.5 81.2 +
25 2 97 9.5 47.3 70.0 +
36 2 100 4.9 87.5 216.5 +
48 2 99 5.6 58.2 104.0
72 2 100 3.7 151.0 -
96 1 100 2.5 204.0 _
* Indicates time from injection to 25% and 95% recovery
+ Indicates recovery data available from one volunteer only
Table 29
Neuromuscular effects of BWA938U in volunteers
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BWA938U no HR MAP Plasma
Dose (% Control) (% Control) Histamine
(/zg kg -1) {% Control)
25 2 100 105 144
36 2 98 99 66
48 2 96 98 66
72 2 100 101 73
96 1 100 93 163
Table 30
Maximum percent change in heart rate (HR), mean arterial pressure
(MAP), and plasma histamine 2 minutes following BWA938U
administration.
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BWA938U dose produced dose related increases in the depth and
duration of neuromuscular blockade as well as decreases in onset
time.
BWA938U appears to be devoid of effects on mean arterial pressure
and heart rate at doses greater than three times the ED95. No
patient was observed to develop a precipitous blood pressure
decrease consistent with histamine release. There was no
significant rise in histamine levels following administration of
BWA938U. This data indicates that BWA938U is devoid of
haemodynamic effects when administered in clinically useful doses.
This profile may represent an important safety advantage for
BWA938U when compared to other long acting neuromuscular blocking
agents that have the potential for significant haemodynamic effects
in individual patients (ie, pancuronium, tubocurarine).
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CHAPTER 15
PQXACURIUM CHIQRIDE: A PRELIMINARY CLINICAL TRIAE
As a result of the initial animal studies and of the volunteer
study reported in the previous chapter, preliminary clinical
studies were commenced in the USA. These investigations suggested
that doxacurium was a potent, long acting drug, devoid of
cardiovascular and histamine releasing side effects at clinically
effective doses [122, 123]. The ED95 dose to block contraction of
the adductor pollicis muscle was reported to be approximately 25 ug
kg -1.
The following study was the first investigation of doxacurium
chloride performed in Europe. The study was designed to assess its
onset, intubation conditions, effect of multiple increments and
ease of antagonism with edrophonium and neostigimine. A
preliminary report of this study was presented to the Anaesthetic
Research Society.
Methods
Twenty seven ASA Class 1 or 2 adult patients (weights 45 - 100 kg)
scheduled to undergo elective surgery expected to last 120 minutes
were studied. Each patient gave written, informed consent for this
study, which was also approved by the local hospital ethics
committee.
The patients were premedicated with papaveretum (15-20 mg kg -I),
and hyoscine (0.3 - 0.4 mg kg -1) i.m. one hour before surgery.
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Before induction of anaesthesia, the skin over one forearm and the
hand was degreased using an alcohol solution. Five silver-chloride
electrodes were placed, two over the ulnar nerve, one over the
midpoint of the distal skin crease at the wrist, one over the
palmer aspect of the head of the fifth metacarpal, and one over the
belly of the adductor pollicis muscle. These were connected to a
Datex Relaxograph. Anaesthesia was induced with thiopentone (5 mg
kg -1) iv, and fentanyl (2-3 /zg kg -1) iv
Neuromuscular monitoring was commenced using train-of-four stimuli
(2 Hz at 20 second intervals) to the ulnar nerve and the gated
rectified and integrated EMG from the adductor pollicis was
recorded. The size of the gain setting, supramaximal stimulus and
the stimulus artefact were noted. Anaesthesia was maintained with
66% nitrous oxide in oxygen, and the lungs were ventilated
artificially to maintain normocapnia. The patients were allocated
to three groups of nine and patient order was randomised.
Following randomisation, the first 18 patients studied (and hence
the last nine also) were equally divided between the three groups.
When an initially stable record was obtained, doxacurium 37.5 ug kg
-1 i.v. (1.5 x ED95) was administered to group A, and 62.5 ug kg -1
i.v. (2.5 x ED95) to groups B and C with the bolus being given
either into a continuous infusion or flushed through a cannula with
a 5 ml bolus of saline. The bolus was given to coincide with a
train-of-four sequence to give an accurate time mark on the record.
Intubation conditions were assessed by the same investigator (RPFS)
each time at four minutes after the administration of doxacurium in
groups A and B and at three minutes in group C. The conditions
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were graded on a scale of 1-4 (excellent, good, poor or not
possible) [124].
The onset of block was determined as the time from injection to the
appearance of either complete block or the maximum degree of block.
Following maximal block, anaesthesia was maintained with nitrous
oxide in oxygen plus 0.5% halothane. Additional doses of fentanyl
and thiopentone were administered as required. When the first
response of the train-of-four (Tl) had recovered to 20% of control,
a bolus of doxacurium 5 ug kg -1 was given; this was repeated when
Tl had recovered again to 20%. The duration and degree of block
produced by each increment were noted.
At the end of surgery, when Tl had recovered to greater than 10% of
control, the residual block was antagonised with edrophonium 1 mg
kg -1 intravenously in the first 18 patients (six in each of groups
A, B and C) and neostigmine 50 /zg kg -1 i.v. in the last nine
patients (n=3 in each group). Glycopyrrolate or atropine
intravenously in an appropriate dose was given concurrently. The
percentage recovery of Tl following the injection of the
anticholinesterase agent was continuously recorded.
Heart rate was observed continuously from a Hewlett Packard ECG
monitor and the arterial pressure measured every two minutes using
a Hewlett Packard noninvasive monitor. To detect decreases in core
and hand temperatures during the operation, nasopharyngeal
temperature was measured. All infusions were warmed to body
temperature, a condensor humidifier was used in the breathing
system and the forearm was insulated by wrapping in towelling.
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Neuromuscular monitoring was stopped when the patient was awake and
neuromuscular function was evaluated clinically during the recovery
period by assessing patients' grip strength and ability to headlift
for five seconds [38]. Each patient was reassessed 24-48 hours
after surgery and questioned with regard to any adverse experience
noted.
Non-parametric and Students T test were used as appropriate to
assess statistical significance.
Results
There were no significant differences between the ages, weights or
ASA categories of the three groups of patients studied (Table 31).
The duration of surgery was defined as the time from administration
of the initial bolus of doxacurium until administration of the
antagonising agent. Intubation conditions ranged between grades
excellent and poor in all three groups, but only one patient in
each group achieved excellent conditions (Table 32). Intubation
was accomplished successfully in all patients, although 100% block
of adductor pollicis was not achieved before intubation was
performed.
Because patients in groups B and C all received doxacurium 62.5 ug
kg -1, these two groups were analysed together and compared with
group A (doxacurium 37.5 ug kg -1) (Table 33). Three patients in
group A failed to achieve 80% block following the initial bolus and
one patient was antagonised at 10% recovery. In the remaining
five, it took an average of 51 minutes to recover to T1 of 20%.
With the higher dose, in one patient the initial block was only to
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n Age Weight Duration of Sex
(yr) (kg) surgery (M/F)
(min)
Group A 9 52.5 (11.8) 67.3 (10.7) 127.8 (58.4) 5/4
Doxacurium
37.5 fig kg -1
Group B 9 60.7 (11.2) 69.8 (15.8) 161.4 (48.6) 7/2
Doxacurium
62.5 fig kg -1
Group C 9 49 (14.0) 74.5 (15.0) 139.6 (38.7) 6/3
Doxacurium
62.5 fig kg -1
Table 31
Patient characteristics (mean (SD))
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Tine of Intubation score (no. patients)
intubation







141 30 2.27 (0.66) 55.2 (32.9)
Group B 161 1 0 2.0 (0.5) 80.1 (15.5)
Doxacuriui
62.5y«g kg -1




Intubation data. Score 1 = excellent, 2 = good, 3 = poor, 4 = not possible.
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Max block Time to Duration to
achieved max block 20% recovery
(Tl%) (min) of T1 (min)
Group A 9 83.6(18.3)[55-100] 10.5(2.2)[6-14] N/A*
Doxacurium
37.5 /ig kg -1
Group B 18 97.6(5.2)[78-100] 9.85(6.17)[5-31] 101.7(41.8)
Doxacurium [31-75]
62.5 /iq kg -1 (n = 15)
* Three patients failed to achieve 80% block.
Table 33
Onset and duration data (mean (SD) [range]).
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75% and in two, the recording was lost following movement of the
patient by theatre staff and loss of electrode placement. In the
remaining 15, the time to 20% T1 recovery was on average 102
minutes after the initial dose (Table 33). There was no
significant correlation between the age of the patients and the
duration of block at the higher dose.
Only 13 patients received increments of doxacurium as, in the
remainder, the initial bolus dose of doxacurium was adequate to
last throughout the operation. The incremental doses administered
at 20% recovery of T1 produced a moderately wide between patient
variation in response, both with regard to percent increase in
block of T1 and time to return to 20% Tl. However, the response in
any one patient was consistent, with increments producing the same
increase in paralysis and a constant duration of effect (Table 34).
Two patients with poor recovery recordings were omitted from the
antagonism data analysis. The mean percent recovery of Tl at the
time of administration of the antagonist was almost the same in the
edrophonium and neostigmine groups (Table 35). The first twitch of
the train-of-four was antagonised well after giving neostigmine.
The Tl antagonism response to edrophonium was rapid in onset but
was incomplete and subsequently appeared to be similar to that of a
spontaneous recovery. In eight (47%) patients in the edrophonium
group, a train-of-four (TOF) ratio less than 0.5 was still present
when recording had to be stopped. Only four (24%) patients
achieved a TOF ratio greater than 0.7. One patient with a TOF
ratio of 0.5 at the end of recording failed a five second head lift
30 minutes after administration of edrophonium. Ten minutes later
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No patients Increase in Duration No
receiving block T1 to return to increments
increments (%) 20% (min)
at 20%
recovery
Total 13* 8(3.3)[2.5-15] 31.3(31.1)[9.5-42] 3.9(3.8)[1-12]
* Group A n = 4; group B n = 4; group C n = 5
Table 34





Drug admin 1 min
23.8(8.8)[10-37] 59.2(22.8)
22.5(6.7)[10-32.5] 40.6(21.2)
Recovery of T1 (I) at




Data on antagonism of block by edrophonium or neostigmine (mean (SD) [range])
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he had a successful head lift following administration of
neostigmine 2.5 mg. In the neostigmine group, no neuromuscular
block could be detected by clinical assessment in the recovery
room. One patient had a TOF ratio less than 0.5 following
antagonism at the end of the recording. Four patients (50%)
achieved a TOF ratio greater than 0.7. The mean period of
recording following administration of both agents was approximately
14 minutes.
Twelve (44,4%) patients required administration of an intravenous
anticholinergic agent during operation to correct a heart rate of
less than 50 beats per minute.
The bradycardias were gradual in onset and generally occurred 30 to
60 minutes after induction of anaesthesia and seemed unrelated to
the administration of doxacurium.
No adverse experiences were reported by the patients on follow up
at 24 hours.
Piscussipn
This study confirms that doxacurium is a potent, long acting
neuromuscular blocking agent. Although a formal dose response
study was not carried out in these patients, the drug appeared to
be less potent than might have been anticipated from the volunteer
study reported in the previous chapter and also other reports.
Other studies suggest that the ED95 lies between 13.6 and 25 ug kg
-1, depending on the anaesthetic conditions [122, 123, 125, 12b].
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The dose regime in this study was based on the initial report by
Basta and colleagues which suggested that the ED95 under balanced
anaesthesia was 25 fig kg -1 [122]. In this study, group A received
1.5 times the ED95 and groups B and C received 2.5 times the ED95,
This study, however, showed that at 37.5 fig kg -1 (1.5 x ED95) the
maximum block achieved was 83.6% Tl. This apparent difference in
potency may result from the fact that we compared EMG responses to
mechanomyographic forms of measurement [122, 123]. In addition,
the drug may appear less potent because of the lighter depth of
anaesthesia during induction. The effect of anaesthetic agents on
the pharmacodynamics of a muscle relaxant was noted in one of the
author's previous studies on high dose atracurium. Alternatively,
there may be an Anglo-American difference in potency for doxacurium
as has been described previously for tubocurarine [127].
Intubating conditions were similar to those described by other
workers [128, 129] and could only be described as excellent in one
patient in each group; in no patient was 100% blockade of Tl
achieved before intubation. In two patients the intubating
conditions were between groups two and three by the intubation
criteria of Twohig and his colleagues [124], and therefore they
scored 2.5. Even at the high dose (62.5 ug kg -1) the mean onset
time to 90% block of Tl was some 4.9 minutes (n=17). Nevertheless,
in no patient was intubation impossible and the mean conditions in
all three groups could be said to be good.
In the patients receiving multiple maintenance increments of
doxacurium, there was no evidence of an increase in duration or
degree of block following each bolus.
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In all patients except the two with poor recordings in whom
antagonism was blind, the block was antagonised between 10 and 37%
recovery of Tl. It could be argued that the poor antagonism with
edrophonium was related to base line drift of the electromyographic
recording, which has been well documented by other authors [130,
131]. However, the antagonism of Tl by neostigmine was complete;
this would confirm a real difference in ability to antagonise
doxacurium by these two anticholinesterase agents. As a result of
time constraints imposed on this clinical study, TOF fade was still
present in several patients when stimulation had to be stopped as
the patient awakened. Nevertheless, with the exception of one
patient who received edrophonium, all other patients appeared to
have appropriate clinical antagonism of block and had satisfactory
grip strength and five second head lift when tested between 20 and
40 minutes after admission to the recovery ward.
It is unlikely that the gradual onset of bradycardia could be
attributed to doxacurium; the measurements of heart rate and
arterial pressure confirm the findings of the volunteer study and
other reports that doxacurium is a haemodynamically stable agent
[122, 132]. There was no clinical evidence of histamine release.
Konstadt [133] also noted a decrease in heart rate and attributed
this to progressive reduction in sympathetic tone resulting from
anaesthesia. The effect of opioids and volatile agents on heart
rate is well documented [134].
In conclusion, we found doxacurium to be a potent, long acting
haemodynamically stable, non-depolarising neuromuscular blocker.
Although intubation was possible in all patients in the three
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groups studied, with the dosage used in this study, doxacurium did
not provide intubating conditions which could be described as
excellent. In common with vecuronium and atracurium, this drug
does not have the protective vagolytic effect of pancuronium and it
is recommended that an anticholinergic agent be availabe
immediately if vagal stimuli are likely to be encountered during
surgery. Neostigmine would appear to be more suitable than
edrophonium as an antagonist for doxacurium.
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CONCLUSION AND UPDATE
Most of the important research into new muscle relaxants can be
divided into two distinct chemical groups, namely the
benzylisoquinolinium compounds, and the steroids.
For a number of years now, Savarese and colleagues at the
Massachusetts General Hospital, USA, have been collaborating with
pharmacologists and molecular chemists at Burroughs Wellcome,
Research Triangle Park, North Caroline, USA. They have been
particularly interested in the bisbenzylisoquinolinium diester
non-depolarising compounds known to undergo hydrolysis in the
presence of plasma cholinesterase. While a number of prototypes
offered many features of 'the ideal muscle relaxant', the major
stumbling block with this class of experimental drugs has been
histamine release. This side effect, well recognised in other
benzylisoquinolines, notably tubocurarine, metocurine, and to a
lesser extent atracurium, has resulted in the withdrawal of some
otherwise potentially useful agents following volunteer studies.
Benzylisoquinoline ester compounds can be readily chemically
manipulated to undergo more rapid metabolism or degradation,
thereby shortening the neuromuscular effect. Atracurium was the
first to find clinical success in which the ester linkage
facilitates both the Hofmann elimination and ester hydrolysis
pathways of breakdown. With BWB1090U (mivacurium) the basic
benzylisoquinOline structure provides good potency, while two ester
linkages allow rapid breakdown by plasma cholinesterase at about
88% of the rate of suxamethonium hydrolysis [135], Preliminary
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data in vitro and in the cat, however, suggest that mivacurium
might also undergo liver uptake and metabolism. This could explain
the poor correlation of the duration of action of bolus doses of
mivacurium with the plasma cholinesterase activity of individual
subjects. The metabolites have been identified in the bile and
urine of both cat and dog, as well as in human urine [135].
Since enzymatic hydrolysis is most likely the major route of
clearance, the duration of action of mivacurium may be longer in
people with low cholinesterase activity. Savarese et al [135]
postulate that the relative increase in duration of action,
however, may not be as great as in the case of suxamethonium for
three reasons:-
1. The upper limit of the clinical dose range is greater with
suxamethonium than mivacurium, and therefore represents a
relatively greater overdose, and consequently higher clearance
load;
2. Other clearance pathways for mivacurium seem likely; and
3. The complicating process of phase two block cannot occur in the
case of mivacurium.
Mivacurium's duration of action is about one third to one half that
of an equipotent dose of atracurium or vecuronium, or about one and
a half to two times longer than suxamethonium. Its onset time,
however, is more similar to atracurium or vecuronium than
suxamethonium. Rather than engage in the often discussed
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definition of cumulation, it is simpler to say that mivacurium's
recovery indices are relatively short and do not change over a wide
dose range, nor after prolonged continuous administration by
infusion [136]. The addition of isoflurane may, however, prolong
the recovery index [137]. Interestingly, A1i et al [136] noted a
significant correlation between the infusion rate of mivacurium
required to maintain 95% twitch depression and the plasma
cholinesterase activity of individual subjects.
Antagonism of mivacurium induced block by anticholinesterase agents
would seem at least as easy as reversal of any other
non-depolarising drug. It is likely that during reversal
hydrolysis of mivacurium may be slowed for a brief period due to a
short lasting inactivation of plasma cholinesterase. Nevertheless,
moderate levels of mivacurium block are readily antagonised by
neostigmine due to acetylcholinesterase inhibition. Presumably,
within about 20 minutes following neostigmine administration,
plasma cholinesterase activity should have recovered sufficiently
to destroy any residual mivacurium ester material.
Since mivacurium is a benzylisoquinolinium substance, it shares the
generic side effect of this group of compounds, namely histamine
release. This side effect would seem to be relatively mild and its
cardiovascular effects are similar to those of atracurium [135].
Like atracurium, the transient, haemodynamic response to a high
bolus can be attenuated by slowing the speed of injection to about
60 seconds.
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BWA938U (doxacurium) would appear to be the most potent,
non-depolarising relaxant ever studied in man [132].
This long acting bisquarternary benzylisoquinolinium diester was
identified as a byproduct of the programme to develop a short
acting agent. It has a similar duration of effect to pancuronium
given in equipotent doses and provided there is some evidence of
recovery, as assessed by using a peripheral nerve stimulator, the
drug may be reversed satisfactorily with neostigmine. Edrophonium,
however, would appear to be an unsatisfactory antagonist for this
agent.
The onset time is slow and probably slower than that of pancuronium
in equipotent dose [122, 132]. Thus, doxacurium would seem to be
an unsuitable agent for rapid tracheal intubation.
Its major advantage is its haemodynamic stability in both healthy
adult patients and those with cardiac disease [138]. Although some
decrease in heart rate [138] may be observed over time, this is
unlikely to be an effect of doxacurium. The vagal effects of
anaesthesia and certain surgical stimuli which are concealed by the
vagolytic effect of pancuronium, may occasionally be exposed with
this drug. A similar phenomenon is seen not infrequently with
vecuronium, which is also stable on the circulatory system.
Unlike other benzylisoquinoline analogues, it does not release
histamine in the clinical dose range [122]. This is almost
certainly due to its high potency making the margin of safety
between the neuromuscular blocking dose and the dose at which
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histamine release is observed, that much wider.
Although the drug has been identified in human bile, it is thought
that doxacurium is largely eliminated unchanged by the kidney. The
hydrolysis rate in vitro as catalysed by purified pooled human
plasma cholinesterase is only 6% of the rate of suxamethonium.
It will have become apparent from the foregoing discussion that
there is still a need for a rapid onset, non-depolarising drug, or
if you like, a suxamethonium substitute without the depolarising
side effects. That is effectively where most research into muscle
relaxant molecular chemistry will be directed from now on. It
would seem that there are two philosophies on how to achieve this
ideal agent. Chemists working with the benzylisoquinoline
structure believe that a highly potent ultra short acting drug is
the answer; their hypothesis being that it will be possible to give
large doses to improve onset time without an undue prolongation of
blockade. Furthermore, the more potent the drug is regarding
neuromuscular blocking activity, the greater the margin of safety
for histamine will be: this chemical group's major side effect.
Steroidal chemists, however, are working on an entirely different
hypothesis. They believe that highly potent drugs by definition
have a high affinity for receptors and therefore rapid onset can
only be achieved at the expense of a very prolonged duration of
action. An analysis of the relationship between neuromuscular
blocking potency and duration of action has revealed that it is
reciprocal, suggesting that a non-depolarising equivalent of
suxamethonium, when discovered, may necessarily be a drug of low
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potency [139]. Work in this area has already produced some
encouraging results, albeit in animals [140, 141].
Two fast onset short duration steroids, 0RG7617 and 0RG9616,
although significantly less potent that vecuronium, have
demonstrated a pharmacodynamic profile similar to suxamethonium.
The problem with reducing potency of steroidal compounds is that
vagolytic and autonomic side effects begin to appear. Initial
animal studies suggest these two experimental agents may not be
haemodynamically stable, at least at higher doses.
However, two fast onset intermediate duration steroids, 0RG9426 and
ORG9273, are being investigated and have produced only minor
changes in blood pressure and heart rate in all species at three
times EC90 blocking doses. Although, once again, considerably less
potent than vecuronium, they display a similar duration and faster
onset of action at equipotent dose.
It should be borne in mind that the duration of drug action is
briefer, the smaller the species of animal, presumably because of
faster blood flow and metabolism. Nevertheless, the relative time
course of action in the cat of these new drugs compared with
suxamethonium and vecuronium, is encouraging.
We await the results of the full clinical trials.
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ATRACURIUM: ITS SPEED OF ONSET.
A COMPARISON WITH SUXAMETHONIUM
R. P. F. Scott and V. A. Goat
summary
Forty healthy patients were randomly selected to receive either atracurium 0.6 mg kg-1, or suxamethonium
1 mgkg"1. Onset of neuromuscular blockade and the time to full peripheral paralysis were measured using
a train-of-four stimulus repeated once every 12 s. Atracurium appeared to be a potent non-depolarizing
muscle relaxant, with a rapid onset of action. However, full peripheral paralysis took longer to achieve than
with suxamethonium. There were no significant problems with recovery.
Atracurium dibesylate is reported to be a potent
non-depolarizing muscle relaxant in both laboratory
animals (Hughes and Chappie, 1980; Hughes and
Chappie, 1981) and man (Hunt, Hughes and Payne,
1980). It is a short-acting agent and a qualitative
evaluation of the drug has suggested that it has a
rapid onset of action (Payne and Hughes, 1981).
There have been many studies to evaluate the
speed of action of muscle relaxants. In some, judge¬
ment of paralysis has been largely subjective, using
clinical criteria such as jaw relaxation, ease of trache¬
al intubation and the absence of response to laryn¬
goscopy and intubation (Harrison and Feldman,
1981; Hey, 1973). Despite all efforts to eliminate
bias, ease of intubation will depend not only upon
the degree of neuromuscular blockade, but also
upon the depth of anaesthesia, the anatomical con¬
figuration of the patient and not least upon the skill
of the anaesthetist. An objective comparison of the
rate of onset of neuromuscular blocking drugs can
best be obtained by recording the response of a
muscle to stimulation of its motor nerve.
In this study the speed of action of atracurium was
monitored using a repeated 2-Hz train-of-four
stimulus, and compared with suxamethonium. This
comparison was chosen since the fast onset time
reported in a preliminary study (Payne and Hughes,
1981) had suggested to the investigators that this
new non-depolarizing muscle relaxant could well be
used as an alternative to suxamethonium.
Ralph P. F. Scott, b.sc., m.b., ch.b.; Valerie A. Goat, m.b.,
CH.b., f.f.a.r.c.S.; Nuffield Department of Anaesthetics, Rad-
cliffe Infirmary, Oxford.
Correspondence to R. P. F. S.
0007-0912/82/090909-03 $01.00
METHOD
Forty healthy patients undergoing minor dental
surgery requiring intubation were studied. The pa¬
tients, who gave informed consent to the trial, were
between 18 and 45 years of age. Any patient receiv¬
ing concurrent medication, apart from the con¬
traceptive pill, or in whom pregnancy was sus¬
pected, was excluded. Ethical consent for this study
was obtained and the trial was conducted with the
authority of a clinical trial certificate issued by the
Committee on the Safety of Drugs.
After premedication with papaveretum and hyo-
scine, a modified Elcomatic transducer (Armstrong,
Goat and Loach, 1977) was attached to the patient's
dominant hand and positioned to achieve maximal
mechanical response to thumb adduction. Anaes¬
thesia was induced with fentanyl 3/tgkg"1 and
thiopentone 5mgkg"1, and maintained with nitrous
oxide and oxygen; ventilation of the lungs was as¬
sisted via a face-mask. Stimulation of the ulnar
nerve at the wrist was carried out via cutaneous
electrodes, using a Grass S48 nerve stimulator and
S1U5 isolation unit. The stimulus width was 0.2 ms.
Once it was certain that the stimulus was supramaxi¬
mal, the stimulator was set to produce a 2-Hz train-
of-four stimulus, repeated once every 12 s. The
mechanical response to nerve stimulation was meas¬
ured by the transducer and displayed on an Elcoma¬
tic recorder.
The patients had been randomly selected to re¬
ceive either atracurium 0.6mgkg"1 of suxa¬
methonium 1 mgkg"1, diluted to the same volume
for injection. All drugs were administered via a
peripheral indwelling needle, and the relaxant in¬
jected at the time of nerve stimulation, the start of
© The Macmillan Press Ltd 1982
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injection coinciding with the first stimulus of the
train. The time from the administration of the mus¬
cle relaxant to the first depression of any response in
the train was noted. This was called the onset time.
The time at which full peripheral paralysis occurred
was also noted. At this time no recorded response
was obtained from the stimulus. Tracheal intuba¬
tion was attempted by one of the authors (V.A.G.) at
full peripheral paralysis, using the nasal route under
direct vision.
During induction of anaesthesia, the e.c.g. was
monitored continuously to detect changes in heart
rate. After intubation 1% halothane was added to
the anaesthetic; this concentration was reduced dur¬
ing surgery to allow a rapid return of consciousness
at the end of the procedure. Neuromuscular'
monitoring was not continued during surgery, and
at the completion of the operation, those patients
who had received atracurium were given neostig¬
mine 2.5mg with atropine 1.2 mg. The time of
administration of these drugs was noted, and rever¬
sal of paralysis shown by the ability of the patient to
maintain a head-lift for 5 s (Dam and Guldmann,
1961).
After operation all patients received standard
analgesic and antiemetic drugs and were inter¬
viewed at 24 h. They also received a questionnaire
which they were asked to return after 72 h, in order
to detect any major problems.
Results were analysed using the unpaired two-
tailed Student rtest.
RESULTS
The results are summarized in table I. Patients were
evenly distributed according to age and weight in
both groups. The onset of neuromuscular block was
faster by almost 15 s in those patients receiving
suxamethonium, and this difference in onset time is
significant.
Full peripheral paralysis occurred in all patients
in both groups. A highly significant difference was
seen in the time to full peripheral paralysis, with
atracurium taking nearly twice as long as suxa¬
methonium.
Retrospective analysis of the data showed that in
several cases in both groups full peripheral paralysis
had been anticipated, and intubation had com¬
menced on the penultimate train-of-four. This gave
an inconsistent starting point for intubation and
intubating conditions between the drugs could not
be compared reliably.
Changes in heart rate were minimal in both
groups and there was no significant difference be¬
tween the two groups (table II). No specific prob¬
lems were encountered after operation in those pa¬
tients receiving atracurium, although 11 patients in
the suxamethonium group complained of moderate
to severe muscle pains.
Table II. Heart rate change
No.
patients
No. with heari rate change
>10beatmin 1 < 10 beatmin-1
Suxamethonium 20 2 2
Atracurium 20 2 2
DISCUSSION
The speed of onset of atracurium has been studied
by others (Payne and Hughes, 1981), who followed
the time course of blockade by using the response of
the adductor pollicis muscle to repeated tetanic
stimulation. The mean onset of maximal effect was
reported to be 1.2 min at a dose of 0.6mgkg~'. The
time to full peripheral paralysis in this study was just
over 2 min (129s)^The discrepancy between these
















Suxamethonium 20 24.9 64.9 10 34.8 69.9
(SD 5.4) (SD 11.9) (SD 11.6) (SD 18.5)
Atracurium 20 24.3 63.8 7 49.8* 129.0**
(SD 6.8) (SD 11.1) (SD 8.9) (SD 24.3)
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results could be explained by the mode of stimula¬
tion used. Although the response to tetanic stimula¬
tion is a more sensitive indication of receptor occlu¬
sion than either the single twitch response or the
train-of-four, tetanic stimulation may distort subse¬
quent neuromuscular transmission (Lee and Katz,
1980) and increase the apparent degree ' of
neuromuscular blockade. The train-of-four
stimulus was chosen for this study since it is slightly
more sensitive to receptor occlusion than is the
single twitch (Lee, 1975). It also lacks the equivalent
of post-tetanic distortion of the subsequent muscle
response, and is therefore suitable for repeated ap¬
plication up to once every 12 s.
The use of volatile anaesthetic agents was avoided
until after monitoring had been discontinued, be¬
cause of the well documented interaction between
volatile and neuromuscular blocking agents (Waud
and Waud, 1979).
In this study, atracurium appeared to be a potent
competitive neuromuscular blocking agent, and its
effect at the neuromuscular junction is readily re¬
versed . Although the onset of paralysis is rapid, with
full peripheral paralysis occurring in just over 2 min,
this is significantly slower than the action of sux¬
amethonium. No significant changes in heart rate
were seen and no perioperative problems encoun¬
tered.
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ATRACURIUM: SA RAPIDITE D'ACTION. UNE
COMPARAISON AVEC LE SUXAMETHONIUM
RESUME
Quarante sujets en bonne sante ont ete choisis de fapon aleatoire
pour recevoir soit 0,6mgkg_1 d'atracurium, soit lmgkg-1 de
suxamethonium. L'apparition de bloc neuromusculaire et le
temps d'obtention d'une paralysie peripherique totale ont ete
mesures en utilisant un stimulus par train de quatre repete toutes
les 12 s. L'atracurium s'est montre un curare non depolarisant
puissant, d'action rapide. Cependant, I'obtention d'une paralysie
peripherique complete a ete plus longue qu'avec le sux¬
amethonium. II n'y a pas eu de problemes significatifs de decurar-
isation.
ATRACURIUM, DIE GESCHWINDIGKEIT
SEINES WIRKUNGSEINTRITTS IM VERGLEICH
ZU SUXAMETHONIUM
ZUSAMMENFASSUNG
Vierzig gesunde Patienten wurden randomisiert ausgewahlt, um
entweder 0,6 mg kg-1 Suxamethonium zu erhalten. Der Beginn
der neuromuskularen Blockade und die Zeit der vollen periphe-
ren Blockade wurde gemessen, indem ein train of four-Stimulus
alle 12 Sekunden gesetzt wurde. Atracurium schien ein potentes
nicht-depolarisierendes Muskelrelaxans zu sein, mit schnellem
Wirkungseintritt. Die voile periphere Lahmung jedoch trat spa-
ter ein als bei Suxamethonium. Es wurden keine Schwierigkeiten
bei der Antagonisierung oder in Zusammenhang mit der Opera¬
tion beobachtet.
ATRACURIO: SU VELOCIDAD INICIAL.
UN ESTUDIO COMPARATIVO CON EL
SUXAMETONIO
SUMAJUO
Se seleccionaron cuarenta pacientes sanos de forma aleatoria para
administrarseles 0,6mgkg"1 de atracurio o lmgkgr1 de sux-
ametonio. Se midio el inicio del bloqueo neuromuscular y el
tiempo transcurrido hasta alcanzar una paralisis periferica total,
haciendo uso de una serie de cuatro estimulos que se repitieron
una vez cada 12 segundos. El atracurio parecio ser un potente
rela jantemuscular de caracter no despolarizante que presento una
temprana actividad. Sin embargo, el tiempo necesario para al-
canzer la paralisis periferica total fue mayor que en el caso del
suxametonio. No se presentaron problemas de importancia en lo
tocante a la recuperacion.
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ATRACURIUM: CLINICAL STRATEGIES FOR PREVENTING
HISTAMINE RELEASE AND ATTENUATING THE
HAEMODYNAMIC RESPONSE
R. P. F. SCOTT, J. J. SAVARESE, S. J. BASTA, N. SUNDER, H. H. ALI,
M. GARGARIAN, M. GIONFRIDDO AND A. G. BATSON
All basic compounds may disrupt mast cells and
cause the release of histamine if the dose is large
enough (Paton, 1957). Among the neuromuscular
blocking drugs, this effect appears to be most pro¬
nounced with tubocurarine, possibly because of its
free hydroxyl groups which are thought to enhance
histamine-releasing potency (Buckett and Frisk-
Holmberg, 1970). Unfortunately, the lack of a sensi¬
tive and reliable assay for plasma histamine has
made it difficult to document the role of the his¬
tamine so released in drug-induced cardiovascular
changes. The recent development of a radioenzyma-
tic technique (Snyder, Baldasserarini and Axelrod,
1966; Beavan, Jacobsen and Horakova, 1972;
Beavan and Horakova, 1978; Iverson, Iverson and
Snyder, 1979) and its improvement by the discovery
of renal histamine-n-methyltransferase (Shaff and
Beavan, 1979) have greatly enhanced our ability to
detect histamine in clinically important situations.
The histamine-releasing property of tubocurarine
occurs within the clinical dose range, and a close cor¬
relation between the dose of tubocurarine adminis¬
tered and the amount of histamine released has been
documented in man (Moss et al., 1982). In addition,
a correlation exists between the plasma histamine
concentration and the extent of systemic arterial
hypotension. When plasma concentrations are
increased by about 200% of control, significant
changes are noted in heart rate and arterial pressure
(Moss et al., 1982).
More recently, it has been shown that atracurium
will also release histamine at the upper end of its
r. p. f. Scott, b.sc., m.b., ch.b., f.f.a.r.c.s.; j. j. Savarese,
m.d.; s.j. basta,m.d.; N. sunder, m.d.; H. H. ALI, m.d.; M.
gargarian, m.d.; M. glonfriddo, b.a.; Department of
Anesthesia, Harvard Medical School, at Massachusetts General
Hospital, Boston, Massachusetts, U.S.A. A. G. Batson, b.s.,
Medical Department, Burroughs Wellcome Company, Research
Triangle Park, North Carolina, U.S.A.
SUMMARY
This study was designed to determine the effects
of a rapid bolus dose ofatracurium 0.6 mg kg'1 on
arterialpressure, heart rate and plasma histamine
concentration (n = 9), and to compare these val¬
ues with those obtained by (a) giving the same
dose of atracurium slowly (over 75 s) (n = 9), or
(b) pre-treating with Hr and H2- antagonists
(n = 9). The rapid (5-s) bolus dose of atracurium
i.v. resulted in a significant increase in plasma
histamine concentration (P < 0.05) and was
associated with a decrease in mean arterial pres¬
sure and an increase in heart rate. Administering
the same dose of atracurium slowly (over 75 s)
prevented the increase in plasma histamine con¬
centration, and abolished the subsequent
haemodynamic response. Pretreatment with
cimetidine 4 mg kg'1 i.v. and chlorpheniramine
0.1 mg kg'1 i.v. abolished the haemodynamic
response despite a moderate increase in his¬
tamine concentration (0.1 > P > 0.05).
clinical dose range (0.6 mg kg"1) and this is
associated with corresponding changes in cardiovas¬
cular indices (Basta etal., 1983, 1984). The ability of
atracurium to release histamine relative to its
neuromuscular blocking potency is approximately
one-half that of dimethyltubocurarine and less than
one-third that of tubocurarine.
A number of clinical strategies have been used to
attenuate the adverse reactions to the histamine
released by certain drugs. It has been shown that
even small time differences in the rate ofadministra¬
tion of i.v. agents can lead to significant changes in
the likelihood of generating clinically significant his¬
tamine release (Rosow et al., 1980; Basta et al.,
1981). Furthermore, there is abundant evidence
suggesting that the prophylactic use of Hr and H2-
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antagonists can also attenuate the haemodynamic
responses to certain histamine-releasing drugs,
including morphine (Philbin et ah, 1981),
BW 785U (Rosow et al., 1980), Haemaccel (Lorenz
et ah, 1980) and tubocurarine (Moss et ah, 1982).
This study was designed to determine the effects
of a rapid bolus dose of atracurium 0.6 mg kg"1 on
arterial pressure, heart rate and plasma histamine
concentration, and to compare these values with
those obtained by (a) giving the same dose of
atracurium slowly over 75 s and (b) pretreating with
Hr and H2-antagonists.
PATIENTS AND METHODS
Twenty-seven (ASA Class I or II) patients gave
institutionally approved informed consent to the
study, and were assigned to one of three subgroups
at the discretion of the investigator. All the patients
were aged between 18 and 60 yr, weighed 45-
110 kg, and were undergoing elective surgical pro¬
cedures. Any patient with recent exposure to
antihistamines or antidepressants was excluded
from the trial.
Premedication consisted of morphine 0.1 mg kg"1
i.m. and diazepam 0.2 mg kg"1 by mouth. Anaes¬
thesia was induced with fentanyl 3-4 pg kg"1 and
thiopentone 5 mg kg"1 i.v., and maintained with
nitrous oxide in oxygen via a face mask. Heart rate
(by tachograph), ECG and intra-arterial pressure
were recorded continously on a Grass Model 7
polygraph. After a stable 10-min baseline period, a
single bolus of atracurium 0.6 mg kg"1 was adminis¬
tered over 5 s to patients in group I. Patients in
group II received the same dose ofatracurium slowly
(over 75 s). The patients in group III were pre-
treated with cimetidine 4 mg kg"1 and chlor¬
pheniramine 0.1 mg kg"1 i.v. 15 min before induc¬
tion. They were then given atracurium 0.6 mg kg"1
as 5-s bolus. Maximum changes in heart rate and
arterial pressure were noted. Intubation of the
trachea was delayed for 10 min following the
administration of atracurium, to avoid the car¬
diovascular response to laryngoscopy. Arterial
blood samples were drawn immediately before the
injection of atracurium and at 2 and 5 min after
injection; these samples were analysed for histamine
by an isotope radioenzymatic assay technique (Moss
et al., 1981). End-tidal carbon dioxide concentration

















The results are summarized in tables I and II: the
data displayed are mean values. The changes in
mean arterial pressure and heart rate are the
maximum changes that occurred in the 10 min fol¬
lowing the administration of atracurium, calculated
as a percentage of the baseline values. The absolute
values at baseline, 2 min and 5 min for mean arterial
pressure and heart rate are displayed in parentheses
in table I. Figure 1 illustrates the mean changes in
Table I. Effect of atracunum 0.6 mg kg'1 on mean arterial pressure and heart rate. *Actual
values at baseline, 2 and 5 min for mean arterial pressure (MAP) (mm Hg) and heart rate (HR)






Group I: 9 82.1 ±6.4 108.6±4.6
5-s bolus (78.4;63.5;74.8)* (65;70.1;64.1)*
Group II: 9 9|5.7±2.6 97.7±2.3
75-s dose (75.1;71.8;73.5)* (66;64.2;62.4)*
Group III: 9 96.2±2.2 102.3±2.2









H, + H2 prophylaxis
(Group HI)
Fig. 1. Mean plasma histamine concentrations in the three groups
at control, 2 min and 5 mm following administration of
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Group I 715.3±93.6 1415.1 ±203.5* 1086.3±237.9
5-s bolus
Group II 954.1± 131.7 949.9±154.1 939.4± 162.7
75-sslow injection
Group III 751.1 ± 113.3 1107.0±160.4 854.1±146.0
Hi + H2 prophylaxis
plasma histamine concentration in the three groups,
and figure 2 the changes in plasma histamine con¬
centration in the individual patients. Patients in
group I demonstrated a significant increase in
plasma histamine concentration at 2 min
(P < 0.05; analysis of variance). Seven patients
(77%) in this group showed clinical signs of his¬
tamine release, with the development of mild to
moderate erythema over the trunk and face. The
changes in heart rate and arterial pressure in this
group were all transient and had almost returned to
baseline values by 5 min.
A moderate increase in histamine concentration at
the 2-min sample in group III approached, but did
not reach, statistical significance (0.1 > P > 0.05).
None of the patients in groups II or III showed
clinical signs of histamine release nor any
haemodynamic changes of statistical or clinical sig¬
nificance.
DISCUSSION
Simple histamine release by many drugs, including
neuromuscular blocking agents, does not involve
immunological mechanisms but rather a non¬
specific displacement of histamine and possibly
other vasoactive substances from vascular mast
cells. The transient nature of the changes in arterial
pressure and heart rate following a bolus dose of
atracurium 0.6 mg kg i.v. and the significant
increases in plasma histamine concentration would
seem to confirm that this haemodynamic response
results-from the release of endogenous histamine.
Atracurium has a very high margin of safety for
ganglionic blockade (Hughes and Chappie, 1981),
the duration of which tends to parallel neuromuscu¬
lar blockade (Savarese, 1976). Thus, a hypotensive
response to atracurium mediated via ganglionic
















FIG. 2. Plasma histamine concentrations in individual patients in the three groups at control, 2 min and 5 min
following administration of atracurium 0.6 mg kg"' i.v.
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It appears that small differences in the plasma
concentration of a histamine-releasing drug can pro¬
duce large changes in the amount of histamine liber¬
ated. In this study, slowing the administration of
atracurium appeared to prevent the increase in his¬
tamine concentration and the subsequent change in
haemodynamic variables.
The wide variety of agents with which combined
histamine-receptor blockade is effective, dem¬
onstrates the clinical importance of histamine
release as well as the effectiveness of combined block¬
ade. In the present study the patients receiving a
rapid bolus of atracurium i.v. who were pretreated
with Hr and H2-antagonists did show increases in
plasma histamine concentration. The haemo¬
dynamic response, however, was markedly
attenuated.
It should be noted that not all patients will release
histamine at high doses of atracurium, as indicated
by the large standard error. However, as the size of
the bolus dose increases, there is a greater likelihood
of this response occurring (Basta et al., 1981).
Although this transient haemodynamic response is
probably of little clinical significance in the healthy
patient, the effect may be more important in the
haemodynamically unstable patient who is
hypovolaemic, or has cardiovascular disease.
We conclude that the release of histamine by large
bolus doses of atracurium (0.6 mg kg"1), and any
associated haemodynamic response, can be pre¬
vented by administering the dose slowly (over 75 s).
In addition, the haemodynamic response to a rapid
(5-s) bolus can be minimized by pretreatment with
Hr and H2-receptor antagonists such as chlor¬
pheniramine and cimetidine i.v., given 15 min
before the atracurium.
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CLINICAL PHARMACOLOGY OF ATRACURIUM GIVEN IN
HIGH DOSEf
R. P. F. SCOTT, J. J. SAVARESE, S. J. BASTA, P. EMBREE, H. H. ALI,
N. SUNDER AND D. C. HOAGLIN
The newer neuromuscular blocking drugs have
come closer to the ideal (Savarese and Kitz, 1973,
1975) in terms of duration of action and
cardiovascular stability than the earlier agents.
However, the onset times of atracurium and
vecuronium, although similar in equipotent doses
(Gramstad, Lilleaasen and Minsaas, 1983), are
significantly slower than that of suxamethonium in
the clinical dose range (Scott and Goat, 1982;
Gyasi et al., 1983). For rapid sequence induction,
suxamethonium remains the drug of choice.
Since the speed of onset of the intermediate
duration neuromuscular blocking drugs is dose
dependent (Agoston et al., 1980; Payne and
Hughes, 1981; Basta et al., 1982; Durant, 1982),
their administration in high doses should provide
a more rapid onset of action without the
excessively prolonged duration of action that may
be observed following high doses of the longer-
acting agents. Indeed, Waldburger, Nielsen and
Mulroy (1984) have suggested that atracurium
0.8 mg kg-1 will allow satisfactory intubating
conditions in all patients within 90 s of injection
without prolonged blockade or significant vari¬
ation in haemodynamic indices. However, other
studies have shown that atracurium 0.6 mg kg-1
causes a moderate reduction in mean arterial
pressure as a result of histamine release (Basta et
al., 1983)—an effect which may be prevented by
injecting the drug slowly over 75 s or by
pretreating with i.v. H,- and H2-antagonists (Scott
et al., 1985).
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SUMMARY
The safety and efficacy ofatracurium 0.8 mg kg-1
tvas determined in healthypatients with particular
attention to the speed of onset of blockade, and
to changes in haemodynamic variables. Atracu¬
rium 0.8 mg kg~l had a shorter onset time than
atracurium 0.5 mg kg~\ and satisfactory intuba¬
ting conditions were achieved earlier. "Priming "
produced no significant improvement in onset
time or intubating conditions. Onset times were
significantly shorter with nitrous oxide-opioid
anaesthesia than following thiopentone alone.
Although a 0.8-mg kg~l bolus resulted in a
significant reduction in mean arterial pressure to
75% of control and was associated with a
significant increase in plasma histamine concen¬
trations, this response could be prevented by
injecting the drug over 75 s. "Priming " or a 30-s
injection producedno haemodynamic protection.
The protection achieved by pretreatment with
anti-histamines was incomplete: mean arterial
pressure decreased to 83% of control.
More recently, it has been demonstrated that
the speed of onset and degree of blockade of
competitive neuromuscular blocking drugs may be
enhanced if the agents are administered in divided
doses (Schwartz et al., 1985; Mehta et al., 1985).
From these data it is postulated that an initial
subparalysing dose (priming dose) may occupy
70-75% of cholinoceptors without causing un¬
pleasant symptoms in awake patients. Tracheal
intubation might then be performed more rapidly
after a second larger dose that increases receptor
occupancy quickly to the 90-95% necessary for
paralysis. Furthermore, priming may improve the
haemodynamic profile by releasing less histamine,
as divided dosing is another form of slow injection.
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The present study was designed to determine
the safety and efficacy of administering atracurium
0.8 mg kg-1 to healthy patients. The speed of onset
and the haemodynamic response were studied in
an attempt to find modes of administration that
would combine fast onset times with haemodyna¬
mic stability. Some of these data are compared
with previously unpublished data obtained using
the same investigative procedure, but with the
lower dose of 0.5 mg kg-1, the highest recommen¬
ded in the United States.
PATIENTS AND METHODS
Fifty-six (ASA Class 1 or 2) patients gave
informed consent for the study and were assigned
to one of seven sub-groups at the discretion of the
investigator. The patients were aged 18 to 60 yr,
weighed between 45 and 110 kg, and were
undergoing elective surgical procedures. Any
patient with recent exposure to anti-histamines,
anti-depressants, or aminoglycoside antibiotics
was excluded.
Premedication consisted of morphine 0.1 mg
kg-1 i.m. and diazepam 0.2 mg kg-1 orally. In
groups I-V, anaesthesia was induced with fentanyl
5 pg kg-1 and thiopentone 5 mg kg-1 i.v. The
trachea was intubated without the use of a neuro¬
muscular blocking drug, additional increments of
thiopentone being administered when appropriate
to facilitate this procedure. Ventilation of the
lungs was controlled to produce normocapnia and
anaesthesia was maintained with nitrous oxide in
oxygen. Volatile agents were not used. Heart rate,
ECG, radial arterial pressure, and the single
twitch adductor response at the thumb were
recorded continuously on a Grass polygraph. A
Grass S44 stimulator with subcutaneous needle
electrodes and a Statham strain gauge were used.
The single twitch was produced at a frequency of
0.15 Hz with a stimulus duration of 2 ms. After a
stable baseline period (lOmin) a bolus dose of
atracurium 0.8 mg kg""1 was administered in 5 s to
patients in groups I and IV. This dose was given
over 30 s to patients in group II and over 75 s to
patients in group III. Group V patients received
a priming dose of 0.08 mg kg-1 followed 6 min
later by a 0.72-mg kg-1 bolus. Patients in group IV
were pretreated with cimetidine 4 mg kg-1 and
chlorpheniramine 0.1 mg kg-1 i.v. 15 min before
induction. Maximum changes in heart rate and
arterial pressure were noted. Arterial blood
samples were drawn immediately before the
administration of the atracurium, and at 2 and
5 min after injection. These samples were analysed
for histamine concentration by a radioenzymatic
assay technique (Moss et al., 1981).
In groups VI and VII, anaesthesia was induced
with thiopentone 5 mg kg-1 only. Group VI
patients received a priming dose of atracurium
0.08 mg kg-1 5 min before induction, followed by
a bolus of 0.72 mg kg-1 30 s after induction.
Group VII patients received a bolus of atracurium
0.8 mg kg-1 given in 5 s, 30 s after induction. In
these two groups the trachea was intubated 90 s
following this large dose of atracurium, and the
intubating conditions were classified as 1 (excel¬
lent), 2 (satisfactory), 3 (fair), or 4 (poor) according
to the criteria of Lund and Stovner (1970).
Blood samples were not analysed for histamine
concentrations in these two groups as it would be
difficult to correlate any changes in plasma
histamine concentrations with the inevitable
haemodynamic response to intubation. Further¬
more, the histamine response to these two dose
regimens had already been analysed in groups I
and V under stable haemodynamic conditions.
RESULTS
The results are summarized in tables I, II and III.
The data displayed are mean values with standard
errors of the mean (SEM). The changes in mean
arterial pressure and heart rate are the maximum
changes, calculated as a percentage of the baseline
values, that occurred in the 10 min after the
administration of the atracurium. The actual
values at control, 2 min and 5 min for mean
arterial pressure and heart rate are displayed in
parentheses in table I. The data on mean arterial
pressure, heart rate and histamine concentration
(table II) at baseline and 2 min were analysed
according to a 3-factor analysis of variance with
group and time crossed and patient (a random
factor) nested within group. In order to stabilize
their variability and more closely satisfy the
assumptions underlying the analysis of variance,
the histamine data were analysed on a logarithmic
scale. Tests of significance for the change from
baseline to 2 min within each group then used t
statistics, setting the critical value according to
Bonferroni's inequality so that the simultaneous
significance level would not exceed 0.05 (or 0.01,
as appropriate).
There were significant decreases in mean
arterial pressure in groups I, II and V (P < 0.05)
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Table I. Cardiovascular data. Effect of atracurium 0.8 mg kg'1
on mean arterial pressure (MAP) and heart rale (HR). Actual
values at baseline, 2 and 5 min for mean arterial pressure (mmHg)
and heart rate (beat min'1) are shown in parentheses. The range
of the maximum per cent change in MAP and HR is shown in






Group I 8 74.6 + 5* 113.25 ±3.75
(5-s bolus) (80.8/60/76.5) (64.25/72.1/65.8)
[52-97] [100-138]
Group II 8 77 ±7.5* 114.75 ±10.8
(30-s dose) (67.25/50.75/64.75) (60/67.5/58.8)
[49-104] [89-191]
Group III 8 95.7+1.2 102.6+1.17
(75-s dose) (71.1/68.5/70.1) (55.2/56/55.7)
[90-100] [96-107]
Group IV 8 83.3 + 7.1 109.9±3.65
(anti-hist.) (77.3/65.6/75.1) (59.1/64.7/60)
[38-100] [96-125]
Group V 8 76 ±7.6* 109.3±2.83
(prime) (68.5/52.5/64.7) (63.5/69.3/65)
[43-103] [100-126]
(table I). The moderate decrease in group IV
approached, but did not reach, statistical signifi¬
cance (0.1 > P > 0.05). In all patients the changes
in arterial pressure and heart rate were transient
and had returned to baseline values by 5 min.
Patients in groups I, IV and V demonstrated
significant increases in plasma histamine concen¬
tration at the 2-min sample (table II).
There were no significant differences in onset
time (table III) between any of the techniques of
administration when atracurium 0.8 mg kg-1 was
administered during nitrous oxide and fentanyl
anaesthesia. Nor was there a significant difference
between groups VI and VII in which atracurium
was administered following induction with thio¬
pentone. Atracurium 0.8 mg kg-1 produced a
significantly shorter onset time (P < 0.05) than
0.5 mg kg-1 under nitrous oxide-opioid anaes¬
thesia. Atracurium 0.8 mg kg-1 also produced a
significantly more rapid onset than 0.5 mg kg-1
following induction with thiopentone alone
(P < 0.05).
The depth of anaesthesia appeared to have an
effect on onset time, and both the bolus (group I)
and prime (group V) groups had significantly
shorter onset times (P < 0.05) under nitrous
oxide-fentanyl anaesthesia when compared with
the bolus (group VII) and prime (group VI)
groups, respectively, receiving thiopentone alone.
There were no significant differences between
the recovery times or the durations of action in the
four groups in which these were recorded.
The intubation score was slightly better in the
prime group (VI) than in the bolus group (VII),
but this was not significant. The intubation score
produced by the 0.8-mg kg-1 bolus group at 90 s
was the same as that produced by 0.5 mg kg-1 at
150 s.
DISCUSSION
We have shown previously that atracurium
0.6 mg kg-1 given over 5 s is associated with a
doubling of plasma histamine concentrations and
a 21 % reduction in mean arterial pressure. These
changes can be prevented by administering the
drug over 75 s or by pretreating with anti¬
histamines (cimetidine 4 mg kg-1 and chlorphen¬
iramine 0.1 mg kg-1 i.v.) 15 min before the
injection of the neuromuscular blocker.
In this study, decreasing the rate of injection of
Table II. Effect of atracurium 0.8 mg kg 1 on plasma histamine concentrations. By t test: *P < 0.05
(simultaneous); **P < 0.01
Plasma histamine (pg ml ')
n Control + 2 min + 5 min
Group I 8 557 + 232 1646 + 419* 721 + 167
(5-s bolus) [177-2110] [710-4070] [100-1552]
Group II 8 453 + 81 2137 ±984 1030 ±268
(30-s dose) [230-1023] [247-8999] [308-2127]
Group III 8 669 ±171 791 ±123 541 ±86
(75-s dose) [182-1347] [466-1500] [147-972]
Group IV _ 8 485±100 6154±4063** 2251 ±1436
(anti-hist.) [192-922] [105-34064] [59-12016]
Group V 8 203 ±44 1874± 804** 558 ±158
(prime) [94-470] [95-6871] [60-1259]
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Table III. Pharmacodynamic data (mean±SEM). All data in parentheses refer to atracurium 0.5 mg kg 1
(n = 10)
Onset (min)
(end injection 5-95% Duration (min) Intubating
to complete Recovery (injection to conditions
block) (min) 95% recovery) at 90 s
Group I 1.82 + 0.25 20.8 + 1.22 70±1.49
(5-s bolus) (2.3 ±0.2) (24) (59 ±1.9)
Group III 1.71 + 0.21 24 + 2.1 69.7±5.4
(75-s dose)
Group IV 2.0±0.17 30.75 + 3.6 . 83.1 ±6.6
(anti-hist.)
Group V 1.9 ± 0.21 29.8± 1.2 81.25±6.6
(prime)




Group VII 3.48 + 0.54 1.9 ±0.26
(5-s bolus (4.6 + 0.4) (1.9±0.4
thiopentone at 150 s)
only)
atracurium 0.8 mg kg-1 to 75 s also minimized the
haemodynamic changes and prevented the increase
in histamine concentration. However, in the
anti-histamine group, the haemodynamic protect¬
ion was incomplete and was associated with a
highly significant increase in plasma histamine
concentration. The patient with the most marked
increase in plasma histamine concentration and
the greatest decrease in mean arterial pressure was
in this group. This large increase in mean plasma
histamine concentration may have been the result
of the known inhibitory effect of cimetidine on
histamine-N-methyltransferase, the enzyme res¬
ponsible for one of the major catabolic pathways of
histamine. The substantial increase in plasma
histamine concentration in this group probably
overcame the protection offered by the anti¬
histamines by a simple dose-response effect.
Although there was almost a 5-fold increase in
plasma histamine concentrations following the
30-s injection, this was not found to be statistically
significant because of the large between-patient
variation and, hence, the large standard deviation
in this group. Considerable variability for histamine
release among subjects is well recognized. Not all
patients will release histamine after high doses of
atracurium but, as the size of the bolus dose
increases, there is a greater likelihood of this
occurring in most individuals. In animal studies,
mast cells from different species and even
individual tissues within a single animal are shown
to vary markedly in their response to a given
inducer of histamine release (Pearce, 1982).
This histamine-releasing response to the higher
doses of atracurium must be kept in perspective.
Basta and colleagues (1983) have shown that the
ability of atracurium to release histamine, relative
to its neuromuscular blocking potency, is only
one-half that of di-methyl tubocurarine and less
than one-third that of tubocurarine. Nevertheless,
this response could be of significance in the
hypovolaemic patient or the patient with cardio¬
vascular disease.
Several studies have demonstrated more rapid
onset of blockade and superior intubating condit¬
ions when the priming principle was used (Hutton
et al., 1983; Bevan et al., 1984; Nagashima et al.,
1984; Mehta et al., 1985; Schwartz et al., 1985).
However, there is little uniformity among these
studies in terms of the drugs used, the priming
dose, the intubating dose, the time between
priming and intubating dose and the anaesthetic
technique used. These variables may require
proper adjustment for each competitive neuro¬
muscular blocking agent. We can only conclude
that, with the dose regimen and time interval used
in this study, priming does not improve onset
times or intubating conditions; nor does it have
any protective haemodynamic effect.
A wide variety of onset times at a number of
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different doses has been reported for atracurium
(Payne and Hughes, 1981; Scott and Goat, 1982;
Foldes et al., 1983; Gergis et ah, 1983). However,
standardization of anaesthetic technique is very
important before any effective comparison can be
made. In particular, the starting point and end
point in the measurement of onset time, the mode
ofperipheral nerve stimulation and the anaesthetic
agents used should all be defined clearly. This is
emphasized in this study by the significantly
shorter onset times under nitrous oxide—opioid
anaesthesia compared with those associated with
thiopentone alone.
We conclude that atracurium 0.8 mg kg-1 will
produce a significantly more rapid onset of
blockade than 0.5 mg kg-1with a similar intubation
score 1 min earlier (at 90 s compared with 150 s).
This may. be associated with a transient but
significant decrease inmean arterial pressure. This
effect, which is probably of little importance in the
healthy patient can, however, be attenuated by
injecting the drug more slowly—over 75 s.
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New Muscle Relaxants and the
Cardiovascular System
In the early 1980s the most commonly used muscle
relaxants in anesthetic practice in the United States
were succinylcholine, tubocurarine, metocurine,
pancuronium and, to a lesser extent, gallamine.
, However, these agents have certain cardiovascular
side effects that limit their use. These effects are
generally due to stimulation or inhibition of periph¬
eral autonomic sites, to the release of histamine and
possibly other vasoactive substances from vascular
mast cells, or to increases in serum potassium levels
secondary to motor end-plate depolarization. A
major reason for developing new neuromuscular
fMocking agents is to produce drugs that avoid these
f»dl-known side effects. A careful examination of
ylhe advantages and disadvantages of the above agents
lead to the conclusion that a nondepolarizing
ramscle relaxant such as pancuronium, without car¬
diovascular side effects, would provide a significant
< i"H>iuvctnent.
^
_ The accumulated knowledge of structure-
icovity relationships in the field of neuromuscular
"°ckade allows chemists to produce effective neuro-
'•Vr*Cl"ar h'<K^n8 drugs more predictably, with less
on chance, than is the case with any other
drugs. Consequently, most kinds of




molecular design; and new compounds that produce
unwanted effects can be discarded at an early stage in
preclinical testing. The development of atracurium
and vecuronium has marked an exciting stage in the
production of drugs with improved cardiovascular
stability. These two drugs fall into the intermediate
duration class, but research is continuing to find
agents of similar cardiovascular stability with shorter
and longer durations of action.
PHARMACOLOGY OF THE AUTONOMIC
NERVOUS SYSTEM
In order to understand the autonomic responses
to existing muscle relaxants and the developmental
pharmacology of new agents, it is important to have
a working knowledge of the autonomic nervous sys¬
tem, and, in particular, the possible sites of interac¬
tion between muscle relaxants and cholinoceptors.
Acetylcholine acts on both muscarinic and nico¬
tinic receptors (Table 5-1). Muscarinic receptors are
present in various smooth muscles, cardiac muscle,
and exocrine glands. They are termed "muscarinic"
because muscarine, a quaternary amine alkaloid, has
Copyright © 1987 by Grune & Stratton, Inc.
All rights of reproduction in any form reserved.
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Table 5-1
Cholinoceptive Sites
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Fig. 5-1. Structural relationship of acetylcholine to two
neuromuscular blocking agents. Succinylcholine (diacetyl¬
choline) is simply two molecules of acetylcholine linked
through the acetate methyl groups. Pancuronium may be
viewed as two acetylcholine-like fragments (outlined in
dark print) properly orientated conformationally on a bulky,
rigid, inflexible steroid nucleus.
actions similar to those of acetylcholine at the sites
indicated. The muscarinic receptor is blocked by
atropine and related drugs. The nicotinic receptors of
acetylcholine are located in autonomic ganglia and at
the skeletal neuromuscular junction. They are termed
"nicotinic" because nicotine also acts on these recep¬
tors. However, the nicotinic receptors in the auto¬
nomic ganglia and skeletal muscle are not identical.
The effect of acetylcholine on autonomic ganglia is
blocked by tubocuranne and related compounds.
Further cholinoceptive sites are found on the esteratic
receptors of acetylcholinesterase and plasma cholin-
esterase. Crystalographic analysis of acetylcholine
and related agonists provides a tentative answer to
the nature of the cholinergic receptor. Acetylcholine
is a flexible molecule, and rotation is possible at two
different bonds (Fig. 5-1). Muscarinic and nicotinic
drags differ from acetylcholine in the degree of rota¬
tion at the sites of torsion. Thus, acetylcholine has
both muscarinic and nicotinic effects, whereas the
purely muscarinic or nicotinic congeners have con¬
straints imposed on them by conformational factors.
In order for neuromuscular blocking drags to interact
with the recognition sites of the cholinoceptors at the
neuromuscular junction, the drags must bear some
chemical relationship to acetylcholine. Conse¬
quently, there is the possibility that they might com¬
pete with or mimic acetylcholine at other sites (eg.
cholinesterases, nicotinic autonomic ganglionic re¬
ceptors, and muscarinic receptors).
Mew Muscle Relaxants 153
d- TUBOCURARINE DIMETHYL TUBOCURARINE
Fig. 5-2. The chemical structure of some common nondepolarizing neuromuscular
blocking agents.
Interaction of Neuromuscular Blocking
Agents at Different Cholinoceptive
Sites
AUTONOMIC GANGLIA
Tubocurarine (Fig. 5-2) blocks ganglionic nico¬
tinic receptors and produces some ganglionic block¬
ade in a dose range similar to that required to produce
neuromuscular blockade. It may have a slightly more
powerful action on parasympathetic than on sympa¬
thetic ganglia.' Autonomic reflexes arising in the
course of surgical operations may be impaired by the
ganglionic blocking action, and this action may con¬
tribute to hypotension.2-3 Recent evidence, however,
suggests that the role of ganglionic blockade in the
hypotensive action of tubocurarine is possibly less
"hportant than its ability to release histamine.4
Metocurine (dimethyltubocurarine) and alcuro-
nium (diallyltoxiferine) are weaker ganglionic block¬
ers; and other neuromuscular blocking drugs (eg,
gallamine, pancuronium, atracurium, and vecuro¬
nium) have no ganglionic blocking activity in the
doses used clinically (Fig. 5-2). Succinylcholine has
a weak autonomic ganglion stimulant action that may
have some clinical importance, since a hypertensive
response is occasionally observed (Fig. 5-3).5
MUSCARINIC RECEPTORS
Evidence has accumulated in recent years that
muscarinic receptors are probably not a homogene¬
ous group.6 By definition they are all stimulated by
muscarine and they are all blocked by atropine, but
they may differ with respect to their interactions with
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Fig. 5-3. Hypertensive response to succinylcholine (SDC). Increased arterial pressure
after succinylcholine administration may represent a clinical manifestation of its ganglion
stimulating action. This patient had a hypertensive response to succinylcholine. There
was no other anesthetic or surgical intervention.
other agonists and antagonists. Figure 5-4 is a diagra-
matic representation of the main components of the
autonomic nervous system with respect to the heart.
For the purpose of the diagram, the muscarinic cho-
linoceptors have been labeled "Ml," "M2." and
"M3" receptors, but this is not a strict classification
and is probably an oversimplification.7
The first indication that muscarinic receptors
may not all be identical in character came from Riker
and Wescoe8 who showed that gallamine, although
generally free from atropine-like activity in smooth
muscle, nevertheless blocked muscarinic receptors in
the cat heart, and, consequently, inactivated the car¬
diac vagus nerve. In Figure 5-4 the cardiac mus¬
carinic receptors are included in the "M2" group to
distinguish them from the more usual type labeled
"Ml." Other workers have since shown that pan¬
curonium,9 fazadinium,10 alcuronium," and ster-
curonium12 also block the cardiac muscarinic
receptors in doses approximating those required to
produce muscle relaxation. Tubocurarine, meto-
curine, vecuronium, and atracurium block cardiac
muscarinic receptors and other muscarinic receptors
only in doses that greatly exceed the neuromuscular
blocking dose.13"'5
Arterioles also have muscarinic receptors, but
< • Blocking Action
-!—- Focibtotes Reieose
Fig. 5-4. Diagrammatic representation of the autonomic nervous system with respect to
the heart, and sites of action of some neuromuscular blocking drugs on this system. The
muscarinic receptors have been divided into three subclasses (M|,'M:, M3). By permis¬
sion of the authors. N = nicotinic receptor, P = pancuronium, G = gallamine, F =
fazadinium, dTc = 4-tubocurarine.
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these receptors are not innervated. They resemble
most of the noncardiac muscarinic receptors in their
agonist and antagonist selectivity, and are labeled
"Ml" in Figure 5-4. The vasopressor response to
methacholine, although blocked by atropine, is not
affected by pancuronium, showing that the mus¬
carinic receptors involved in the arterioles are not the
same type as those in the sinoatrial node.
Experiments have shown that cardiac muscarinic
receptors are not the only muscarinic receptors that
are blocked by certain neuromuscular blocking
drugs. Stimulation of the vagus nerve has been
shown to reduce the release of norepinephrine from
concomitantly stimulated sympathetic nerves to the
heart.16 It is, therefore, believed that vagus nerve
terminals impinge not only on the nodal and atrial
cells of the heart, but also on the sympathetic nerve
endings where they act to inhibit the release of norep¬
inephrine. The cholinergic receptors on the sympa¬
thetic nerve endings are of the muscarinic type, and
there is indirect evidence that they are blocked by
gallamine and pancuronium, but much less effec¬
tively by vecuronium.17 This effect would enhance
the tachycardia arising from blockade of the cardiac
muscarinic receptors. Because the muscarinic recep¬
tors on the sympathetic terminals resemble the car¬
diac muscarinic receptors in being blocked by
gallamine and pancuronium, they have both been
labeled "M2," but the evidence of similarity is not
very strong.
Another location of muscarinic cholinoceptors
that are blocked by pancuronium and gallamine and
are, therefore, indicated as "M2" receptors in Figure
5-4 is on the small dopaminergic intemeurons on
sympathetic ganglia. These cells are activated
through muscarinic receptors stimulated by acetyl¬
choline that is released from collaterals of the pre¬
ganglionic cholinergic nerve fibers. Dopamine
released from these cells onto the ganglion cells
hyperpolarizes them and, therefore, suppresses gan¬
glionic transmission.18 Blockade of these inhibitory
cells by gallamine or pancuronium may, therefore, at
appropriate stimulation frequencies, facilitate trans¬
mission through the ganglia by inactivating the inhib¬
itory modulating influence of the dopaminergic cell
loop.19
Transmission through sympathetic ganglia is
mediated by acetylcholine acting on nicotinic recep¬
tors. There are, however, muscarinic cholinoceptors
present on sympathetic ganglia whose physiological
function is as yet unknown. These are labelled "M3"
receptors in Figure 5-4. They differ from those
labeled "M2" in that they are not blocked by gal¬
lamine or pancuronium; and, they differ from those
labeled "Ml" and "M2" in that they are especially
sensitive to certain unusual muscarinic agonists.20 It
should be noted that gallamine causes norepinephrine
release in guinea pig and cat atria and in anesthetized
cats by a mechanism that may be quite independent
of muscarinic blockade.21 Similarly, very large con¬
centrations of pancuronium produce norepinephrine
release in isolated guinea pig atria under conditions
in which parasympathetic block could not be
involved.22 Pancuronium and fazadinium have also
been shown to block norepinephrine reuptake into
sympathetic nerve endings both in cardiac muscle
and in smooth muscle in guinea pigs and rats.22"24 In
the cat, the main mechanism through which certain
neuromuscular blocking drugs depress cardiovagal
activity is by blocking postjunctional muscarinic cho¬
linoceptors as described above. However, Lee Son
and Waud calculated that the concentrations of pan¬
curonium and gallamine that block responses to post¬
junctional vagal stimulation are too low to exert
significant blocking action on the postjunctional
muscarinic receptors; they concluded that the main
site of action of these two drugs in blocking the
guinea pig cardiac vagus is on the postganglionic
nerve terminals.25
It can be concluded from the foregoing discus¬
sion that a combination of any of the above actions of
gallamine, pancuronium, and fazadinium may
account for the cardiovascular effects of these drugs.
There is considerable species difference with regard
to the relative importance of these effects. It is not
known which effect is the most predominant in
humans, but it is likely that the relative importance
varies from patient to patient according to such fac¬
tors as the pre-existing autonomic balance, the type
of premedication, the anesthetic, and any concurrent
drug therapy.
The Demonstration of Autonomic
Effects of Neuromuscular Agents in
Whole Animals
There are no appropriate means for testing the
autonomic effects of relaxants in man, and most of
the knowledge of these actions is derived from exper¬
iments performed in isolated organ systems or in
whole animals such as the cat. In the cat, measure¬
ments of neuromuscular and autonomic functions
may be accomplished simultaneously. Neuromuscu¬
lar function is assessed by recording the twitch
response of the tibialis anterior (or other appropriate
muscle) evoked indirectly via the sciatic or peroneal
nerve. Vagal function is determined by quantitation
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Fig. 5-5. Sympathetic (ganglionic) inhibition by nondepolarizing relaxants in the cat. (JJ
Savarese, unpublished data).
of the bradycardia and hypotension elicited by stimu¬
lation of the nerve. Sympathetic ganglionic responses
(Fig. 5-5) are assayed by preganglionic stimulation
of the sympathetic trunk, central to the superior cer¬
vical ganglion, and recording the evoked contraction
of the nictitating membrane (Fig. 5-6).
The separation of neuromuscular blocking action
from autonomic effects can be described for each
drug as its autonomic margin ofsafety. This indicates
the number of multiples of a dose of relaxant, pro¬
ducing 95 percent neuromuscular blockade, that must
be administered in order to produce side effects. The
higher the autonomic margin of safety, the lower the
probability of occurrence of a side effect. The fol¬
lowing quotients are used:
1. ED50 (Ganglion block)
ED95 (Neuromuscular block)
2. ED5Q (Cardiac vagal block)
ED95 (Neuromuscular block)
3. ED50 (Histamine release)
ED95 (Neuromuscular block)
Calculation of autonomic margins of safety for neu¬
romuscular blocking drugs in man is not possible
because suitable methods for quantitating autonomic
responses in humans are not available. There is con¬
siderable indication, however, that when a neuro¬
muscular blocking drug produces an autonomic
effect in the cat within or near the neuromuscular
dose range, the neuromuscular blockade in humans
will be accompanied by cardiovascular changes cor¬
responding to those autonomic actions (Table 5-2).
The ED95 for neuromuscular blockade for some
of the nondepolarizing relaxants in humans, under
nitrous oxide, has been determined. These values,
together with the ED50 for ganglion and vagal block
derived in the cat (since these cannot be determined
in humans), were used to calculate the values in the
table. The ED50 for histamine release can, however,
be calculated in humans, using an isotope radioenzy-
matic assay. The relative importance of ganglion
block, vagal block, and histamine release for each of
the nondepolarizing relaxants is outlined in Table
5-3.
Anesthesiologists encounter both immunologi¬
cally mediated reactions and chemically mediated
reactions associated with the administration of mus¬
cle relaxants. Immunological reactions to muscle
relaxants have never attracted as much attention as
those to intravenous induction agents. These reac¬
tions are rare but no less dangerous in their manifes¬
tations, since many have been severe enough to
necessitate cardiopulmonary resuscitation. Reactions
to succinylcholine are more common than with any
other muscle relaxant.
Chemically mediated reactions happen much
more frequently and occur when the injected sub¬
stance acts directly on tissue cells and basophil leu¬
kocytes, leading to the release of histamine without
antibody or complement involvement. Most organic
bases can release histamine, and most neuromuscular
blocking drugs have been shown to produce this
effect when sufficiently large doses or concentrations





Fig. 5-6. Simultaneous recording of autonomic and neuromuscular function in a cat
anesthetized with chloralose. Recordings are (top to bottom) of heart rate, femoral arterial
pressure, contractions of the left and right nictitating membranes elicited preganglioni-
cally and postganglionically, and tibialis anterior muscle twitch. At times indicated by
dots below the graphs, stimulation of the right vagus nerve and both sympathetic trunks
(left postganglionically, and right preganglionically) was applied at 20 Hz for 10 seconds.
At times indicated by arrows below graphs, d-tubocurarine in doses indicated (mg/kg)
was given intravenously. Lower figures indicate cumulative dosage. Note that vagal
response (bradycardia and hypotension), ganglionic response (preganglionically stimu¬
lated nictitating membrane) and neuromuscular response are all inhibited at a cumulative
dose of 0.8 to 1.6 mg/kg. Marker H between the upper two graphs indicates cardiovascu¬
lar changes suggestive of histamine release. Marker V indicates points of vagal stimula¬
tion with little or no response. (From Savarese JJ: The autonomic margins of safety of
metocurine and d-tubocurarine in the cat. Anesthesiology 50:40, 1979, with permission.)
Table 5-2
Autonomic Margin of Safety of Nondepolarizing Relaxants in Man
Drug
Neuromuscular




releaseED9S in Man Ganglion block Vagal block
d-tubocurarine 0.51 2.94 0.59 1
Metocurine 0.28 18.6 2.86 2
Pancuronium 0.07 328.6 2.86 High
Alcuronium 0.25 18.0 1.84 High
Vecuronium 0.056 89.2 40.6 High
Atracurium 0.28 35.7 8.7 3
*ED95 in humans (mg/kg)
Autonomic margin of safety =
Margin of safety for
histamine release
ED50 for autonomic inhibition in the cat
ED95 for neuromuscular block in man
EDW for histamine release in man
ED95 for neuromuscular block in man.
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Tubocurarine * - *** i I 1 -
Metocurine - - * i - 1 -
Pancuronium - »* - - T t T
Gallamine - *♦* - - T T T
Alcuronium * * - i T 1 t
Fazadinium ** ** - I T f T
Vecuronium - - - - - - -
Atracurium - - (- to *) (- or -l) (- ort) (- ori) -





are used.26 It is important to know, however, whether
the effect is likely to occur with the dosage used in
clinical practice. It has been recognized that tubo-
curarine is a potent liberator of histamine, and this is
possibly the major cause of the hypotension occur¬
ring in most patients given clinical doses.
Recent work has demonstrated that the release of
histamine by muscle relaxants in humans is dose-
dependent (Fig. 5-7), and that the release is well-
correlated with significant hemodynamic effects
(Fig. 5-8).4 Further studies, however, have shown
that there are clinical strategies, such as slowing the
injection rate (Fig. 5-7), or administering histamine
receptor blockers (HI and H2), that can blunt these
effects in humans.27
The ability of atracurium to release histamine
relative to its neuromuscular blocking potency is
approximately one-half that of dimethyltubocurarine.
and about one-third that of tubocurarine.28 Succinyl-
choline has a histamine-liberating activity about 1
10.000-
-g i • 8oluS
\ 8C001- o Infusion
^ p< 0.05
Fig. 5-7. Slowing the injection rate of d-tubocurarine minimizes histamine release. In a
study with d-tubocurarine, Moss et al found dose-related increases in plasma histamine
occurring 2 minutes after injection in the groups receiving boluses, but not in those
receiving a slow (60-90 sec) infusion. (From Moss J, Rosow CE. Savarese JJ, et al: Role
of histamine in the hypotensive action of d-tubocurarine in humans. Anesthesiology
55:19, 1981, with permission.)
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Fig. 5-8. Relationship between the decrease in blood pres¬
sure and plasma histamine concentration 2 minutes after the
administration of indicated doses of d-tubocurarine in 21
patients. (From Moss J, Rosow CE. Savarese JJ. et ai: Role
of histamine in the hypotensive action of d-tubocurarine in
humans. Anesthesiology 55:19, 1981, with permission.)
percent that of tubocurarine, while gallamine, pan¬
curonium, and vecuronium have minimal potential
for releasing histamine in clinical doses.
STRUCTURE-ACTIVITY RELATIONSHIPS
The natural transmitter at the neuromuscular
junction, acetylcholine, has a positively charged
ammonium group, which is attracted to the nega¬
tively charged cholinergic receptor sites. This feature
is also common to the neuromuscular blocking drugs
that contain at least one quaternary ammonium group
(Figs. 5-1 and 5-2).
The neuromuscular blocking agents show certain
structural similarities to acetylcholine. Succinylcho-
line is essentially two molecules of acetylcholine
linked through the acetate-methyl groups. Depolariz¬
ing agents, such as succinylcholine, generally stimu¬
late nicotinic and muscarinic receptors in imitation of
the role of acetylcholine. The depolarizing action of
succinyl choline is due to the presence in the mole¬
cule of the trimethyl ammonium group and the car-
boxyl groups in a linear flexible chain (Fig. 5-1). The
separation of the quaternary ammonium functions
from the carboxyl groups by a distance of 4.5 A, as
occurs with acetylcholine, also contributes to the
agonist (depolarizing) action of succinylcholine.:9
Removal of the carboxyl groups of succinylcholine
results in decamethonium, which has much weaker
autonomic stimulating properties than succinylcho¬
line.30
The shape and flexibility of the molecule is
important. Most agonists such as succinylcholine are
flexible, long, and slender. Bulky molecules such as
pancuronium with a rigid ring system cannot activate
or stimulate the receptors themselves, but block the
approach of acetylcholine, and, therefore, produce a
nondepolarizing block by antagonism or receptor
inhibition.
Tubocurarine (Fig. 5-2) has now been shown to
have only one quaternary ammonium group and a
tertiary amine group in equilibrium with a proton at
physiological pH.31 The new formula supports the
autonomic ganglionic properties of tubocurarine as a
monoquatemary structure, which is more likely to
produce ganglionic blockade than a bisquaternary
compound. The histamine-releasing properties of
tubocurarine are probably due to the presence of the
tertiary amine.32 In general, bisquaternary com¬
pounds do not possess strong ganglionic blocking or
histamine-releasing properties. Methylation of tubo¬
curarine to produce metocurine or dimethyltubocura-
rine (a bisquaternary compound) reduces the
histamine-releasing and ganglion-blocking activities
associated with tubocurarine, and results in a muscle
relaxant that is three times less potent than tubo¬
curarine in blocking sympathetic and parasym¬
pathetic ganglia."-13 Gallamine (a trisquatemary
compound) has marked vagolytic properties probably
due to the presence of the three positively charged
nitrogen atoms.SJI
THE DEVELOPMENTAL CHEMISTRY OF THE
NEW DRUGS
In 1973, a model of the perfect relaxant was
described by Savarese and Kitz33 as a drug having a
brief, noncumulative, nondepolarizing neuromuscu¬
lar blocking action with a rapid onset and recovery. It
should be readily reversible by an appropriate antag¬
onist, cause neither histamine release nor ganglionic
blockade, and give rise to minimal cardiovascular
side effects. It should be highly potent and its metab¬
olites should neither accumulate nor have any phar¬
macologic activity or toxicity.
In 1851, coincidentally in the same year that
Claude Bernard first described the action of curare on
the neuromuscular junction, A.W. Hofmann
described his method of degrading quaternary ammo¬
nium compounds, now known as "Hofmann elimina¬
tion," which required strong alkaline conditions and
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Fig. 5-9. Proposed pathways of inactivation of atracurium by Hofmann elimination
reaction and ester hydrolysis. (From Basta SJ, Ali HH. Savarese JJ. et al: Clinical
pharmacology of atracurium besylate (BW 33A): A new non-depolarizing muscle relax¬
ant. Anesth Analg 61:723, 1982, with permission.)
very high temperatures. More than 100 years later
these two apparently unrelated events were brought
together and led to the development of atracurium.
Professor J.B. Stenlake of the University of Strath-
clyde, Glasgow, had the novel idea of incorporating
these features into the chemical structure of a neuro¬
muscular blocking agent that would allow the Hof¬
mann elimination to proceed under physiological
conditions at body pH and temperature.34 The idea
was that the incorporation of this self-destructing
mechanism would provide a drug that was not depen¬
dent on hepatic or renal function for the termination
of its action. This nonenzymatic biodegradation
mechanism (Fig. 5-9) is promoted by the combined
electron-withdrawing properties of the two beta-
linked estercarbonyl groups and the positively
charged nitrogens of the quaternary ammonium
groups. Nucleophylic attack by hydroxyl ions occurs
readily at physiological pH and temperature. It
results in the destruction of the bisquaternary struc¬
ture essential for neuromuscular blocking activity
through molecular fragmentation to laudanosine and
other products without significant neuromuscular or
cardiovascular effects.35 Hydrolysis of the ester
groupings is similarly promoted by the electron-with¬
drawing effects of the positively charged quaternary
ammonium groups. Hofmann elimination is. there¬
fore, accompanied by ester hydrolysis, which further
fragments the molecule to inactive components.
Breakdown and loss of potency of atracurium in
human plasma is independent of plasma esterase
activity. The time course of action is unaffected by
hepatic metabolism or renal function.
The rates of Hofmann elimination and ester
hydrolysis of atracurium control the stability and life
of the intact molecule both in vivo and in vitro. Both
reactions are base-catalyzed so that potency and
duration of the full block are reduced and recovery is
hastened by alkalosis. Ester hydrolysis is also acid
catalyzed, but Hofmann elimination is increasingly
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inhibited with the decreasing pH. Stability of the
molecule, as a whole, is, therefore, achieved at about
pH 3.5, and aqueous jnjection solutions at this pH
stored under refrigerated conditions have a shelf life
adequate for clinical use. It follows that artificial
lowering of body temperature in vivo as in open heart
surgery may, therefore, slow the inactivation of atra-
curium to advantage; whereas rewarming should
enhance this decomposition and hasten recovery.
Hofmann elimination was originally postulated
to be the major route of in vivo degradation of atracu-
rium, although a recent in vitro study in human
plasma has demonstrated that ester hydrolysis is pos¬
sibly of more importance as the major metabolic
pathway.36 If these findings can be confirmed, the
hypothetical potential adverse effects from the acry-
late end-products of Hofmann elimination would be
lessened. A further hypothetical side effect of an
atracurium metabolite is the known convulsant effect
of laudanosine. This, however, occurs at blood levels
unlikely to be achieved even by prolonged atracu¬
rium administration.37
Savage et al are responsible for the manipulation
of the steroid nucleus that resulted in the develop¬
ment of many neuromuscular blocking drugs, the
most successful being the bisquatemary compound,
pancuronium (Fig. 5-1).38 In order to provide a non¬
depolarizing neuromuscular blocker with a more
rapid onset of action and a shorter duration of action,
the monoquaternary vecuronium bromide (Fig. 5-2)
was developed from a continuation of the research
that originally resulted in pancuronium. Extensive
studies of many analogues of pancuronium identified
the importance of retaining an intact ring D-acetyl-
choline-like fragment to ensure high neuromuscular
blocking activity.39 However, when the acetylcholine
moiety involving ring A is modified, resulting in a
tertiary nitrogen atom at position 2, the remaining
monoquaternary derivative, vecuronium bromide,
exhibits an unusually high selectivity for the post¬
junctional cholinoceptors at the neuromuscular junc¬
tion. It is considered that the high selectivity for the
postjunctional cholinoceptors that vecuronium and
pancuronium display can be attributed to the unique
hydrogen-bonded, cagelike structure of this particu¬
lar ring D-acetylcholine fragment.
Although vecuronium differs from pancuronium
only in the nature of its 2-piperidine nitrogen atom,
which is tertiary, as distinct from quaternary, this
single apparently minor molecular modification
results in a drug molecule that is significantly differ¬
ent in both physical and chemical properties and in
chemical reactivity. Although both vecuronium and
pancuronium are hydrophilic, vecuronium is slightly
more lipophilic because it is a monoquaternary rather
than a bisquaternary compound. Increased lipophilic-
ity should enhance penetration into membranes and
could alter vecuronium's route of elimination, as
compared with pancuronium, which has proved to be
the case. In short, vecuronium is a significantly dif¬




When dose-response curves are constructed, the
ED95 (ie, the mean dose of neuromuscular blocking
drug that depresses twitch tension by 95 percent) can
be derived. This dose usually provides adequate
relaxation in an anesthetized patient. The ED90 and
ED95 reported by different investigators40-49 have
varied because of several factors, including the anes¬
thetic and the method of peripheral nerve stimulation
used (eg, single twitch tension, train of four). How¬
ever, an approximate ED95 value for atracurium is
0.28 mg/kg, for vecuronium, 0.056 mg/kg, and for
pancuronium, 0.07 mg/kg. Vecuronium is the most
potent muscle relaxant currently available for use in
clinical practice. The log dose-response curves for
vecuronium, pancuronium, and atracurium are essen¬
tially parallel (Fig. 5-10).
Volatile anesthetic agents will enhance a nonde¬
polarizing neuromuscular block more than a nitrous
oxide-narcotic technique. Studies have shown that
enflurane is the most potent volatile agent, followed
by isoflurane, and then halothane in enhancing neu¬
romuscular blockade.50 The potencies of atracurium
and vecuronium appear to be influenced less by the
choice or concentration of volatile anesthetic than are
the potencies of tubocurarine and pancuronium.
Enflurane and isoflurane augment tubocurarine and
pancuronium neuromuscular blockade about twice as
much as does an equipotent concentration of halo¬
thane.51-53 In contrast, the augmentation of a vecuro¬
nium- or atracurium-induced neuromuscular
blockade by enflurane or isoflurane is only 20-30
percent greater than the augmentation produced by
halothane or nitrous oxide-narcotic anesthesia.54-56
Changes in the end-tidal concentration of inhaled
anesthetics also have a lesser influence on neuromus¬
cular blockade produced by vecuronium or atracu¬
rium than those produced by other nondepolarizing
neuromuscular blockers. The reasons for vecuronium
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Fig. 5-10. The log dose-response curves for vecuronium
(V). pancuronium (P), and atracurium (A). (From Gram-
stad L. Lilleaason P. Minsaas B: Comparative study of atra¬
curium, vecuronium (Org NC 45) and pancuronium. Br J
Anaesth 55(Suppl 1):95S, 1983, with permission.)
and atracurium being less influenced by the specific
anesthetic and its dose or concentration are unknown.
Pharmacokinetics
Both vecuronium and atracurium have distinct
pharmacokinetic properties as compared with cur¬
rently used nondepolarizing muscle relaxants. For
example, unlike pancuronium, metocurine, tubo-
curarine. or gallamine, neither vecuronium nor atra¬
curium depends heavily on the kidney for
elimination. Because atracurium is metabolized
nearly completely through Hofmann elimination and
ester hydrolysis, it should be excreted either in the
urine or bile mostly in the form of metabolites.
Although urinary and biliary excretion have not been
determined in humans, the elimination half-life has
been shown to be about 20-30 minutes.57"58 Further
confirmation of rapid metabolism is the appearance
of laudanosine in the blood within 5-20 minutes.57
Only 10-25 percent of an injected dose of
vecuronium is excreted in the urine.59"61 The pre¬
dominant route of elimination is almost certainly the
bile.59 Although vecuronium should be metabolized
into its 3-hydroxy, 17-hydroxy, and 3,17-hydroxy
metabolites as is pancuronium, only small amounts
of these metabolites have been detected by methods
such as thin layer chromatography.60 The precise
extent to which vecuronium is metabolized has not
yet been determined, although most of the drug
seems to be excreted unchanged in the urine and
bile.59 The proposed metabolites have little or no
cardiovascular or neuromuscular effects, and. there¬
fore, are of little concern.62"6-1 In humans, vecuro¬
nium has a more rapid clearance (5.2 ml/kg/min) and
a shorter elimination half-life (71 min) than pancuro¬
nium (1.8 ml/kg/min; 140 min).64 These two charac¬
teristics probably account for the shorter duration of
action of vecuronium compared to pancuronium.
Although atracurium and vecuronium produce
neuromuscular blockade of similar duration, calcu¬
lated values for their pharmacokinetic variables are
quite different. For example, the elimination half-life
is about 22 minutes for atracurium, and 71 minutes
for vecuronium.64 It appears that the inter-relation-
ship between pharmacokinetic variables and neuro¬
muscular blockade differs for these two drugs. All
previous pharmacokinetic models, including that for
vecuronium, assume that elimination of a drug
occurs from only one compartment. This approach is
obviously inappropriate for atracurium because Hof¬
mann elimination can occur from all body compart¬
ments.
Onset Time and Priming
The onset time (time from administration of
muscle relaxant to its peak effect) is similar for both
vecuronium and atracurium. The doses of atracurium
and vecuronium that depress twitch height less than
100 percent have onset times ranging from 4 to 8
minutes, and the speed of onset of these intermedi¬
ate-duration muscle relaxants is dose depen¬
dent.4'-48-49 By using high doses of these
intermediate-duration drugs it is possible to achieve a
more rapid onset without the excessively prolonged
duration of action that may be observed following
high doses of the longer-acting agents. For example,
four times the ED05 of vecuronium has an onset time
of 1.3 minutes.65 When three times the ED95 of atra¬
curium was given, onset times were 1.248 and 1.366
minutes. The onset times of atracurium and vecuro¬
nium. however, although similar in equipotent doses,
are significantly slower than succinylcholine in the
clinical dose range.67
Several authors have recently shown that it is
possible to accelerate the onset of the nondepolariz¬
ing block by administering a small "priming" dose
about 3-6 minutes before the full dose in order to
more rapidly produce intubating conditions. Foldes
et al advocate administration of 0.015 mg/kg of
vecuronium or 0.08 mg/kg of atracurium 6 minutes
before giving 0.05-0.06 mg/kg of vecuronium or
0.25-0.3 mg/kg of atracurium, respectively, for intu-
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bation.68 They claim that intubation can be easily
accomplished within 60-90 seconds using this prim¬
ing principle. Later studies, however, most of them
still in progress, indicate that in order to ensure good
intubating conditions within 90 seconds, the doses
given for intubation should be at least twice as large
as recommended by Foldes et al, ie 0.5-0.6 mg/kg of
atracurium or 0.12-0.15 mg/kg of vecuronium.
There is no doubt that priming will become an impor¬
tant maneuver, but for a rapid sequence induction,
succinylcholine is still the drug of choice.
Duration and Recovery of Action
When equipotent doses are compared, both
vecuronium and atracurium have a similar duration
of action, about one-third to one-half that of pancuro¬
nium.41-42'44'45-47''19 For doses depressing twitch ten¬
sion less than 100 percent, duration of action is about
15-30 minutes.40'41'44-45-47-49 When three times the
ED95 of these drugs is given, duration of action is
between 50 and 76 minutes.4I'48-49 In contrast, when
only two times the ED95 of pancuronium was given,
the time from administration of the muscle relaxant
to only 25 percent recovery of control twitch tension
was 158 minutes. Recovery time (time from 25 to 75
percent recovery of control twitch tension) is also
30-50 percent shorter for vecuronium and atracurium
than for pancuronium;40-42'46'47-49 these times range
from 9 to 12 minutes for both atracurium and vecuro-
nium.40-42'44'45-49
After a single dose of vecuronium or pancuro¬
nium, plasma concentration falls rapidly because of
redistribution from the central to the peripheral com¬
partment. With subsequent doses, muscle relaxant in
the peripheral compartment limits this distribution
phase, and the decrease in plasma concentration
results from elimination or metabolism. Thus, both
pancuronium and. to a lesser extent, vecuronium can
be demonstrated to have cumulative effects. This is
not the case for atracurium. For although biphasic
pharmacokinetic models have been described, there
is not a distinct distribution phase with a rapid
decrease in plasma concentration. Recovery from the
effects of atracurium depends predominantly upon
elimination (in this case metabolism by Hofmann
elimination and ester hydrolysis) rather than redis¬
tribution. As a result, recovery from the neuromuscu¬
lar effects of atracurium is similar for the first and all
subsequent doses. This lack of accumulation makes
atracurium the ideal agent for use as an infusion.
Gargarian et al found that a mean infusion rate of 8.4
Mg/kg/min produced excellent muscle relaxation and
maintained 90-99 percent suppression of the single
twitch.69 There was no difference in recovery rates
following a single bolus administration or continuous
infusion.
Hepatic and Renal Failure
Because of its unique degradation pathways, the
pattern of neuromuscular blockade produced by atra¬
curium has been shown to be remarkably little
affected by renal or hepatic failure.70 Hofmann elimi¬
nation is a nonbiological process, so atracurium is
not dependent on the liver or kidney for its removal
from the body and does not accumulate even in renal
or hepatic failure, where its behavior is much the
same as in normal patients. Atracurium is therefore
the nondepolarizing relaxant of choice in these
patients because of this advantage.
Vecuronium is the first and only relaxant to be
eliminated mainly via the liver. Most of this elimina¬
tion seems to be as the unchanged molecule with the
kidney a secondary route. Some authors have postu¬
lated spontaneous deacetylation of vecuronium to
account for its relative lack of cumulative property,
but this is not yet proven. Since vecuronium is
excreted mainly by the liver, it is a good second
choice in renal failure where the pharmacokinetic
profile of a single bolus is very similar to the profile
in normal subjects.61 There is a small cumulative
effect after 1V2 to 2 hours of vecuronium administra¬
tion to patients in renal failure. Although statistically
significant, this cumulative effect is probably of
minor clinical importance. In cirrhotic patients, how¬
ever, the duration is approximately double.71
THE CARDIOVASCULAR EFFECTS OF THE
NEW MUSCLE RELAXANTS
Atracurium
Dose-response curves for atracurium obtained
from results in anesthetized cats, dogs and rhesus
monkeys (Fig. 5-11) demonstrate that there is a wide
separation between the doses required for neuromus¬
cular paralysis and those that inhibit autonomic
mechanisms.72-73 In cats, significant hypotension and
slight bradycardia were evident after 4 mg/kg IV, but
this dose was 16 times that required for full neuro¬
muscular paralysis. Similar results were found in rhe¬
sus monkeys. In dogs, atracurium, 2 mg/kg, reduced
mean arterial pressure to 53 percent of the control
value, but this dose was 8 times that required for full
neuromuscular paralysis. Atracurium at high concen-
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Fig. 5-11. Dose-response curves for neuromuscular and autonomic function inhibition in cats following
pancuronium, tubocurarine and vecuronium; and in monkeys following atracurium. Note that vecuronium and
atracurium cause insignificant autonomic inhibition at doses considerably in excess of that required to produce
100 percent depression of the single twitch. (Data modified from Durant NW, Marshall IG, Savage DS, et al:
The neuromuscular and autonomic blocking activities of pancuronium. ORG NC 45, and other pancuronium
analogues in the cat. J Pharm Pharmacol 31:831, 1979, and from Hughes R, Chappie DJ; The pharmacology of
atracurium, a new competitive neuromuscular blocking agent. Br J Anaesth 53:31, 1981, with permission.)
trations had no inotropic or chronotropic effects on
spontaneously beating guinea pig atria.
Cardiovascular studies in man have been carried
out under halothane, enflurane and isoflurane anes¬
thesia. During halothane anesthesia (0.7-0.9 percent
end-tidal), maximum changes in mean arterial blood
pressure and mean heart rate following intravenous
doses of 0.2 and 0.4 mg/kg of atracurium were 6 and
8 percent, respectively, in one study;74 and changes
averaged less than 5 percent in another study.75
Hilgenberg et al investigated the hemodynamic
effects of 0.2 and 0.4 mg/kg of atracurium during
enflurane anesthesia (1.0 to 1.25 percent inspired)
and found no change in heart rate, cardiac index,
stroke index, central venous pressure, or systemic
mean arterial pressure.76 Systemic vascular resis¬
tance was decreased by 7 percent, compared with the
control value, following both doses of atracurium.
Similarly, Ramsey et al found no significant changes
in heart rate and arterial blood pressure during
enflurane anesthesia (1.16 end-tidal) after adminis¬
tration of 0.36 mg/kg of atracurium.55 During
isoflurane anesthesia (1.25 percent), Sokoll et al
reported that there were no clinically significant
changes in mean arterial blood pressure, mean heart
rate, systemic vascular resistance, cardiac index, or
central venous pressure after 0.2 and 0.4 mg/kg
doses of atracurium.77
In man, under nitrous oxide/narcotic anesthesia,
mean arterial pressure and heart rate first showed
significant changes from control values at 0.6 mg/kg,
double the full paralyzing dose (Fig. 5-12).28 Maxi-


















Fig. 5-12. The transient hemodynamic response occasion¬
ally observed following a bolus of 0.6 mg/kg of atracurium.
Illustrated are the heart rate (by tachograph), intra-arterial
blood pressure, and the single twitch at 0.15 Hz. Atracu¬
rium, 0.6 mg/kg, was injected as a rapid bolus at the arrow
mark to a patient under balanced anesthesia.
mum heart rate and arterial pressure changes
occurred 1-2 minutes after drug injection, and
returned to normal within approximately 5 minutes.
These changes have been shown to be due to a dose-
dependent release of histamine, and the increase in
plasma histamine levels correlates with the heart rate
and arterial pressure changes. Scott et al have shown
that these changes can be abolished by either slowing
the rate of injection of atracurium to 75 seconds or by
intravenous pretreatment with HI and H2 blockers
(chlorpheniramine and cimetidine) (Fig. 5-13).78 A
subsequent study by the same group has shown that
doses as high as 0.8 mg/kg of atracurium can be
administered safely, with hemodynamic stability, pro¬
vided the injection rate is slowed.79 Although atracu¬
rium will release histamine when high doses are
bolused intravenously, it is important to keep this side
effect in perspective. The ability of atracurium to
release histamine relative to its neuromuscular block¬
ing potency is only one-half that of dimethyltubocura-
rine, and less than one-third that of tubocurarine.28
Vecuronium
Since initial testing with vecuronium, it has been
























Fig. 5-13. Histamine release by atracurium (0.6 mg/kg) and the subsequent hemody¬
namic response is prevented by administering this dose slowly over 75 seconds. Pretreat-
mem with intravenous H, and H; antagonists does not prevent histamine release but does
attenuate the hemodynamic response. (From Scott RPF, Savarese JJ, Basta SJ. et al:
Atracurium: Clinical strategies for preventing histamine release and attenuating the
haemodynamic response. Br J Anaesth 57:550, 1985, with permission.)
216
166 Scott and Savarese
blocking dose of this drug and the dose producing
cardiovascular and autonomic effects is very wide.
Results obtained in anesthetized cats and dogs (Fig.
5-11) have demonstrated that vecuronium, even in
doses 20 times greater than those required for neuro¬
muscular blockade, has no effect on heart rate, ar¬
terial pressure, autonomic ganglia, alpha- or
beta-adrenoreceptors, or baroreceptor reflex activ¬
ity.72-80 Studies in pithed rats and guinea pig atria
have further shown that vecuronium has little effect
on cardiac muscarinic receptors or on norepinephrine
reuptake mechanisms.80 In contrast to its analogue,
pancuronium, vecuronium appears to have far less
indirect sympathomimetic activity.81
Eighteen adult patients studied under nitrous
oxide-narcotic anesthesia demonstrated no signifi¬
cant changes in heart rate or arterial pressure with
doses of vecuronium up to 150 Mg/kg. which is
nearly 3 times the 95 percent blocking dose.82 Equi¬
pment doses of pancuronium and vecuronium were
compared in 20 patients receiving halothane anesthe¬
sia. Pancuronium (0.08 mg/kg) caused a significant
increase in heart rate, insignificant change in arterial
pressure, and significant changes in systolic time
intervals.83 The roughly equipment dose of vecuro¬
nium. 0.057 mg/kg, caused no significant changes in
heart rate, arterial pressure, or systolic time inter¬
vals. In both experimental animals and in humans,
vecuronium has shown minimal potential for hista¬
mine release.82-83
In a clinical study that measured skin redness
and induration caused by the intradermal injection of
tubocurarine, metocurine. pancuronium, and vecuro¬
nium. vecuronium caused the smallest reaction, and
tubocurarine and metocurine the largest. These
results indicate that vecuronium had the least ten¬
dency to release histamine of the drugs tested. In a
comparative study with tubocurarine, metocurine,
and atracurium, Basta demonstrated that following
0.2 mg/kg of vecuronium (2 times the normal intu¬
bating dose) the heart rate, mean arterial pressure,
and serum histamine levels were not altered.84
CARDIAC SURGERY AND
CARDIOPULMONARY BYPASS
Since they have little or no cardiovascular
effects, vecuronium and atracurium may be appropri¬
ate neuromuscular blocking drugs for cardiac surgery
or noncardiac surgery on patients with cardiac dis¬
ease. Very large doses of vecuronium (eg. 0.28 mg/
kg) can be given with no cardiovascular effects.85 As
already indicated, however, large doses of atracu¬
rium may occasionally cause hypotension. Pokarand
Brandt administered atracurium in doses of 0.6-1.0
mg/kg into right atrial catheters in patients who had
undergone coronary artery bypass surgery.86 Of the 9
patients, 4 had a decrease of more than 10 percent in
arterial blood pressure. In a further study, when atra¬
curium, 0.3 mg/kg. was given to 8 patients about to
undergo elective coronary artery surgery, 1 patient
had a decrease in mean arterial pressure (from 70 to
55 mm Hg) and other signs consistent with histamine
release.87 It is possible that prior diuretic therapy had
made this patient more susceptible to even the slight
histamine release associated with atracurium admin¬
istration.
The hemodynamic stability of vecuronium may
be a disadvantage when high-dose fentanyl or sufen¬
tanil anesthesia is used. The vagolytic action of pan¬
curonium often protects against the tendency of the
narcotics to produce bradycardia. When vecuronium
is used with high-dose narcotic anesthesia, however,
the heart rate often decreases.88 This effect may be
more apparent in patients who are receiving beta-
blocker therapy during anesthesia for cardiac sur¬
gery.
Hypothermia and cardiopulmonary bypass can
also affect the amount of atracurium or vecuronium
required for neuromuscular blockade. Flynn et al
found that 43 percent less atracurium was required to
maintain a 90-95 percent neuromuscular blockade
during the hypothermic cardiopulmonary bypass
period.89 They attributed the apparent increased
potency of atracurium to the fact that hypothermia
reduces the rate of Hofmann degradation. Buzello et
al compared pancuronium and vecuronium before
and after cardiopulmonary bypass.90 Before bypass,
pancuronium acted about twice as long as vecuro¬
nium. However, during hypothermic bypass, the
durations of action of pancuronium and vecuronium
increased 1.8-fold and 5-fold, respectively. It thus
appears that during hypothermic bypass, pancuro¬
nium and vecuronium have similar durations of
action. It may therefore be concluded that hypother¬
mic cardiopulmonary bypass is associated with a
marked increase in the duration of the neuromuscular
blockade of both atracurium and vecuronium.91 This
point is, however, largely academic as the majority
of patients requiring cardiopulmonary bypass will be
ventilated postoperatively for a period longer than the
duration of any muscle relaxant.
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effects of muscle relaxants on
cardiac rhythm
Nondepolarizing Agents
The nondepolarizing agents generally do not
produce cardiac dysrhythmias. In fact, there is evi¬
dence that tubocurarine increases the dose threshold
for the production of epinephrine-induced dysrhyth¬
mias in dogs under halothane and nitrous oxide anes¬
thesia.92-93
Dysrhythmias after administration of pancuro¬
nium and gallamine may occur as a result of the
following factors:
1. A sudden shift of autonomic balance
towards the adrenergic side due to the vagal
blocking effect of these drugs
2. A possible indirect sympathomimetic effect
3. A relatively greater inhibition of the AV
node than the sinus node
These mechanisms may manifest themselves
clinically as single or multifocal premature ventricu¬
lar contractions, ventricular tachycardia, or nodal
(junctional) tachycardia. In the case of gallamine,
there is a higher incidence of ventricular dysrhyth¬
mias under light halothane or cyclopropane anesthe¬
sia probably because of the lowering of the threshold
for ventricular excitability caused by these anesthet¬
ics.94 In patients with sinus node disease, a vagolytic
effect might cause a relatively greater increase in the
spontaneous rate of activity of the atrioventricular
node than the sinus node, the result being nodal
tachycardia.
Succinylcholine
In man, succinylcholine is probably the only
neuromuscular blocking agent that may itself precipi¬
tate cardiac dysrhythmias during anesthesia. It stimu¬
lates all cholinergic autonomic receptors, nicotinic
receptors in both sympathetic and parasympathetic
ganglia, and muscarinic receptors in the sinus node
of the heart. The development of cardiac dysrhyth¬
mias is a clinical manifestation of this generalized
autonomic stimulation; and sinus bradycardia, junc¬
tional rhythms, and ventricular dysrhythmias ranging
from unifocal premature ventricular contractions to
ventricular fibrillation have all been documented.
However, many authors have noted these dysrhyth¬
mias in the presence of intense autonomic stimuli,
most notably including tracheal intubation; and it is
not always clear whether the cardiac irregularities are
due to the action of succinylcholine alone or to the
presence of extraneous autonomic stimulation.
Sinus bradycardia after succinylcholine occurs
most commonly in nonatropinized, relatively sym-
pathotonic individuals (eg, children), and is due to
stimulation of cardiac muscarinic receptors in the
sinus node.95 Sinus bradycardia has also been noted
in adults, and appears more commonly after a second
dose of the drug given approximately 5 minutes after
the first.96-97 It has been suggested that the higher
incidence of bradycardia after a second dose of suc¬
cinylcholine may be due to the hydrolysis products
sensitizing the heart.98 Thiopental, atropine, gan¬
glion-blocking drugs, and nondepolarizing relaxants
have all been used to prevent the bradycardia.
Nodal rhythms commonly occur as bradycardias
and are probably due to the relatively greater stimula¬
tion of the sinus node than the atrioventricular node.
The result is suppression of the sinus mechanism and
the emergence of the atrioventricular node or even a
ventricular focus as the pacemaker. The incidence of
a junctional rhythm is higher after a second dose of
succinylcholine, but is prevented by prior administra¬
tion of tubocurarine.96-"-100
Succinylcholine lowers the threshold of the ven¬
tricle to catecholamine-induced dysrhythmias in the
monkey101 and the dog92 under stable anesthetic con¬
ditions. Other autonomic stimuli, such as endotra¬
cheal intubation, hypoxia, hypercarbia, and surgery
are probably additive to the effect of succinylcholine
and may provoke ectopic activity. Ventricular escape
may also occur after severe sinus and atrioventricular
nodal slowing, secondary to succinylcholine admin¬
istration.
The depolarizing nature of the drug encourages
ventricular dysrhythmias by releasing potassium
from skeletal muscle.102 The rise of potassium in
normal people following a 1-mg/kg dose of the drug
is about 0.5 mEq/1.102 However, marked increases
may occur within 1-2 minutes of succinylcholine
administration in the following groups:
1. Burned patients99
2. Patients with extensive denervation of skele¬
tal muscle due to injury or disease of the
central nervous system
3. Massively traumatized patients103
4. Patients with severe intra-abdominal infec¬
tion 104
The period of danger in these groups begins
within a few days in the burned and denervated
patients, and within a few hours in the traumatized
217
168 Scott and Savarese
patient. Studies in baboons have shown that hyperka¬
lemia following surgical denervation begins as early
as 4 days after the establishment of the lesion, and
reaches a peak within 14 days.105 Whether the
hyperkalemic response to succinylcholine in these 4
groups represents a permanent lesion is not known.
Uremic patients and patients at least 6 months past
complete healing of bums are probably not at risk.106
A study in dogs has suggested that immobilization
atrophy does not seem to provoke the hyperkalemic
response either.107 The use of succinylcholine is
probably contraindicated in these various groups. A
modest dose of a nondepolarizing relaxant (6 mg of
tubocurarine, 40 mg of gallamine, 3 mg of meto-
curine, or 1 mg of pancuronium) administered 3 min¬
utes before succinylcholine may attenuate but will
not guarantee the absence of the hyperkalemic
response.
curarine affected the dysrhythmogenic dose of epi¬
nephrine during halothane anesthesia in dogs.109 This
finding indicates that the usual guidelines for the
administration of adrenaline during halothane anes¬
thesia are not affected by concomitant administration
of these two nondepolarizing muscle relaxants. Gal¬
lamine and tubocurarine may decrease the incidence
of epinephrine-induced dysrhythmias, in contrast to
succinylcholine, which may enhance epinephrine's
effects.92
Occasionally, drug interactions may be advanta¬
geous. Combinations of pancuronium and meto-
curine not only potentiate neuromuscular block¬
ade,110 but minimize the heart rate change associated
with pancuronium on its own. At twice the ED«?.
the heart rate increased significantly more in the
pancuronium group than in the pancuronium/meto-
curine combination group.
DRUG INTERACTIONS WITH THE
CARDIOVASCULAR EFFECTS OF THE
RELAXANTS
Succinylcholine lowers the threshold of the
ventricle to catecholamine-induced dysrhythmias.
To this must be added the possible influence of
drugs such as digitalis, tricyclic antidepressants,
monoamine-oxidase inhibitors, catecholamines, and
anesthetic drugs such as halothane and cyclopropane,
all of which may lower the ventricular threshold for
ectopic activity or increase the dysrhythmogenic
effect of the catecholamines.
The nondepolarizing agents may also produce
cardiovascular effects upon interaction with other
drugs. Edwards et al showed that simultaneous
administration of pancuronium and imipramine
caused a tachycardia in an additive manner.108 An 80-
/xg/kg dose of pancuronium produced premature ven¬
tricular contractions and ventricular tachycardia,
which rapidly progressed to ventricular fibrillation in
2 of the 10 dogs given imipramine, 8 mg/kg/day, and
4 of 10 dogs given 16 mg/kg/day. The authors con¬
cluded that severe ventricular dysrhythmias may
occur as a result of administration of pancuronium in
dogs anesthetized with halothane and chronically
receiving imipramine. Since vecuronium is much
less potent than pancuronium in blocking norepi¬
nephrine uptake, the possibility of ventricular dys¬
rhythmias arising during halothane anesthesia in
patients on tricyclic antidepressants would presum¬
ably be reduced.
In another study, neither pancuronium nor tubo-
THE CARDIOVASCULAR EFFECTS OF THE
ANTAGONISTS
Cardiovascular complications have been associ¬
ated with the use of anticholinesterase drugs as antag¬
onists of nondepolarizing neuromuscular blockade.
Dysrhythmias and cardiac arrest following the
administration of neostigmine and atropine have been
reported."1112 As a result, various techniques have
been described to improve the safety of reversal.
These include hyperventilation to produce mild res¬
piratory alkalosis, simultaneous injection of atropine
and neostigmine, slow administration of neostigmine
and atropine in a ratio of 2.5:1, and maintenance of
adequate oxygenation throughout the period of rever¬
sal.113-114
The cardiac arrests have been attributed to cho¬
linergic (muscarinic) stimulation of the heart by
neostigmine combined with insufficient atropine.
The relationship of dysrhythmias such as inverted P
waves, Wenckebach phenomena, premature atrial
contractions, junctional rhythms, atrioventricular
dissociation, premature ventricular contractions, and
bigeminy to atropine, neostigmine, or their combi¬
nation is less clear.115"118 Many of these reports
occurred during emergence from anesthesia when
changing anesthetic concentrations, surgical stimula¬
tion, and ventilation may have caused the dysrhyth¬
mias. However, dysrhythmias may occur even when
these variables are held constant.119 A decrease in the
amount of atropine or replacement of it with another
anticholinergic drug, such as glycopyrrolate. have
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been used to attenuate the tachycardia and reduce the
frequency of dysrhythmias.120
Patients receiving glycopyrrolate with neos¬
tigmine have smaller changes in heart rate than those
who receive atropine.121 Glycopyrrolate also
decreases the frequency of dysrhythmias when com¬
bined with neostigmine, pyridostigmine, or edropho¬
nium. "9,I20J22 Although a greater frequency of
dysrhythmias occurs with atropine, there is insuffi¬
cient evidence to implicate it as the etiological agent.
It is possible that glycopyrrolate blocks the dysrhyth-
mogenic stimulus of the anticholinesterase agents
more effectively than atropine.
In view of this, the antagonist that requires the
least amount of vagal blockade to prevent a bradycar¬
dia may provide an advantage clinically in terms of
dysrhythmias. Edrophonium has two distinct advan¬
tages:123 It has a shorter onset time than neostigmine
or pyridostigmine; and it requires about half as much
atropine to block adverse cardiac muscarinic effects
as neostigmine. In order to minimize changes in
heart rate, the rapidly acting edrophonium and atro¬
pine should be given together, and the slower acting
neostigmine and glycopyrrolate together. Edropho¬
nium has fewer muscarinic actions than neostigmine,
and its predominant mechanism of action is probably
presynaptic.
4-Aminopyridine has no muscarinic proper¬
ties.124 When it is combined with neostigmine or
pyridostigmine, approximately 5 ng/kg of atropine is
required to prevent bradycardia.125 The atropine dose
must be increased to 15 ng/kg when either neos¬
tigmine or pyridostigmine is used alone. 4-Amino¬
pyridine is devoid of anticholinesterase activity and
acts by increasing the amount of acetylcholine
released by nerve impulses. However, the facilitatory
actions of 4-aminopyridine are not confined to the
neuromuscular junction. Transmission is also facili¬
tated at autonomic, adrenergic, and cholinergic junc¬
tions including sympathetic ganglia and central
synapses. In animal studies, 4-aminopyridine pro¬
duced increases in left ventricular systolic pressure
and dP/dtnlax, right atrial pressure, stroke volume,
myocardial blood flow, myocardial oxygen con¬
sumption, external cardiac work, arterial oxygen
content, and blood hemoglobin.126 These effects
were attributed to facilitation of sympathetic trans¬
mission to the blood vessels, heart and spleen. Heart
rate was not greatly affected because facilitation of
vagal transmission to the sinoatrial node counteracted
the increased sympathetic effect. While 4-aminopyri¬
dine may be useful in certain relatively rare condi¬
tions of neuromuscular transmission failure, such as
botulism, myasthenia gravis, and Eaton-Lambert
syndrome, its actions are too widespread for routine
use as an antagonist to nondepolarizing drugs.
Reversal of neuromuscular blockade after pro¬
longed tricyclic antidepressant therapy can also lead
to electrocardiographic disturbances. Results of one
study demonstrated that minor ST-T wave and
myocardial conduction changes observed in cats
under chloralose anesthesia during chronic amitripty-
line treatment markedly intensified during reversal of
tubocurarine blockade with neostigmine alone or
with a mixture of neostigmine and atropine.127 This
is probably due to the effect of neostigmine on the
heart, coupled with the quinidine-like activity and
direct action of tricyclic drugs on the myocardium.
Because of the relatively rapid recovery pattern
of the new intermediate duration drugs, it may be
possible in many cases to avoid the necessity of
antagonism of residual blockade if dosing is carefully
judged, properly timed, and monitored. When the
new drugs have been employed, reversal should be
done on clinical indication rather than as a routine.
Anticholinesterases need not be administered, partic¬
ularly if patients show no fade on train of four, are
ventilating adequately, are responsive, and can dem¬
onstrate adequate head lift or grip strength.
MUSCLE RELAXANTS OF THE FUTURE
Pipecuronium
Pipecuronium bromide is an analogue of pan¬
curonium with the quaternary nitrogen groups situ¬
ated at the more remote nitrogen of the piperazine
groups substituted at the 2 and 16 positions of the
androstane skeleton (Fig. 5-14). In contrast to pan¬
curonium it has no acetylcholine-like fragments, and
the interonium distance is considerably larger than in
pancuronium.
In isolated nerve-muscle preparations (rat
phrenic-nerve diaphragm and chick biventor cervicis
muscle), pipecuronium produced a pure nondepo¬
larizing type of neuromuscular blockade, showing a
relative potency of 1.7-3 times that of pancuronium
under similar experimental conditions.128 The nonde¬
polarizing mode of action has been further demon¬
strated in experiments in vivo in cats, rabbits, and
dogs.128 Further observations in animals suggest that
this new compound possesses remarkable cardiovas¬
cular stability.129
The initial clinical data on pipecuronium has
been generated and reported mainly in Hun-
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Fig. 5-14. The structural formula of pipecuronium bro¬
mide. (From Agoston S, Richardson FJ: Pipecuronium bro¬
mide—a new long-acting nondepolarizing neuromuscular
blocking drug. Clin Anesthesiol 3:361. 1985, with permis¬
sion.)
gary.130131 In many respects pipecuronium is similar
to pancuronium. In man, neuromuscular blocking
potency is equal to or slightly greater than that of
pancuronium and, consequently, its routine use in
clinical practice should follow the existing pattern for
pancuronium. A dose of 0.05 mg/kg after intubation
with succinylcholine will provide adequate muscle
relaxation for 40-50 minutes. For intubation, how¬
ever. the dose should be increased to 0.08-0.1 mg/
kg, which will give satisfactory intubating conditions
in 2.5-3 minutes and adequate surgical relaxation for
80-120 minutes. As with pancuronium, cumulative
effects after repeated doses and potentiation of inha-
lational anesthetic agents, particularly enflurane, can
be expected.
Pipecuronium appears to be free from histamine-
releasing properties. The most important advantage
of this compound in comparison with other long-
acting drags like pancuronium or alcuronium is that it
is devoid of circulatory effects. Pipecuronium does
not cause a tachycardia as does pancuronium, and in
patients undergoing abdominal surgery there was no
significant changes in blood pressure, central venous
pressure, pulmonary capillary wedge pressure, or
cardiac index.132
Pipecuronium. like vecuronium, has a minor
disadvantage in that it has to be dissolved in solvent
before use. The ampules currently used contain 4 ma
of the agent that should be dissolved in 2 ml of sol¬
vent. Pipecuronium should be stored in a refrigerator
at 4°C and should be used shortly after dissolving the
powder.
BWB109OU
For a number of years, workers have been inves¬
tigating a series of nondepolarizing bulky diester
compounds that are metabolized by plasma cholines-
terase. In 1979. BW785U, a short-acting nondepo¬
larizing ester neuromuscular blocking agent was
described. During a brief clinical trial, neuromuscu¬
lar blocking activity of BW785U was indeed found to
be very short.133 A hypotensive response, however,
first noted in animals and apparently due to histamine
release, was found to be much more prominent in
humans and forced the cancellation of further trials.
BWA444U was another compound in the benzyliso-
quinolinium series.134 Pharmacodynamically this
agent's neuromuscular blocking effect was very simi¬
lar in duration to that of atracurium, but its margin of
safety for histamine release was somewhat less, so
that it was withdrawn from further studies. Addi¬
tional structure activity studies have since led to the
development of BWB109OU.
BWB109OU (Fig. 5-15) is another short-acting
nondepolarizing benzylisoquinolinium ester. The
duration of action in the rhesus monkey was found to
be about one-third that of atracurium and vecuro¬
nium. Its safety margin for histamine release was
found to be about 10 times as great as that of
BW785U. In initial clinical studies, the ed95 has
been estimated to be approximately 0.08 mg/kg. The
duration of action (injection to 95 percent return of
twitch) is 25-30 minutes at 0.15-0.25 mg/kg. doses
that produce 100 percent block. Spontaneous recov¬
ery time (5-95 percent) averages 14-15 minutes for
all doses above 0.10 mg/kg. There is no significant
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Fig. 5-16. Chemical stmcture of BWA938U.
difference in recovery times between single bolus
doses or after 1-3 hour infusions. Neuromuscular
blockade is readily reversed with neostigmine. In a
further trial of 53 ASA class I and II patients, the
cardiovascular effects and histamine-releasing prop¬
erties of large doses were studied.135-136 Brief
decreases in arterial pressure after 2.5 and 3.1 times
the ED95, given as a rapid bolus, corresponded with
elevations in plasma histamine levels. Cardiovascu¬
lar changes were less after a second identical dose of
BWB109OU or after slower bolus administration.
The cardiovascular effect of BWB109OU, therefore,
seems attributable to a relatively weak histamine-
releasing property. The safety margin for this side
effect is 2.5 to 3 times greater than that of tubo-
curarine or roughly similar to that of atracurium (2.5
to 3 times ED95).
BWA938U
BWA938U (Fig. 5-16) is another benzyliso-
quinolinium ester.137 Preclinical pharmacological
studies in cats, dogs and rhesus monkeys showed that
BWA938U is a very potent and rather safe nondepo¬
larizing neuromuscular blocking agent. Compared
with BWB109OU and atracurium, BWA938U is
more potent, has a longer onset time, and longer
duration of action. The ED95 for BWA938U in the
monkey is estimated to be 0.017 mg/kg; the ED95 in
man is 0.025-0.03 mg/kg. Bolus doses of 9 times the
ED95 of BWA938U produced no significant cardio¬
vascular effects in dogs. In patients under balanced
anesthesia, doses of 0.08 mg/kg (three times ED95)
produced no significant cardiovascular effect.
In summary, BWA938U is a very potent, long-
acting nondepolarizing neuromuscular blocking
agent, about three times as potent as pancuronium.
Preclinical data suggests that two properties of
BWA938U may significantly distinguish it from
other long-acting agents. These properties are a lack
of cardiovascular effects at several multiples of the
ED95 dose for neuromuscular blockade, and a lack of
cumulative effects following repeated dosing. These
properties have been confirmed recently in volunteer
studies and clinical trials evaluating the safety and
efficacy of this drug. This agent has a small advan¬
tage over pipecuronium in that it is stable in solution
and may be stored at room temperature.
CONCLUSIONS
The history and development of neuromuscular
blocking agents have been characterized by a pro¬
gressive reduction in side effects and improvement in
pharmacodynamic profiles. Atracurium and vecuro¬
nium have set new standards in this field, and several
of the older drugs would be unlikely to pass the ani¬
mal testing stage today. This is certainly true in terms
of cardiovascular side effects
Most of the commonly used nondepolarizing
muscle relaxants can be classified as either steroids
(pancuronium, vecuronium) or benzylisoquinolinium
compounds (tubocurarine, metocurine, atracurium);
and further research is continuing with both of these
groups of substances. In the future, there will proba¬
bly be more published about pipecuronium, a pan¬
curonium analogue with a similar duration to its
parent compound but without the tachycardia.
Research with the benzylisoquinoliniums is also pro¬
ducing a number of interesting new agents. This
group of compounds has a wide variety of pharama-
codynamic profiles (BWB109OU and BWA938U).
Work on the structure-activity relations on both types
of compounds has resulted in three new drugs reach¬
ing full-scale clinical trials; with successful comple¬
tion of human studies, the new drugs should be
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EFFECT-OF SUXAMETHONIUM GIVEN DURING
RECOVERY FROM ATRACURIUM
R. P. F. SCOTT AND J. NORMAN
i
At the end of an abdominal operation, muscle
relaxation may be inadequate and a transient
increase in block may be needed to facilitate
closure. Suxamethonium is the only agent of short
duration available currently [1] and has been used
in these circumstances. Whilst interactions with
long acting competitive agents have been des¬
cribed [2-5], there are no descriptions of its effect
on recovery from the block produced by atra-
curium. This study was designed to assess the
effects of increasing doses of suxamethonium on
the recovery of block produced by atracurium and
on the subsequent interaction with neostigmine.
PATIENTS AND METHODS
Thirty-eight patients (18-70 yr, 45-110 kg)under-
going elective surgical procedures were studied
after they had given informed consent. No patient
who had received aminoglycoside antibiotics was
studied. The study was approved by the local
Ethics Committee.
Diazepam 10-20 mg and metoclopramide 10
mg were given by mouth 1 h before anaesthesia
was induced with thiopentone 4-76 mg kg"1 and
fentanyl 2 — 4 pg kg"1. Anaesthesia was main¬
tained with 66 % nitrous oxide and 0.5 % en-
flurane in oxygen supplemented by additional
doses of fentanyl and thiopentone as required.
End-tidal carbon dioxide tension was maintained
at 4-5 kPa.
The integrated, rectified and gated electro¬
myographic response of the hypothenar muscles
was recorded in response to supramaximal train-
of-four stimuli delivered to the ulnar nerve at 20-s
intervals using a Datex Relaxograph. Control
R. P. F. Scott, b.sc., m.b., ch.b., f.f.a.r.c.s.; J.Norman,
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Suxamethonium was given in varying doses
when twitch response had returned to 50% of
control following the administration of atra¬
curium in anaesthetized patients. Small doses of
suxamethonium producedantagonism, enhance¬
ment of the block, or a combination showing a
biphasic response. A dose of 3 mg kg'1 was
needed to produce consistently 100% block of
the twitch. The subsequent recovery rate for T1
was as fast as that seen normally after suxa¬
methonium and was not enhanced by neo¬
stigmine.
records were obtained after induction of anaes¬
thesia but before a block was produced with an
initial dose of atracurium 0.4 mg kg"1.
The first twitch (Tl) of the train-of-four was
allowed to recover to 50% of the control value in
22 patients. Suxamethonium 0.25, 0.5, 1, 1.5, 2 or
3 mg kg"1 was given i.v. and the subsequent course
of paralysis noted. When the first twitch had
recovered to 100% (in some patients in whom the
train-of-four ratio remained less than 0.6 after
several minutes of monitoring), the additional
effect of neostigmine 35 pg kg"1 was noted (table
I).
In order to provide comparative recovery
data, three further groups were studied: atra¬
curium 0.4 mg kg"1 with spontaneous recovery,
atracurium 0.4 mg kg"1 with antagonism by
neostigmine 35 pg kg"1 at Tl 10-25 %; and spon¬
taneous recovery of suxamethonium l.Smgkg"1
without any preceding atracurium.
In order to mimic a possible clinical situation,
in a further four patients the initial dose of
atracurium was allowed to recover to 50 % Tl and
suxamethonium 3 mg kg"1 was given in the same
manner as in the first study, but neostigmine 35 pg
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Table I. Study groups. *Suxamethonium administered at
50% T1 recovery from a 0.4-mg kg'1 atracurium block
Atracurium Suxamethonium Neostigmine
n (mg kg*1) (mg kg*1) (pg kg"1)
1 0.4 0.25 at 50% Tl* ±35 at 100% Tl
4 0.4 0.5 at 50% Tl ±35 at 100% Tl
4 0.4 1.0 at 50% Tl ±35 at 100% Tl
3 0.4 1.5 at 50% Tl ±35 at 100% Tl
6 0.4 2.0 at 50% Tl ±35 at 100% Tl
4 0.4 3.0 at 50% Tl + 35 at 100% Tl
4 0.4 3.0 at 50% Tl + 35 at 25% Tl
4 0.4 — —
4 0.4 — + 35 at 10-25% Tl
4 — 1.5 —
Table II. Effect of suxamethonium on a recovering (50% Tl)
atracurium block. *Four patients received neostigmine at 25%
Tl after suxamethonium (see table III). **A 50% change in
block represents 100% block of Tl
No. with Mean (SD) Tl 100%
Dose of Sux. biphasic change in block time
(mg kg"1) n response block (%) (min)
0.25 1 0 -10
0.5 4 2 -1.25 (10.3)
1.0 4 2 -1 (12.5)
1.5 3 2 34 (17.7)
2.0 6 4 40.5 (13.5)
3.0 8* 3 50** 8
kg-1 was given when the Tl had returned again to
25 %. The response to suxamethonium 3 mg kg"1
in this study (n = 4) is included in table II with
the results of the first study of the effect of
suxamethonium on a recovering atracurium block
{n = 4) so that overall, n = 8. However, the
recovery data for these two groups were different
and are tabulated separately (table III).
293
Table III. Reversal data (mean (SD)). AS = Suxamethonium
3 mg kg'1 administered at a 50% Tl atracurium recovery;
AS +N = neostigmine administered at 25% Tl recovery of
AS block; S = suxamethonium l.Smgkg'1; A = atracurium







AS 4 2.75 (0.28) 8.25 (0.95)
AS +N 4 7.25 (3.6) 12.3 (5.9)
S 4 3 (0) 7.75 (0.5)
A 4 13.1 (1.8) 38.3 (7.6)
A +N 4 4.5 (0.57) 14.5 (1.73)
RESULTS
Giving suxamethonium when Tl had recovered
to 50% after the administration of atracurium
produced no effect on the block, a mild increase in
recovery rate, an enhancement of the block, or a
biphasic response. Figure 1 shows a biphasic
response in which there was an initial reversal,
followed by the development of full block and
later recovery. There were marked variations
between patients for each dose of suxamethonium,
but the net effect of the lower doses was to
antagonize the block and of higher doses to
enhance it. Only with suxamethonium 3 mg kg-1
was it possible consistently to produce a complete
block: this lasted some 8 min before recovery
(table II).
When atracurium was given alone the mean
recovery index (25-75% Tl recovery) was 13.1
min, and when neostigmine was given at 10-25%
Tl this time was shortened, on average to 4.5
min. When suxamethonium 3 mg kg"1 was given
at 50 % Tl recovery after atracurium, the recovery
index following the period of 100 % block was
Time (min)





L ^.u! il Hi
Fig 1. Effect of suxamethonium on a recovering atracurium block. Suxamethonium 2 mg kg*1 (Sux.)
was administered at 50% Tl recovery from an atracurium 0.4 mg kg"' blockade. Subsequent biphasic
response followed by a brief period of 100 % Tl block and a rapid recovery.
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2.75 min and the 5-95 % recovery time was 8.25
min. These times are very similar to those
recorded following a spontaneous suxamethonium
1.5 mg kg"1 recovery (3 and 7.75 min, respec¬
tively). However, fade always persisted following
the block induced by suxamethonium after atra-
curium, despite the rapid recovery of T1; but this
fade was always reversed when neostigmine was
administered at 100% T1 recovery (table III).
When suxamethonium 3 mg kg-1 was admini¬
stered at a 50% T1 recovery from atracurium,
and neostigmine was administered subsequently
at the earlier stage of 25 % T1 of this combination
block, fade was reversed. The mean recovery
index, however, was prolonged to 7.25 min and in
one patient neostigmine transiently increased the
block by 10%, prolonging the 5-95% recovery
time to 19 min. Thus the fastest recovery times
were observed after suxamethonium 1.5 mg kg"1
alone, or during the recovery stage of a suxa¬
methonium 3 mg kg^-potentiated atracurium
block. While the addition of neostigmine reversed
fade when administered at 100% T1 after the
combination block, neostigmine slowed recovery
of this block when administered at the earlier
stage of recovery (T1 25%).
Suxamethonium given after atracurium did not
produce muscle fasciculations.
DISCUSSION
This study was designed to mimic a clinical
problem. The blockade produced by atracurium
was allowed to wear off to a point at which T1 had
recovered to 50% and where all four responses to
train-of-four stimulation were apparent. This
level of recovery is usually too great to allow
closure of the abdomen without deep general
anaesthesia, and the anaesthetists should intensify
the block. It was common to use a small dose of
suxamethonium for this rather than give an
increment of a long acting competitive blocker.
Our results show that small doses of suxa¬
methonium may antagonize the partial block seen
during recovery from atracurium, but that larger
doses usually enhance the block. The subsequent
pattern of recovery of a combination block is
faster than that seen with atracurium alone or
when antagonized by neostigmine. However,
during the recovery of a combination block, fade
of the train-of-four response is seen. Similar
results have been reported with the interaction of
suxamethonium with longer acting competitive
blocking drugs [2-5]. Young [4] and Walts [2]
demonstrated similar patterns of dose-related
effect with tubocurarine, as did Katz for pan¬
curonium [3], The biphasic pattern has been
described by Walts [2] and in more derail by
Buzello and his colleagues [5]. This last study
demonstrated that, with a constant dose of suxa¬
methonium 0.5 mg kg"1, the proportional relation¬
ship between reversal and subsequent increase of
blockade depends on the stage of recovery from
non-depolarizing neuromuscular blockade at the
time of administration of suxamethonium. Young
[4] reported similar findings.
What are the mechanisms which produce
these interactions? The traditional view would be
that atracurium produces mainly a competitive
block of the post-synaptic receptors. Such a block
may be overcome by increasing the concentration
of agonist usually, in clinical practice, by the
administration of neostigmine. However, suxa¬
methonium also acts as an agonist and interacts
with the post-synaptic receptors, leading to the
opening of ionic channels and depolarization of
the membrane. In turn, this may initiate a muscle
action potential and contraction. If the amount of
suxamethonium is too great, depolarization is
maintained and the muscle membrane becomes
inexcitable. Hence small doses may act as antago¬
nists, but larger ones produce a block as the
depolarization develops.
We still need to explain why the recovery index
is quicker during recovery from the combination
block, why neostigmine slows it and why fade of
the train-of-four response persists. Again, the
traditional view of block may provide an ex¬
planation. The enhanced recovery index by itself
may be misleading. It is likely that what we are
observing is a simple competitive displacement by
the law of mass action at the post-junctional re¬
ceptor: the dose—response curve of suxametho¬
nium is shifted to the right because of the presence
of atracurium molecules on the receptor.
It appears from Buzello's study [5] that, when
suxamethonium is administered during a pancur¬
onium recovery phase, 100% T1 recovery was
not achieved at 30 min following suxamethonium
when administered at 25% or 75% recovery of
Tl. In our study every patient had recovered to
100% Tl from a combination block (suxa¬
methonium 3 mg kg"1) within 20 min of adminis¬
tration of suxamethonium. This observation sup¬
ports our hypothesis. As suxamethonium is cat-
abolized and the local concentration declines at
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the end-plate, the post-junctional receptors may
be occupied by the longer acting pancuronium
molecules, which are eliminated more slowly.
This does not occur with atracurium, which has
intermediate duration of action, because elimina¬
tion is occurring more rapidly than with pan¬
curonium during the time that suxamethonium is
being hydrolysed. Thus the fast recovery index
reflects the fact that most of the block is produced
by suxamethonium. The fact that neostigmine
slowed recovery after suxamethonium may be a
result of its effect on plasma, in addition to true
cholinesterase, thereby delaying the breakdown
of suxamethonium.
Fade is now believed to result either from a
block of pre-junctional acetylcholine receptors by
competitive drugs or from a use-dependent oc¬
clusion of the post-junctional ion channel [6].
However, the latter hypothesis ignores the find¬
ings of Hutter [7] and Otsuka and colleagues [8]
that tubocurarine-induced fade is associated with
diminished release of acetylcholine and, certainly,
the evidence for drugs used in clinical circum¬
stances favours the first of these two mechanisms.
The fade demonstrable during the recovery from
suxamethonium following atracurium is accoun¬
ted for most probably by the residual pre¬
junctional action of atracurium. It may result
from development of a phase 2 block [9] by
suxamethonium, but this would seem unlikely
because of the rapid recovery time. Furthermore,
neostigmine did not shorten the recovery time,
and on one occasion actually increased block,
adding substance to the hypothesis that a depolar¬
izing block is present. In any event, all these
explanations are speculative, especially with the
difficulties inherent in comparing the evoked
electromyographic responses demonstrable in
man with the precise studies now possible in the
laboratory. A detailed study of the interactions
would presumably need voltage [10] and patch
clamp studies to ascertain which effects result
from interaction with acetylcholine receptors on
the muscle and which from effects on receptors on
the nerve terminals.
The data generated by the indirectly evoked
EMG should be used with some understanding of
its limitations as a predictor of mechanical
response. Although Carter and colleagues [11]
found a good correlation between the two methods
of measurement for both twitch height and train-
of-four ratio (correlation coefficients 0.93 and
0.97, respectively), Kopman [12] found that the
simultaneously evoked (hypothenar) EMG and
MMG did not give identical information. The
regression line for the T1 :Tc (twitch depression/
control twitch) ratio was parallel to the line of
identity, but showed an absolute offset of 15%.
Furthermore, the EMG baseline may drift with
time as a result of a number of possible factors and
return to Tl:Tc control values does not always
occur.
The Datex EMG was chosen in this study
because it is a compact and convenient tool,
providing information on the nature of the
response to be expected from certain drug inter¬
actions, rather than a precise quantification of
effect. Where significant baseline drift was ob¬
served (Tl:Tc<0.85) the data were excluded
from the study. These limitations do not detract
from our conclusions.
Although we did not see prolonged block when
suxamethonium 3 mg kg"1 was given after re¬
covery from atracurium to a 50% Tl level, we
would not recommend giving such a dose to
enhance neuromuscular blockade in clinical prac¬
tice unless a peripheral nerve stimulator were
used to monitor the degree and duration of block.
If such a technique is used, neostigmine appears
not to accelerate the subsequent recovery and
should not be used. It is important to remember
that we gave the suxamethonium at 50% Tl, at
which time all four responses to train-of-four
stimulation were present. An alternative clinical
solution would be to increase the block with a
small increment of atracurium. The intensity,
duration and subsequent recovery of the block
would then depend on the size of dose used.
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EDITORIAL III
DO WE NEED MORE MUSCLE RELAXANTS ?
In 1975 Savarese and Kitz [1] suggested that three
new types of neuromuscular blocking drug were
required. All should be non-depolarizing agents
capable of antagonism and all should be free from
cardiovascular side effects in therapeutic doses.
The first type would replace suxamethonium, the
second was to have a duration of action shorter
than the competitive agents available at that time,
and the third a longer action to replace pancu¬
ronium and tubocurarine. Since then two drugs,
atracurium and vecuronium, have been intro¬
duced and have gained wide acceptance. It seems
that we are about to be offered a further selection.
Do we need the drugs on offer and do we still need
further developments?
Atracurium and vecuronium were developed
and marketed as drugs of intermediate durations
of action. They were tested thoroughly in animal
preparations to ensure that the doses necessary to
show vagolytic, sympathomimetic or ganglion
blocking actions were well in excess of those
needed to produce neuromuscular blockade.
They exhibit remarkably similar durations of
action in equipotent doses and these durations are
less than those possessed by the competitive
agents hitherto available. Atracurium achieves
this by having the, so far unique, property of
Hofmann degradation whereby it degrades spon¬
taneously when warmed to body temperature and
placed at physiological pH. The fact that one of
the end products is laudanosine, which is a central
nervous system excitant in high doses does not
appear to be clinically important even with
prolonged use in intensive care patients in renal
failure [2], The absence of significant prolongation
of action in renal or liver disease is a significant
advantage [3, 4]. One disadvantage may be the
dose-related release ofhistamine seen on occasion,
although* this and the associated haemodynamic
response may be attenuated simply by slowing the
speed of injection [5, 6], In contrast, the short
duration of action of vecuronium appears to result
from rapid uptake by the liver, with elimination
mainly in the bile but also by the kidney [7]. Some
prolongation of the action of vecuronium may be
seen with renal failure, with obstructive jaundice
and with cirrhosis, but the extent is usually much
less than is seen with conventional doses of pan¬
curonium in healthy patients [8]. One addition¬
al problem is seen with both drugs. Neither
shows vagolytic actions nor has sympathomimetic
properties. Thus when they are used with opioids,
with volatile agents such as halothane or when
anaesthesia is insufficiently deep to prevent vagal
responses to traction of viscera, there is a likeli¬
hood of bradycardia which may be severe enough
to present as sinus arrest. The virtues of the
drugs, however, have led to their wide acceptance
for operations of intermediate duration.
In the past decade, there has also been a much
better understanding of pharmacokinetics and
pharmacodynamics. Both atracurium and vecuro¬
nium were marketed as being "non-cumulative",
which appeared to imply that when increments
were given at a cbnstant level of block, each
increment produced a constant duration of block;
but each drug was usually given as an initial large
bolus and increments became necessary only to
replace drug being lost by elimination. Thus
"non-cumulation" could be expected and may be
seen if the traditional agents such as tubocurarine
and pancuronium are studied in the same way.
Nevertheless, the idea of non-cumulation led to
the use of both drugs by infusion which may lead
to relatively easy maintenance of a constant level
of block with easy antagonism when the operation
has been completed [9]. By using either inc¬
remental bolus techniques or by using infusions,
both drugs can be used satisfactorily for long
operations. In effect they can be used as the
Savarese-Kitz type III drugs. Atracurium seems
effective and safe in those few patients who need
paralysis in intensive care; it is not yet clear if
vecuronium is equally effective and shows a rapid
recovery.
What new drugs are on offer? On the West and
East sides of the Atlantic there is some progress
with developments of the benzylisoquinoliniums
and the steroids, respectively. Two long acting
drugs are available which appear devoid of
cardiovascular side effects. Doxacurium (BW
A938U) [10] and pipecuronium [11] are under-
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going clinical trials in a number of centres. Their
pharmacodynamic properties resemble those of
pancuronium and they are probably also excreted
largely by the kidney. Presumably, conditions
which diminish glomerular filtration delay elim¬
ination, but they fit the bill should a replacement
for pancuronium be needed. The absence of
cardiovascular side effects may allow bradycardia
to develop as a result of the vagotonic effect of
certain anaesthetic agents and surgical stimuli.
Their prolonged actions may also pose problems
in antagonism of blockade, and anaesthetists will
have to decide if they wish to use a single injection
of the newer drugs compared with the ease of
repeated bolus injections or infusions of atra-
curium or vecuronium. As for all prolonged
operations, the use of a nerve stimulator will aid
their safe administration.
There is one new drug with an action signifi¬
cantly shorter than that of atracurium or vecu¬
ronium. Mivacurium [12, 13] is another benzyl-
isoquinolinium compound but, unlike atra¬
curium, it is thought to undergo active hydrolysis
by cholinesterase in addition to metabolism by
hepatic microsomal enzyme systems. Its plasma
clearance is faster than that of atracurium and
with equipotent doses its action is 33-50 % that of
atracurium or approximately twice that of suxa¬
methonium. Further, the recovery rate seems to
be almost independent of the initial dose, and
recovery times upon discontinuation of infusions
have not differed significantly from times after
single bolus doses. Its action is antagonized by
neostigmine and it seems a better drug to use for
those operations too long for a single dose of
suxamethonium and too short for an intubating
dose ofatracurium or vecuronium. The temporary
problem of the weak and floppy patient in the
recovery room following attempted antagonism of
drugs of intermediate duration of action after, say,
10-15 min, may be resolved but, as with more
effective drugs, it possesses a disadvantage: its
potential to release histamine seems to be equiv¬
alent to that of atracurium.
However, we still seem no nearer to replacing
suxamethonium. Its unique triad of producing
complete paralysis within 1 min of injection for a
relatively short period of time implies that we
shall continue to use it, although perhaps more
sparingly than before. When there is an urgent
need to facilitate tracheal intubation, to break
laryngospasm and perhaps for short procedures
such as electroconvulsive therapy, there is no
equivalent substitute. It does, of course, have
significant dangers: it can trigger malignant
hyperpyrexia and it may produce life-threatening
anaphylactoid reactions. It may lead to dangerous
hyperkalemia in the recently injured, in the
burnt and in patients with upper and lower motor
neurone lesions. Itmay not paralyse all patients, it
provokes increases in intraocular pressure and it
produces muscle pains. Can we identify why it
remains so useful? Why do the other neuro¬
muscular blocking agents not act so quickly [14],
so well and for so short a time? There seem to be
two features. First, we accept that there is a large
margin of safety at the neuromuscular junction;
the competitive blockers have to block all the
spare receptors and most of the remaining 20-
30% to produce complete block. In contrast,
being a depolarizing drug, suxamethonium may
need to produce depolarization only via the
20-30% to make the junction insensitive. Thus it
may not need as high a concentration gradient to
produce the effect. Second, because it has such a
short half-life (of the order of 2-3 min at most in
the normal patient) it can be given in a
huge overdose, thus increasing the concentration
gradient driving the drug towards the junction.
The short half-life is associated with a very rapid
decrease in concentration and, hence, rapid elim¬
ination. It remains to be seen if it is possible to
produce a competitive blocker with a similar short
half-life, but the signs are encouraging with the
development of mivacurium.
To return to the question posed at the head of
this editorial: "Do we need more muscle relax¬
ants?" The answer is "yes". One reason is that,
as with most drugs containing quaternary nitrogen
groups, anaphylactoid reactions occur to muscle
relaxants and alternatives are needed. The intro¬
duction of new drugs always stimulates a critical
examination of current practice and that is also an
advantage. It is an open question if we need the
long-acting replacements for pancuronium and
tubocurarine, and this may be answered perhaps
when we have more details of the variability in
response to doxacurium and pipecuronium and an
understanding of what factors predict prolonged
responses. As described in this issue [15], miva¬
curium appears to be useful as a "short-inter¬
mediate" drug which may have a role in pro¬
cedures such as those seen commonly in day-case
centres. We still await the replacement for
suxamethonium.
R. P. F. Scott and J. Norman
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DOXACURIUM CHLORIDE: A PRELIMINARY CLINICAL
TRIAL
R. P. F. SCOTT AND J. NORMAN
Doxacurium, in common with atracurium, is a
benzylisoquinolinium, non-depolarizing neuro¬
muscular blocking drug containing two quarter-
nary nitrogen groups. Initial clinical studies in the
U.S.A. suggest that it is a potent, long acting drug
devoid of cardiovascular and histamine releasing
side effects at clinically effective doses [1,2]. The
ED95 dose to block contraction of the adductor
pollicis muscle is approximately 25 |tg kg"1 [1].
Unlike atracurium, it is not susceptible to Hof-
mann degradation, and is probably excreted
largely unchanged by the kidney.
This study of doxacurium was designed to
assess its onset, intubation conditions, effect of
multiple increments and ease of antagonism with
edrophonium and neostigmine. A preliminary
report of this study was presented to the Anaes¬
thetic Research Society.
PATIENTS AND METHODS
We studied 27 ASA I or II adult patients (weights
45-100 kg) scheduled to undergo elective surgery
expected to last 120 min. Each gave written
informed consent for the study which was also
approved by the local Hospital Ethics Committee.
The patients were premedicated with papa-
veretum 15-20 mg and hyoscine 0.3-0.4mg i.m.
1 h before surgery. Before induction of anaes¬
thesia the skin over one forearm and the hand was
degreased using an alcohol solution. Five silver-
silver chloride electrodes were placed, two over
the ulnar nerve, one over the mid-point of the
distal skin crease at the wrist, one over the palmar
aspect of the head of the fifth metacarpal and one
over the belly of the adductor pollicis muscle.
R. P. F. Scott, b.sc., m.b., ch.b., f.f.a.r.c.s.; J.Norman,
ph.d., f.f.a.r.c.s., f.f.a.r.a.c.s. ; Shackleton Department of
Anaesthetics, The University, Southampton General Hos¬




The onset, duration of action and reversibility of
doxacurium were studied in 27 anaesthetized
patients, using doses of 37.5 gg kg'' (1.5 x ED95)
and 62.5 gg kg~' (2.5 x ED95). Onset was slow
and, whilst tracheal intubation was always
possible 3 or 4 min after injection, the conditions
were not ideal. With the higher dose a mean 97.6
(SD 5.2)% block of the response of adductor
pollicis to ulnar nerve stimulation was obtained
in 9.85 (6.17) min and recovery of the integrated
EMG response to 20% of control took 102 min
(42 min). After these initial doses, when in¬
cremental doses were given there was no sign of
cumulation of effect. Antagonism of block with
edrophonium 1 mg kg~', whilst fast in onset, was
rarely complete; with neostigmine 50 gg kg''
antagonism was satisfactory. No adverse haemo-
dynamic effect was seen, although a gradual
onset of bradycardia, which responded to atro¬
pine or g/ycopyrro/ate, was noted in 12 of the
patients. No histamine release or other adverse
effects were noted.
These were connected to a Datex Relaxo-
graph. Anaesthesia was induced with thiopentone
4—5 mg kg"1 i.v. and fentanyl 2-3 pg kg"1 i.v.
Neuromuscular monitoring was commenced
using a train-of-four stimuli (2 Hz at 20-s inter¬
vals) to the ulnar nerve and the gated, rectified
and integrated EMG from the adductor pollicis
was recorded. The size of the gain setting,
supramaximal stimulus and the stimulus artefact
were noted. Anaesthesia was maintained with
66% nitrous oxide in oxygen and the lungs were
ventilated artificially to maintain normocapnia.
The patients were allocated to three groups of
nine and patient order was randomized. Following
randomization the first 18 patients studied (and
hence the last nine also) were equally divided
231
374 BRITISH JOURNAL OF ANAESTHESIA
between the three groups. When an initially stable
record was obtained, doxacurium 37.5 pg kg"1 i.v.
(1.5xED95) was administered to group A, and
62.5 pg kg"1 i.v. (2.5 x ED95) to groups B and C,
with the bolus being given either into a continuous
infusion or flushed through a cannula with a 5-ml
bolus of saline. The bolus was given to coincide
with a train-of-four sequence, to give an accurate
time mark on the record.
Intubation conditions were assessed by the
same investigator (R.S.) each time at 4 min after
the administration of doxacurium in groups A and
B and at 3 min in group C. The conditions were
graded on a scale of 1-4 (excellent, good, poor or
not possible) [3].
The onset of block was determined as the time
from injection to the appearance of either com¬
plete block or the maximum degree of block.
Following maximal block, anaesthesia was main¬
tained with nitrous oxide in oxygen plus 0.5%
halothane. Additional doses of fentanyl and
thiopentone were administered as required. When
the first response of the train-of-four (Tl) had
recovered to 20% of control, a bolus of doxa¬
curium 5 pg kg"1 was given; this was repeated
when Tl had recovered again to 20%. The
duration and degree of block produced by each
increment were noted.
At the end of surgery, when Tl had recovered
to greater than 10% of control, the residual block
was antagonized with edrophonium 1 mg kg"1 i.v.
in the first 18 patients (six in each of groups A, B
and C), and neostigmine 50 pg kg"1 i.v. in the last
nine patients (n = 3 in each group). Glyco-
pyrrolate or atropine i.v. in an appropriate dose
was given concurrently. The percentage recovery
of Tl following the injection of the anti¬
cholinesterase agent was continuously recorded.
Heart rate was observed continuously from a
Hewlett-Packard ECG monitor and the arterial
pressure measured every 2 min using a Hewlett-
Packard non-invasive monitor. To minimize de¬
creases in core and hand temperatures "during
the operation, nasopharyngeal temperature was
measured, all infusions were warmed to body
temperature, a condenser humidifier was used in
the breathing system and the forearm was
insulated by wrapping in towelling.
Neuromuscular monitoring was stopped when
the patient was awake, and neuromuscular func¬
tion was evaluated clinically during the recovery
period by assessing patient's grip strength and
ability to head lift for 5 s [4]. Each patient was
reassessed 24-^18 h after surgery and questioned
with regard to any adverse experience noted.
Non-parametric and Student's t test were used
as appropriate to assess statistical significance.
RESULTS
There were no significant differences between the
ages, weights or ASA groups of the three groups
of patients studied (table I). The duration of
surgery was defined as the time from adminis¬
tration of the initial bolus of doxacurium until
administration of the antagonizing agent. Intu¬
bation conditions ranged between grades excellent
and poor in all three groups, but only one patient
in each group achieved excellent conditions (table
II). Intubation was accomplished successfully in
all patients, although 100% block of adductor
pollicis was not achieved before intubation was
performed.
Because patients in groups B and C all received
doxacurium 62.5 pg kg"1, these two groups were
analysed together and compared with group A
Table I. Patient characteristics (mean (SD))
Duration
Age Weight of surgery Sex
n (yr) (kg) (min) (M/F)
Group A
Doxacurium 9 52.5 (11.8) 67.3(10.7) 127.8 (58.4) 5/4
37.5 pg kg"1
Group B
Doxacurium 9 60.7 (11.2) 69.8(15.8) 161.4 (48.6) 7/2
62.5 pg kg"1
Group C
Doxacurium 9 49 (14.0) 74.5 (15.0) 139.6 (38.7) 6/3
62.5 pg kg"1
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Table II. Intubation data. Score I = excellent, 2 = good; 3 = poor; 4 = not possible
Time of Intubation score (No. patients) Reduction in












3 1 6 0 2 0 2.1 (0.6) 67.1 (26.0)
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(doxacurium 37.5 pg kg"1) (table III). Three
patients in group A failed to achieve 80% block
following the initial bolus and one patient was
antagonized at 10% recovery. In the remaining
five it took an average of 51 min to recover to T1
of 20%. With the higher dose, in one patient the
initial block was only to 75 %, and in two the
recording was lost following movement of the
patient by theatre staff and loss of electrode
placement. In the remaining 15, the time to 20%
T1 recovery was on average 102 min after the
initial dose (table III). There was no significant
correlation between the age of the patients and
duration of block at this higher dose.
Only 13 patients received increments of doxa¬
curium as, in the remainder, the initial bolus dose
of doxacurium was adequate to last throughout
the operation. The incremental doses adminis¬
tered at 20% recovery of T1 produced a moder¬
ately wide between-patient variation in response,
both with regard to percent increase in block of
T1 and time to return to 20% Tl. However, the
response in any one patient was consistent, with
increments producing the same increase in para¬
lysis and a constant duration of effect (table
IV).
Two patients with poor recovery recordings
were omitted from the antagonism data analysis.
The mean percent recovery of Tl at the time of
administration of the antagonist was almost the
same in the edrophonium and neostigmine groups
(table V). The first twitch of the train-of-four was
antagonized well after neostigmine. The Tl
antagonism response to edrophonium was rapid
Table III. Onset and duration data (mean (SD) [range]'). *Three patients failed to achieve 80°o block
Max. block Time to Duration to
achieved max. block 20 °0 recovery
n (Tl %) (min) ofTl(min)
Group A
Doxacurium 9 83.6 (18.3) [55-100] 10.5 (2.2) [6-14] N/A*
37.5 pg kg"1
Groups B + C
Doxacurium 18 97.6 (5.2) [78-100] 9.85 (6.17) [5-31] 101.7 (41.8) [31-175]
62.5 pg kg"1 (n = 15)
Table IV. Response to increments (5 pg kg'1) (mean (SD) [range]), fGroup A n = 4; group B n = 4\
group C n = 5
No. patients Increase in Duration
receiving increments block Tl to return to No.
at 20°0 recovery Tl (%) 20% (min) increments
Total 13f 8 (3.3) [2.5-15] 31.3 (31.1) [9.5-42] 3.9 (3.8) [1-12]
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Table v. Data on antagonism of block by edrophonium or neostigmine (mean (SD) [range])
Recovery of T1 (%) at
n Drug admin. 1 min 3 min 5 min 10 min
Edrophonium 17 23.8 (8.8) [10-37] 59.2 (22.8) 70.9 (17.3) 76.4 (17.4) 78.0(16.7)
Neostigmine 8 22.5 (6.7) [10-32.5] 40.6 (21.2) 70.5 (28.2) 81.8 (21.0) 94.3(12.2)
in onset but was incomplete and subsequently
appeared to be similar to that of a spontaneous
recovery. In eight (47 %) patients in the edro¬
phonium group a train-of-four (TOF) ratio less
than 0.5 was still present when recording had to
be stopped. Only four (24%) patients achieved a
TOF ratio greater than 0.7. One patient, with a
TOF ratio of 0.6 at the end of recording, failed a
5-s head lift 30 min after administration of
edrophonium. Ten minutes later he had a suc¬
cessful head lift following administration of
neostigmine 2.5 mg. In the neostigmine group, no
neuromuscular block could be detected by clinical
assessment in the recovery room. One patient had
a train-of-four ratio less than 0.5 following
antagonism at the end of the recording. Four
patients (50%) achieved a TOF ratio greater than
0.7. The mean period of recording following
administration of both agents was approximately
14 min.
Twelve (44.4%) patients required adminis¬
tration of an i.v. anticholinergic agent during
operation to correct a heart rate of less than 50
beat min"1.
The bradycardias were gradual in onset and
generally occurred 30-60 min after induction of
anaesthesia and seemed unrelated to the adminis¬
tration of doxacurium.
No adverse experiences were reported by the
patients on follow-up at 24 h.
DISCUSSION
This study confirms that doxacurium is a potent,
long acting neuromuscular blocking agent. Al¬
though a formal dose-response study was not
carried out in our patients the drug appeared to be
less potent than might have been anticipated from
previous reports. Other studies [1, 2, 5, 6] suggest
that the ED95 lies between 13.6 and 25 |ig kg"1,
depending on the anaesthetic conditions. The
dose regimen in this study was based on the initial
report by Basta and colleagues which suggested
the ED95 under balanced anaesthesia was 25 pig
kg"1 [1], In our study, group A received 1.5 times
this ED95 and groups B and C received 2.5 times
the ED95. Our data, however, showed that at
37.5 pg kg"1 (1.5xED95) the maximum block
achieved was 83.6% Tl. This apparent difference
in potency may result from the fact that we
compared EMG responses to mechanomyo- •
graphic forms ofmeasurement [1,2]. In addition,
the drug may appear less potent because of the
lighter depth of anaesthesia during induction.
Alternatively, there may be an Anglo-American
difference in potency for doxacurium, as had been
described previously for tubocurarine [7],
Intubating conditions were similar to those
described by other workers [8, 9] and could only
be described as excellent in one patient in each
group; in no patient was 100% blockade of Tl
achieved before intubation. In two patients the
inmbating conditions were between grades 2 and
3 by the intubation criteria of Twohig and his
colleagues [3] and therefore they scored 2.5. Even
at the high dose (62.5 pg kg"1) the mean onset time
to 90% block of Tl was some 4.9 min (n = 17).
Nevertheless, in no patient was intubation impos¬
sible and the mean conditions in all three groups
could be said to be good.
In the patients receiving multiple maintenance .
increments of doxacurium there was no evidence
of an increase in duration or degree of block
following each bolus.
In all patients except the two with poor
recordings, in whom antagonism was blind, the
block was antagonized between 10 and 37%
recovery of Tl. It could be argued that the poor
antagonism with edrophonium was related to
baseline drift of the electromyographic recording,
which has been well documented by other authors
[10, 11], However, the antagonism of Tl by
neostigmine was complete; this would confirm a
real difference in ability to antagonize doxacurium
by these two anticholinesterase agents. As a result
of time constraints imposed on this clinical study,
TOF fade was still present in several patients
when stimulation had to be stopped as the patient
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awakened. Nevertheless, with the exception of
one patient who received edrophonium, all other
patients appeared to have appropriate clinical
antagonism of block and had satisfactory grip
strength and 5-s head lift when tested between 20
and 40 min after admission to the recovery
ward.
It is unlikely that the gradual onset of brady¬
cardia could be attributed to doxacurium; our
measurements of heart rate and arterial pressure
confirm the findings of others that doxacurium is
a haemodynamically stable agent [1, 12]. There
was no clinical evidence of histamine release.
Konstadt also noted a decrease in heart rate and
attributed this to progressive reduction in sympa¬
thetic tone resulting from anaesthesia [13]. The
effect of opioids and volatile agents on heart rate
is well documented [14],
In conclusion, we found doxacurium to be a
potent, long acting, haemodynamically stable,
non-depolarizing neuromuscular blocker. Al¬
though intubation was possible in all patients in
the three groups studied and with the doses used
in this study, doxacurium did not provide intu¬
bating conditions which could be described as
excellent. In common with vecuronium and
atracurium, this drug does not have the protective
vagolytic effect of pancuronium and it is recom¬
mended that an anticholinergic agent be available
immediately if vagal stimuli are likely to be
encountered during surgery. Neostigmine would
appear to be more suitable than edrophonium as
an antagonist for doxacurium.
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Introduction
Important research into new muscle relaxants can be di¬
vided into two distinct chemical groups, namely the ben-
zylisoquinolinium compounds and the steroids.
The benzylisoquinolinium agents
For a number of years now, Savarese and colleagues at
the Massachusetts General Hospital, USA have been col¬
laborating with pharmacologists and molecular chemists
at Burroughs Wellcome, Research Triangle Park, North
Carolina, USA. They have been particularly interested in
the bis-benzylisoquinolinium diesters, a group of non-de¬
polarizing compounds known to undergo hydrolysis in
the presence of plasma cholinesterase. While a number
of prototypes offered many features of 'the ideal mus¬
cle relaxant', the major stumbling block with this class
of experimental drugs has been histamine release. This
side effect, well recognized in other benzyiisoquinolines,
notably d-tubocurarine, metocurine and to a lesser extent
atracurium, has resulted in the withdrawal of some other¬
wise potentially useful agents following volunteer studies.
Two drugs, doxacurium chloride (BWA 938 U) [l], and
mivacurium chloride (BWB 1090 U) [2], have, however,
recently come to full scale clinical trials in both the USA
and Europe.
Doxacurium [1,3,4] would appear to be the most potent
non-depolarizing muscle relaxant ever studied in man. At
an estimated ED95 of 30 pg/'kg doxacurium is two to two
and a half times more potent than pancuronium, and over
16 times more potent than d-tubocurarine.
This long-acting bis quarternary benzylisoquinolinium di-
ester was identified as a byproduct of the programme to
develop a short-acting agent. It has a similar duration of
effect to pancuronium given in equipotent doses [1,3]
and provided there is some evidence of recovery as as¬
sessed by using a peripheral nerve stimulator, the drug
may be reversed satisfactorily with neostigmine [1,3].
Edrophonium, however, would appear to be an unsat¬
isfactory antagonist for this agent [5].
The onset time is slow, and probably slower than that
of pancuronium in equipotent dose [1,3]. At 80 (ig'Tg
(2.7 x ED95) the mean onset to maximum suppression
was only 3-5 min [l]. Thus doxacurium would seem to
be an unsuitable agent for rapid tracheal intubation.
Its major advantage is its haemodynamic stability in both
healthy adult patients and those with cardiac disease
[1,6].-Although some decrease in heart rate [5,6] may
be observed over time, this is unlikely to be an effect of
doxacurium. The vagal effects of anaesthesia and certain
surgical stimuli, which are concealed by the vagolytic ef¬
fect of pancuronium, may occasionally be exposed with
this drug. A similar phenomenon is seen not infrequently
with vecuronium, which is also stable on the circulatory
system.
Unlike other benzylisoquinoline analogues, it does not
release histamine in the clinical dose range [l]. This is
almost certainly due to its high potency making the mar¬
gin of safety between the neuromuscular blocking dose
and the dose at which histamine release is observed, that
much wider.
Early pharmacokinetic studies in humans show elimina¬
tion half-lives (1-2 h) and clearance values (1-2ml/kg
per min) typical of other long-acting agents such as pan¬
curonium or d-tubocurarine. Although the drug has been
identified in human bile, it is thought that doxacurium is
largely eliminated unchanged by the kidney. The hydrol¬
ysis rate in vitro, as catalyzed by purified pooled human
plasma cholinesterase, is only 6% of the rate of suxam¬
ethonium [l],
Benzyiisoquinoline ester compounds can be readily
chemically manipulated to undergo more rapid metabo¬
lism or degradation, thereby shortening the neuromuscu¬
lar effect. Atracurium was the first to find clinical success
in which the ester linkage facilitates both the Hofmann
elimination and ester hydrolysis pathways of breakdown.
With mivacurium, the basic benzylisoquinoline structure
provides good potency, while two ester linkages allow
rapid breakdown by plasma cholinesterase at about 88%
of the rate of suxamethonium hydrolysis [2], Preliminary
data in vitro and in the cat, however, suggests that mivac¬
urium might also undergo liver uptake and metabolism.
This could explain the poor correlation of the duration
of action of bolus doses of mivacurium, with the plasma
cholinesterase activity of individual subjects. The metabo¬
lites have been identified in the bile and urine of both cat
and dog, as well as in human urine [2],
Since enzymatic hydrolysis is most likely the major route
of clearance, the duration of action ofmivacurium may be
© Current Science Ltd ISSN 0952-7907
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longer in people with low cholinesterase activity. Savarese
etal. [2] posit that the relative increase induration of ac¬
tion, however, may not be as great as in the case of sux¬
amethonium for three reasons:
(1) the upper limit of the clinical dose range is
greater with suxamethonium than mivacurium,
and therefore represents a relatively greater over¬
dose and consequently higher clearance load;
(2) other clearance pathways for mivacurium seem
likely, and
(3) the complicating process of phase II block cannot
occur in the case of mivacurium.
Mivacurium's duration of action is about one-third to
one-half that of an equipotent dose of atracurium of ve¬
curonium, or about one and a half to two times longer
than suxamethonium. Its onset time, however, is more
similar to atracurium or vecuronium than suxametho¬
nium. The calculated ED95 for neuromuscular blockade
is 0.08mg/kg. At a dose of 0.3mg/kg (3.8 x ED95), on¬
set can be shortened to the 2 min range, but there is still
a spontaneous recovery to 95% twitch height in some
36min [2]. This pharmacodynamic pattern, where an in¬
crease in dose is accompanied by a disproportionately
small extension of duration of effect, is unlike that of any
other non-depolarizing blocker, with the possible excep¬
tion of atracurium. Rather than engage in the often dis¬
cussed definition of cumulation, it is simpler to say that
mivacurium's recovery indices are relatively short, and
do not change over a wide dose range, nor after pro¬
longed continuous administration by infusion [7]. The
addition of isoflurane may, however, prolong the recov¬
ery index [8], Interestingly, Ali et al. [7] noted a sig¬
nificant correlation between the infusion rate of mivac¬
urium required to maintain 95% twitch depression, and
the plasma cholinesterase activity of individual subjects.
Antagonism of mivacurium-induced block by anticholin¬
esterase agents would seem at least as easy as reversal
of any other non-depolarizing drug. It is likely that dur¬
ing reversal, hydrolysis of mivacurium may be slowed
for a brief period, due to a short-lasting inactivation of
plasma cholinesterase. Nevertheless, moderate levels of
mivacurium block are readily antagonized by neostig¬
mine, due to acetylcholinesterase inhibition. Presumably
within about 20 min following neostigmine administra¬
tion, plasma cholinesterase activity should have recovered
sufficiently to destroy any residual mivacurium ester ma¬
terial.
Since mivacurium is a benzyiisoquinoline substance, it
shares the generic side effect of this group of com¬
pounds, namely histamine release. This side effect would
seem to be relatively mild, and its cardiovascular effects
are similar to those of atracurium [2], Like atracurium,
the transient haemodynamic response to a high dose bo¬
lus can be attenuated by simply slowing the speed of in¬
jection to about 60 s
Mivacurium will be supplied as a solution that is stable
at room temperature.
Steroidal agents
The concept of fusion of acetyicholine-like fragments
with a steroidal skeleton was stimulated following the
discovery of malouetine, a naturally occurring extract of
a jungle plant found in Zaire. Although this substance
had neuromuscular blocking properties, its cardiovascu¬
lar side effects made it unsuitable for clinical trials. Never¬
theless, subsequent molecular design led to the develop¬
ment of pancuronium. The observation in 1974 that the
vagolytic effect of pancuronium was due to the A ring
acetylcholine-like moiety and its a P stereochemistry, re¬
sulted in the emergence of two further steroid analogues
namely vecuronium and pipecuronium bromide.
Pipecuronium was originally synthesized 10 years ago in
Hungary, and indeed has now been approved for clinical
use in a number of Eastern European countries. Despite
this experience, progress through the clinical trials stage
in Western Europe and the USA has been slow. More
recently however, Gideon Richter Ltd (Hungary) have li¬
censed Organon Technika (Belgium) to manufacture and
market the drug, and one would anticipate it being avail¬
able for routine anaesthetic practice in the near future.
In contrast to pancuronium, it has no acetylcholine-
like fragments and the interonium distance is consider¬
ably larger. Although slightly more potent than pancuro¬
nium (ED95, 0.06 mg/kg), all other pharmacodynamic pa¬
rameters, in particular onset, duration, recovery and re¬
versibility are remarkably similar (Agoston and Richard¬
son, Clin Anaesth 1985, 3:361-369; Biaon and Szporny,
World Congress ofAnaestbesiologists 1988, 2A0532).
Renal excretion as the unchanged parent molecule ap¬
pears to be the most important route of elimination, so
it is assumed that impaired renal function may prolong
the duration of action. As with pancuronium, cumulative
effects after repeated doses and potentiation by volatile
anaesthetic agents, especially enflurane, can be expected.
Pipecuronium appears to be free from histamine-releas-
ing properties. Like doxacurium, the most important ad¬
vantage of this drug over other long-acting agents is its
freedom from circulatory side effects [9].
Pipecuronium will be supplied as a freeze-dried powder,
for storage at room temperature and dilution before use.
Future research
It will have become apparent from the foregoing discus¬
sion that there is still a need for a rapid-onset non-de¬
polarizing drug, or, if you like, a suxamethonium substi¬
tute without the depolarizing side effects. This is, effec¬
tively, where most research into muscle relaxant molec¬
ular chemistry will be directed from now on.
It would seem that there are two philosophies on how
to achieve this ideal agent.
Chemists working with the benzvlisoquinoline structure
believe that a highly potent, ultra short-acting drug is the
answer; their hypothesis being that it will then be pos¬
sible to give large doses, to improve onset time with-
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out an undue prolongation of blockade. Furthermore, the
more potent the drug is regarding neuromuscular block¬
ing activity, the greater margin of safety for histamine re¬
lease will be; this chemical group's major side effect.
Steroidal chemists however, are working on an entirely
different hypothesis. They believe that highly potent
drugs, by definition, have a high affinity for receptors,
and therefore rapid onset can only be achieved at the
expense of a very prolonged duration of action. An anal¬
ysis of the relationship between neuromuscular block¬
ing potency and duration of action has revealed that it
is reciprocal, suggesting that a non-depolarizing equiva¬
lent of suxamethonium, when discovered, may necessar¬
ily be a drug of low potency [10]. Work in this area has
already produced some encouraging results, albeit in an¬
imals [11,12],
Two fast onset short-duration steroids, Org 7617 and
Org 96l6, although significantly less potent than vecuro¬
nium, have demonstrated pharmacodynamic profiles sim¬
ilar to suxamethonium. The problem with reducing po¬
tency of steroidal compounds, is that vagolytic and au¬
tonomic side effects begin to appear. Initial animal stud¬
ies suggest these two experimental agents may not be
haemodvnamically stable, at least at the higher doses.
However, two fast onset intermediate duration steroids,
Org 9426 and Org 9273, are being investigated and have
produced only minor changes in blood pressure and
heart rate in all species, at three times EC^ blocking
doses. Although, once again, considerably less potent
than vecuronium, they display a similar duration and
faster onset of action at equipotent dose.
It should be bome in mind that the duration of drug
action is briefer the smaller the species of animal, pre¬
sumably because of faster blood flow and metabolism.
Nevertheless, the relative time course of action in the cat
of these new drugs, suxamethonium and vecuronium, is
encouraging.
We eagerly await the results of the initial volunteer stud¬
ies.
Annotated references and recommended
reading
• Of interest
•• Of outstanding interest
1. Basta SJ, Savarese jj, Embree PB, au HH, Schwartz af, Rudd
• • GD, Wastila WB: Clinical pharmacology of doxacurium
chloride — a new long-acting nondepolarizing muscle re¬
laxant. Anesthesiology 1988, 69:478-486.
A pharmacodynamic and haemodynamic study of 81 ASA 1 or II patients.
Pancuronium has a marginally faster onset time, but otherwise the phar¬
macodynamics are similar in equipotent doses. Doxacurium was devoid
of dose-related effects on heart rate, at up to and including 2.7 x ED95
for twitch suppression.
2. Savarese JJ, Au HH, Basta SJ, Embree PB, Scott RPF, Weakly
• • JN, Sunder N, Wastila WB, El-Sayad HA; The clinical
neuromuscular pharmacology of mivacurium chloride (BW
B1090U): a short-acting nondepolarizing ester neuromus¬
cular blocking drugs. Anesthesiology 1988, 68:723-732.
A pharmacodynamic study in 72 ASA I or II patients. This may constitute
a versatile new addition to anaesthetic practice, since its administration
seems particularly adaptable to short procedures or to maintenance of
relaxation by infusion. Mivacurium chloride would appear to have sim¬
ilar onset times and histamine-releasing potential to atracurium.
3. Murray DJ, Mehta MP, Choi ww, Forbes RB, Sokoll MD,
• Gergis SD, Rudd GD, Aboudonia MM: The neuromus¬
cular blocking and cardiovascular effects of doxacurium
chloride in patients receiving nitrous oxide narcotic anes¬
thesia Anesthesiology 1988, 69:472—477.
Pancuronium had a significantly faster onset than doxacurium. The de¬
creases in blood pressure and heart rate noted may be related to study
design.
4. Sarner JB, Brandom BW, Cook DR, Dong M-L, Horn MC,
• Woelfel SK, Davis pj, Rudd GD, Foster vj, McNulty BF:
Clinical pharmacology of doxacurium chloride (BW A938U)
in children. Anesth Analg 1988, 67:303-306.
At equipotent doses of doxacurium, both the time to onset of maxi¬
mum blockade and time to recovery of neuromuscular transmission to
T25 are shorter in children, during halothane anaesthesia, than in adults
during narcotic anaesthesia No significant effects on heart rate or blood
pressure were observed.
5. scott RPF, Norman J: Doxacurium chloride: a preliminary
• clinical trial. Br J Anesth 1988, 61:505.
In this UK study, doxacurium appeared less potent than had been anti¬
cipated from North American studies. Edrophonium was an unsatisfac¬
tory antagonist of the doxacurium-induced blockade. A gradual onset of
bradycardia was observed, but was probably unrelated to doxacurium
administration.
6. Stoops CM, Curtis CA, Kovach DA, McCammon RL, Stoelting
• RK, Warren TM, Miller D, Abou-Donia MM: Hemodynamic
effects of doxacurium chloride in patients receiving oxygen
sufentanil anesthesia for coronary artery bypass grafting or
valve replacement. Anesthesiology 1988, 69:365-370.
Doxacurium showed no clinically significant effect on measured or de¬
rived haemodynamic variables, at doses up to 3 times its ED 95, in ASA
III or IV patients undergoing cardiac surgery.
7. au HH, Savarese JJ, Embree PB, Basta SJ, Stout RG, Bottros
• LH, Weakly jn: Clinical pharmacology of mivacurium
chloride (BW-B1090U) infusion — comparison with ve¬
curonium and atracurium. Br J Anaesth 1988, 61:541-546.
Recovery times following infusions of mivacurium did not differ sig¬
nificantly from those following single bolus doses, and were approxi¬
mately 50% of those for equivalent durations of infusion of atracurium
or vecuronium. There was a significant correlation between the infu¬
sion rate of mivacurium required to maintain 95% twitch depression,
and the plasma cholinesterase activity of individual subjects.
8. Weber S, Brandom BW, powers DM, Sarner JB, Woelfel
• SK, Cook RD, Foster vj, McNulty BF, Weakly JN: Mi¬
vacurium chloride (BW B1090U)-induced neuromuscular
blockade during nitrous oxide-isoflurane and nitrous oxide-
narcotic anesthesia in adult surgical patients. Anesth Analg
1988, 67:495-499.
The addition of isoflurane (0.5-0.75% end-tidal concentration) to ni¬
trous oxide narcotic anaesthesia, augments the degree of neuromuscu¬
lar blockade from a given dose of mivacurium, and also prolongs the
recovery index.
9. Tassonyi E, Neidhart P, Pittet J-F, Morel DR, Gemperle
• M: Cardiovascular effects of pipecuronium and pancuro¬
nium in patients undergoing coronary artery bypass graft¬
ing. Anesthesiology 1988, 69:793-796.
In patients about to undergo coronary artery bypass grafting, pipecuro¬
nium in doses up to 3 x ED9S was associated with haemodynamic sta¬
bility. Previous reports of bradycardia could not be confirmed.
10. Bowman WC, Rodger IW, Houston J, Marshall RJ,
• • McIndewar 1: Structure/action relationships among some
desacetoxy analogues of pancuronium and vecuronium in
the anesthetized cat. Anesthesiology 1988, 69:57-62.
496 Muscle relaxants
The greater neuromuscular blocking potency of pancuronium and ve¬
curonium is lost after removal of 1 or both of the acetylcholine moi¬
eties. An analysis of the relationship between neuromuscular blocking
dose and duration of action revealed that it is reciprocal and it is sug¬
gested that a non-depolarizing equivalent of suxamethonium, when dis¬
covered, may necessarily be a drug of relatively low potency.
11. Boou LHDJ, Marshall 1G, Crul JF, Muir AW: (Abstracts)
• Pharmacology of four steriod muscle relaxants. World
Congress ofAnaestbesiologiss 1988, 2A0533.
The pharmacodynamics in animals of 2 rapid-onset, short-duration
steroids and 2 rapid-onset, intermediate-duration steroids is reviewed.
12. Marshall rj, Muir AW, Booij L, Crul J, Marshall IG: The
• cardiovascular effects of four new non-depolarising neuro¬
muscular blocking drugs in rats, cats dogs, pigs and mon¬
keys. World Congress of Anaestbesiologists 1988, 2A0534,
The rapid-onset, short-duration steroidal muscle relaxants may have
a vagolytic and/or autonomic side effects in the clinical dose range,
in animals. The rapid-onset, intermediate-duration steroids look more
promising haemodynamically.
240
